Blood sample collection tube

Information

  • Patent Grant
  • 11116695
  • Patent Number
    11,116,695
  • Date Filed
    Friday, June 21, 2019
    4 years ago
  • Date Issued
    Tuesday, September 14, 2021
    2 years ago
Abstract
A blood sample collection tube and other vessels are described including an article surface and a coating set comprising a tie coating or layer of SiOxCy or SiNxCy applied to the article surface, a barrier coating or layer of SiOx, and a pH protective layer of SiOxCy or SiNxCy. The vessels optionally contain a fluid with a pH of 4 to 8, alternatively 5 to 9. The barrier coating or layer prevents oxygen from penetrating into the thermoplastic vessel, and the tie coating or layer and pH protective coating or layer together protect the barrier layer from the contents of the vessel.
Description
FIELD

The present invention relates to the technical field of thermoplastic blood collection vessels, for example such vessels in which blood samples are collected and transported to a medical laboratory for testing.


BACKGROUND

Blood sample collection vessels, commonly tubes, are used for drawing blood from a patient for medical analysis. The tubes are commonly sold stoppered and evacuated. The patient's blood is communicated to the interior of a tube by inserting one end of a double-ended hypodermic needle into the patient's blood vessel and impaling the closure of the evacuated blood collection tube on the other end of the double-ended needle. The vacuum in the evacuated blood collection tube draws the blood (or more precisely, the blood pressure of the patient pushes the blood) through the needle into the evacuated blood collection tube, increasing the pressure within the tube and thus decreasing the pressure difference causing the blood to flow. The blood flow typically continues until the tube is removed from the needle or the pressure difference is too small to support flow.


Evacuated blood collection tubes should have a substantial shelf life to facilitate efficient and convenient distribution and storage of the tubes prior to use. For example, a one-year shelf life is desirable, and progressively longer shelf lives, such as 18 months, 24 months, or 36 months, are also desired in some instances. The tube desirably remains essentially fully evacuated, at least to the degree necessary to draw enough blood for analysis (a common standard is that the tube retains at least 90% of the original draw volume), for the full shelf life, with very few (optimally no) defective tubes being provided.


A tube having a lower-than-standard vacuum level at the time of use is likely to cause the phlebotomist using the tube to fail to draw sufficient blood. The phlebotomist might then need to obtain and use one or more additional tubes to obtain an adequate blood sample.


To meet this shelf-life requirement, evacuated blood collection tubes have typically been made of glass. Glass vessels have been favored because glass is more gas tight and inert to pre-filled contents than untreated plastics. Also, due to its traditional use, glass is well accepted, as it is known to be relatively innocuous when contacted with blood or other medical samples.


Glass vessels, however, have several serious disadvantages when used as blood tubes. They can break, and if broken form sharp shards from remnants of the vessel that can injure workers or patients, both due to the direct effects of laceration and by transmitting infections via lacerated skin. Breakage after a sample is collected can also cause the sample to be compromised or lost. Glass vessels also are expensive to manufacture, as glass cannot be injection molded.


Thermoplastic blood collection tubes have been developed to overcome the disadvantages of glass vessels. Plastic vessels are rarely broken in normal use, and if broken do not form sharp shards from remnants of the vessel, like a glass tube would. As-molded thermoplastic blood collection tubes previously have not had gas barrier properties adequate to provide a commercially desirable shelf life when used as evacuated blood collection tubes. Plastic has allowed small molecule gases to permeate into (or out of) the article. The permeability of plastics to gases has been significantly greater than that of glass. Many plastics have allowed water vapor to pass through articles to a greater degree than glass. Some plastic vessels contain organic or inorganic metal compounds in the plastic that can leach out or be extracted into the sample vessel.


U.S. Pat. No. 7,985,188 discloses barrier-coated thermoplastic blood collection tubes including a barrier coating or layer applied by plasma-enhanced chemical vapor deposition (PECVD) to improve their gas barrier and leaching properties. An example of a suitable barrier coating disclosed by U.S. Pat. No. 7,985,188 is SiOx, in which x in this formula is from about 1.5 to about 2.9 as characterized by x-ray photoelectron spectroscopy (XPS).


Some blood collection tubes, as sold, contain an aqueous reagent, for example EDTA, heparin or sodium citrate, to preserve the blood between the times of collection and analysis. Some such reagents can attack and dissolve the barrier coating over time, leading to increased permeation of external atmospheric gas, reduction in the vacuum level, and thus a shorter shelf life of the barrier-coated thermoplastic evacuated blood collection tubes.


Since many of these blood collection vessels are inexpensive and used in large quantities, for certain applications it will be useful to reliably obtain the necessary shelf life without increasing the manufacturing cost to a prohibitive level.


Thus, there is a desire for plastic pharmaceutical packages or other vessels, in particular plastic vessels, with gas and solute barrier properties which approach the properties of glass without unduly increasing the manufacturing cost.


SUMMARY

A first embodiment is a blood sample collection tube comprising a wall and a coating set on the surface. The wall has an interior surface comprising a cyclic olefin polymer (COP) or a cyclic olefin copolymer (COC). The coating set on the surface comprises a tie coating or layer, a barrier coating or layer, and a pH protective coating or layer.


In this first embodiment, the tie coating or layer comprises SiOxCy or SiNxCy wherein x is from about 0.5 to about 2.4 and y is from about 0.6 to about 3. The tie coating or layer has an outer surface facing the wall surface, and the tie coating or layer has an interior surface.


In this first embodiment, the barrier coating or layer comprises SiOx, wherein x is from 1.5 to 2.9, and is from 2 to 1000 nm thick. The barrier coating or layer of SiOx has an outer surface facing the interior surface of the tie coating or layer, and the barrier coating or layer of SiOx has an interior surface. The barrier coating or layer is effective to reduce the ingress of atmospheric gas through the wall compared to an uncoated wall.


In this first embodiment, the pH protective coating or layer comprises SiOxCy or SiNxCy wherein x is from about 0.5 to about 2.4 and y is from about 0.6 to about 3. The pH protective coating or layer can be formed on the barrier coating or layer. The pH protective coating or layer is formed by chemical vapor deposition of a precursor selected from an acyclic siloxane, a monocyclic siloxane, a polycyclic siloxane, a polysilsesquioxane, a monocyclic silazane, a polycyclic silazane, a polysilsesquiazane, a silatrane, a silquasilatrane, a silproatrane, an azasilatrane, an azasilquasiatrane, an azasilproatrane, or a combination of any two or more of these precursors.


In this first embodiment, the rate of erosion of the pH protective coating or layer, if directly contacted by a fluid composition having a pH at some point between 5 and 9, is less than the rate of erosion of the barrier coating or layer, if directly contacted by the fluid composition.


A second embodiment is a blood sample collection tube comprising a vessel having a lumen defined at least in part by a wall. The wall has an interior surface comprising a cyclic olefin polymer (COP) or a cyclic olefin copolymer (COC) facing the lumen, and the wall has an outer surface. A coating set on the interior surface comprises a tie coating or layer, a barrier coating or layer, and a pH protective coating or layer.


In this second embodiment, the tie coating or layer comprises SiOxCy or SiNxCy wherein x is from about 0.5 to about 2.4 and y is from about 0.6 to about 3. The tie coating or layer has an interior surface facing the lumen and an outer surface facing the wall interior surface.


In this second embodiment, the barrier coating or layer comprises SiOx, wherein x is from 1.5 to 2.9, from 2 to 1000 nm thick. The barrier coating or layer of SiOx has an interior surface facing the lumen and an outer surface facing the interior surface of the tie coating or layer. The barrier coating or layer is effective to reduce the ingress of atmospheric gas into the lumen compared to an vessel without a barrier coating or layer.


In this second embodiment, the pH protective coating or layer comprises SiOxCy or SiNxCy wherein x is from about 0.5 to about 2.4 and y is from about 0.6 to about 3. The pH protective coating or layer has an interior surface facing the lumen and an outer surface facing the interior surface of the barrier coating or layer.


In this second embodiment, the combination of the tie coating or layer and the pH protective coating or layer is effective to increase the calculated shelf life of the package (total Si/Si dissolution rate).


In this second embodiment, a fluid composition is contained in the lumen and has a pH between 5 and 9.


In this second embodiment, the calculated shelf life of the package is more than six months at a storage temperature of 4° C.


A third embodiment is a blood sample collection tube comprising a thermoplastic wall, a fluid composition, a tie coating or layer, a barrier coating or layer, and a pH protective coating or layer.


In this third embodiment, the thermoplastic wall has an interior surface comprising a cyclic olefin polymer (COP) or a cyclic olefin copolymer (COC) and encloses a lumen.


In this third embodiment, the fluid composition contained in the lumen has a pH greater than 5 and is disposed in the lumen.


In this third embodiment, the tie coating or layer comprises SiOxCy or SiNxCy wherein x is from about 0.5 to about 2.4 and y is from about 0.6 to about 3. The tie coating or layer has an outer surface facing the wall surface, and the tie coating or layer has an interior surface.


In this third embodiment, in the barrier coating or layer of SiOx, x is between 1.5 and 2.9. The barrier coating or layer is applied by plasma-enhanced chemical vapor deposition (PECVD). The barrier coating or layer is positioned between the interior surface of the tie coating or layer and the fluid composition, and the barrier coating or layer is supported by the thermoplastic wall. The barrier coating or layer has the characteristic of being subject to being measurably diminished in barrier improvement factor in less than six months as a result of attack by the fluid composition.


In this third embodiment, in the pH protective coating or layer of SiOxCy, x is between 0.5 and 2.4 and y is between 0.6 and 3. The pH protective coating or layer is applied by PECVD, and the pH protective coating or layer is positioned between the barrier coating or layer and the fluid composition and supported by the thermoplastic wall. The pH protective coating or layer and the tie coating or layer together are effective to keep the barrier coating or layer at least substantially undissolved as a result of attack by the fluid composition for a period of at least six months.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 shows a plastic vessel of any type provided with a trilayer coating according to any embodiment.



FIG. 2 is a detail view of the plastic vessel of FIG. 1.



FIG. 3 corresponds to FIG. 23 of U.S. Pat. No. 7,985,188 and shows a vessel 268 configured as an evacuated blood collection tube according to any embodiment. In FIG. 3 the closure 270 is an assembly of a stopper and a shield with the vessel 268.



FIG. 4 is a plot of silicon dissolution versus exposure time at pH 6 for a glass container versus a plastic container having an SiOx barrier layer coated in the inside wall according to any embodiment.



FIG. 5 is a plot of silicon dissolution versus exposure time at pH 7 for a glass container versus a plastic container having an SiOx barrier layer coated in the inside wall according to any embodiment.



FIG. 6 is a plot of silicon dissolution versus exposure time at pH 8 for a glass container versus a plastic container having an SiOx barrier layer coated in the inside wall according to any embodiment.



FIG. 7 is a plot of the SiOx coating thickness necessary initially to leave a 30 nm residual coating thickness when stored with solutions at different nominal pH values from 3 to 9 according to any embodiment.



FIG. 8 shows the silicon dissolution rates at pH 8 and 40° C. of various PECVD coatings according to any embodiment.



FIG. 9 is a plot of the ratio of Si—O—Si symmetric/asymmetric stretching mode versus energy input per unit mass (W/FM or KJ/kg) of a PECVD coating using as the reactive precursor gases OMCTS and oxygen according to any embodiment.



FIG. 10 is a plot of silicon shelf life (days) versus energy input per unit mass (W/FM or KJ/kg) of a PECVD coating using as the reactive precursor gases OMCTS and oxygen. according to any embodiment



FIG. 11 is a Fourier Transform Infrared Spectrophotometer (FTIR) absorbance spectrum of a PECVD coating according to any embodiment.



FIG. 12 is a Fourier Transform Infrared Spectrophotometer (FTIR) absorbance spectrum of a PECVD coating according to any embodiment.



FIG. 13 is a Fourier Transform Infrared Spectrophotometer (FTIR) absorbance spectrum of a PECVD coating according to any embodiment.



FIG. 14 is a Fourier Transform Infrared Spectrophotometer (FTIR) absorbance spectrum of a PECVD coating according to any embodiment.



FIG. 15 is a Fourier Transform Infrared Spectrophotometer (FTIR) absorbance spectrum of a PECVD coating, originally presented as FIG. 5 of U.S. Pat. No. 8,067,070, annotated to show the calculation of the O-Parameter referred to in that patent, according to any embodiment.



FIG. 16 is a schematic view of a syringe with a trilayer coating according to FIGS. 1, 2, and 3, showing a cylindrical region and specific points where data was taken, according to any embodiment.



FIG. 17 is a Trimetric map of the overall trilayer coating thickness versus position in the cylindrical region of a syringe illustrated by FIGS. 16, 1, and 2, representing a vessel according to any embodiment.



FIG. 18 is a photomicrograhic sectional view showing the substrate and coatings of the trilayer coating at position 2 shown in FIG. 16, according to any embodiment.



FIG. 19 is another Trimetric map of the overall trilayer coating thickness versus position in the cylindrical region of a vessel illustrated by FIGS. 16, 1, and 2, according to any embodiment.



FIG. 20 is a plot of coating thickness, representing the same coating as FIG. 19, at Positions 1, 2, 3, and 4 shown in FIG. 16, according to any embodiment.



FIG. 21 is a schematic illustration of a vessel, showing points on its surface where measurements were made in a working example, according to any embodiment.



FIG. 22 is a photograph showing the benefit of the present trilayer coating in preventing pinholes after attack by an alkaline reagent, as discussed in the working examples, according to any embodiment.



FIG. 22A is an enlarged detail view of the indicated portion of FIG. 22, according to any embodiment.



FIG. 23 is a view similar to FIG. 3 showing a vessel 268 configured as an evacuated blood collection tube according to any embodiment containing a fluid 218.





The following reference characters are used in the drawing figures according to any embodiment:


















210
Pharmaceutical package



212
Lumen



214
Wall



218
Fluid



268
Vessel



270
Closure



274
Lumen



285
Vessel coating or layer set



285a
Closure coating or layer set




(inner surface)



285b
Closure coating or layer set




(side surface)



286
pH protective coating or layer



288
Barrier layer



289
Tie coating or layer










In the context of the present invention, the following definitions and abbreviations are used:


The word “comprising” according to any embodiment does not exclude other elements or steps, and the indefinite article “a” or “an” does not exclude a plurality unless indicated otherwise. Whenever a parameter range is indicated, it is intended to disclose the parameter values given as limits of the range and all values of the parameter falling within said range.


“First” and “second” or similar references to, for example, deposits of coatings or layers, processing stations or processing devices according to any embodiment refer to the minimum number of deposits, processing stations or devices that are present, but do not necessarily represent the order or total number of deposits, processing stations and devices or require additional deposits, processing stations and devices beyond the stated number. These terms do not limit the number of processing stations or the particular processing carried out at the respective stations. For example, a “first” deposit in the context of this specification can be either the only deposit or any one of plural deposits, without limitation. In other words, recitation of a “first” deposit allows but does not require an embodiment that also has a second or further deposit.


For purposes of the present invention according to any embodiment, an “organosilicon precursor” is a compound having at least one of the linkages:




embedded image



which is a tetravalent silicon atom connected to an oxygen or nitrogen atom and an organic carbon atom (an organic carbon atom being a carbon atom bonded to at least one hydrogen atom). A volatile organosilicon precursor, defined as such a precursor that can be supplied as a vapor in a PECVD apparatus, is an optional organosilicon precursor. Optionally, the organosilicon precursor is a linear siloxane or a monocyclic siloxane, or a combination of any two or more of these precursors.


A “vessel” in the context of the present invention can be any type of vessel with at least one opening and a wall defining an inner or interior surface, according to any embodiment. The substrate can be the wall of a vessel having a lumen, according to any embodiment.


The term “at least” in the context of the present invention according to any embodiment means “equal or more” than the integer following the term. Thus, a vessel in the context of the present invention has one or more openings. One or two openings, like the openings of a sample tube (one opening) or a vessel (two openings) are preferred. A vessel according to the present invention can be a sample tube, for example for collecting or storing biological fluids like blood according to any embodiment.


A vessel according to any embodiment can be of any shape, a vessel having a substantially cylindrical wall adjacent to at least one of its open ends being preferred. Generally, the interior wall of the vessel is cylindrically shaped, like, for example in a sample tube. Sample tubes are contemplated, according to any embodiment.


The values of w, x, y, and z according to any embodiment are applicable to the empirical composition SiwOxCyHz throughout this specification. The values of w, x, y, and z used throughout this specification should be understood as ratios or an empirical formula (for example for a coating or layer), rather than as a limit on the number or type of atoms in a molecule. For example, octamethylcyclotetrasiloxane, which has the molecular composition Si4O4C8H24, can be described by the following empirical formula, arrived at by dividing each of w, x, y, and z in the molecular formula by 4, the largest common factor: Si1O1C2H6. The values of w, x, y, and z are also not limited to integers according to any embodiment. For example, (acyclic) octamethyltrisiloxane, molecular composition Si3O2C8H24, is reducible to Si1O0.67C2.67H8. Also, although SiOxCyHz is described as equivalent to SiOxCy according to any embodiment, it is not necessary to show the presence of hydrogen in any proportion to show the presence of SiOxCy.


The atomic ratio according to any embodiment can be determined by XPS. Taking into account the H atoms, which are not measured by XPS, the coating or layer may thus in one aspect have the formula SiwOxCyHz (or its equivalent SiOxCy), for example where w is 1, x is from about 0.5 to about 2.4, y is from about 0.6 to about 3, and z is from about 2 to about 9.


DETAILED DESCRIPTION

The present invention will now be described more fully, with reference to the accompanying drawings, according to any embodiment. This invention can, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth here. Rather, these embodiments are examples, which has the full scope indicated by the language of the claims. Like numbers refer to like or corresponding elements throughout. The following disclosure relates to all embodiments unless specifically limited to a certain embodiment.


Vessels and Coating Sets


Every embodiment, illustrated most broadly by FIGS. 1 and 2, is a vessel 210 including a wall 214 enclosing a lumen 212 and a vessel coating or layer set 285 on at least a portion of the wall 214 facing the lumen 212. FIG. 1 shows a vessel having at least a single opening; vessels having two openings or more than two openings are also contemplated in any embodiment.


The vessel 210 in any embodiment may also include a closure as shown generically in FIG. 1. Several examples of the closure of FIG. 1 are a stopper, septum, or the like.


The vessel in any embodiment is made of a thermoplastic material, for example cyclic olefin polymer (COP) or cyclic olefin copolymer (COC).


An embodiment of the vessel coating or layer set 285, 285a, or 285b in any embodiment is at least one tie coating or layer 289, at least one barrier coating or layer 288, and at least one pH protective coating or layer 286, illustrated in FIGS. 1-2 and present in any embodiment. This vessel coating or layer set is sometimes known as a “trilayer coating” in which the barrier coating or layer 288 of SiOx is protected against contents having a pH otherwise high enough to remove it by being sandwiched between the pH protective coating or layer 286 and the tie coating or layer 289, each an organic layer of SiOxCy as defined in this specification. Specific examples of this trilayer coating in any embodiment are provided in this specification. The contemplated thicknesses of the respective layers in nm (preferred ranges in parentheses) are given in the Trilayer Thickness Table.












Trilayer Thickness Table









Adhesion
Barrier
Protection





 5-100
 20-200
 50-500


(5-20)
(20-30)
(100-200)









The trilayer coating set 285 includes as a first layer an adhesion or tie coating or layer 289 that improves adhesion of the barrier coating or layer to the COP substrate. The adhesion or tie coating or layer 289 is also believed to relieve stress on the barrier coating or layer 288, making the barrier layer less subject to damage from thermal expansion or contraction or mechanical shock. The adhesion or tie coating or layer 289 is also believed to decouple defects between the barrier coating or layer 288 and the COP substrate. This is believed to occur because any pinholes or other defects that may be formed when the adhesion or tie coating or layer 289 is applied tend not to be continued when the barrier coating or layer 288 is applied, so the pinholes or other defects in one coating do not line up with defects in the other. The adhesion or tie coating or layer 289 has some efficacy as a barrier layer, so even a defect providing a leakage path extending through the barrier coating or layer 289 is blocked by the adhesion or tie coating or layer 289.


The trilayer coating set 285 includes as a second layer a barrier coating or layer 288 that provides a barrier to oxygen that has permeated the COP wall. The barrier coating or layer 288 also is a barrier to extraction of the composition of the vessel wall 214 by the contents of the lumen 214.


The trilayer coating set 285 includes as a third layer a pH protective coating or layer 286 that provides protection of the underlying barrier coating or layer 288 against contents of the vessel, including where a surfactant is present.


The features of each layer of the trilayer coating set are further described below.


Tie Coating or Layer


The tie coating or layer 289 has at least two functions. One function of the tie coating or layer 289 is to improve adhesion of a barrier coating or layer 288 to a substrate, in particular a thermoplastic substrate. For example, a tie coating or layer, also referred to as an adhesion layer or coating can be applied to the substrate and the barrier layer can be applied to the adhesion layer to improve adhesion of the barrier layer or coating to the substrate.


Another function of the tie coating or layer 289 has been discovered: a tie coating or layer 289 applied under a barrier coating or layer 288 can improve the function of a pH protective coating or layer 286 applied over the barrier coating or layer 288.


The tie coating or layer 289 can be composed of, comprise, or consist essentially of SiOxCy, in which x is between 0.5 and 2.4 and y is between 0.6 and 3. Alternatively, the atomic ratio can be expressed as the formula SiwOxCy, The atomic ratios of Si, O, and C in the tie coating or layer 289 are, as several options:

    • Si 100: O 50-150: C 90-200 (i.e. w=1, x=0.5 to 1.5, y=0.9 to 2);
    • Si 100: O 70-130: C 90-200 (i.e. w=1, x=0.7 to 1.3, y=0.9 to 2)
    • Si 100: O 80-120: C 90-150 (i.e. w=1, x=0.8 to 1.2, y=0.9 to 1.5)
    • Si 100: O 90-120: C 90-140 (i.e. w=1, x=0.9 to 1.2, y=0.9 to 1.4), or
    • Si 100: O 92-107: C 116-133 (i.e. w=1, x=0.92 to 1.07, y=1.16 to 1.33)


The atomic ratio can be determined by XPS. Taking into account the H atoms, which are not measured by XPS, the tie coating or layer 289 may thus in one aspect have the formula SiwOxCyHz (or its equivalent SiOxCy), for example where w is 1, x is from about 0.5 to about 2.4, y is from about 0.6 to about 3, and z is from about 2 to about 9. Typically, tie coating or layer 289 would hence contain 36% to 41% carbon normalized to 100% carbon plus oxygen plus silicon.


Optionally, the tie coating or layer can be similar or identical in composition with the pH protective coating or layer 286 described elsewhere in this specification, although this is not a requirement.


The tie coating or layer 289 is contemplated generally to be from 5 nm to 100 nm thick, preferably from 5 to 20 nm thick, particularly if applied by chemical vapor deposition. These thicknesses are not critical. Commonly but not necessarily, the tie coating or layer 289 will be relatively thin, since its function is to change the surface properties of the substrate.


Barrier Layer


A barrier coating or layer 288 optionally can be deposited by plasma enhanced chemical vapor deposition (PECVD) or other chemical vapor deposition processes on the vessel of a pharmaceutical package, in particular a thermoplastic package, to prevent oxygen, carbon dioxide, or other gases from entering the vessel and/or to prevent leaching of the pharmaceutical material into or through the package wall.


The barrier coating or layer for any embodiment defined in this specification (unless otherwise specified in a particular instance) is a coating or layer, optionally applied by PECVD as indicated in U.S. Pat. No. 7,985,188. The barrier layer optionally is characterized as an “SiOx” coating, and contains silicon, oxygen, and optionally other elements, in which x, the ratio of oxygen to silicon atoms, is from about 1.5 to about 2.9, or 1.5 to about 2.6, or about 2. These alternative definitions of x apply to any use of the term SiOx in this specification. The barrier coating or layer is applied, for example to the interior of a pharmaceutical package or other vessel, for example a sample collection tube or another type of vessel.


The barrier coating 288 comprises or consists essentially of SiOx, wherein x is from 1.5 to 2.9, from 2 to 1000 nm thick, the barrier coating 288 of SiOx having an interior surface 220 facing the lumen 212 and an outer surface 222 facing the wall 214 article surface 254, the barrier coating 288 being effective to reduce the ingress of atmospheric gas into the lumen 212 compared to an uncoated vessel 250. One suitable barrier composition is one where x is 2.3, for example. For example, the barrier coating or layer such as 288 of any embodiment can be applied at a thickness of at least 2 nm, or at least 4 nm, or at least 7 nm, or at least 10 nm, or at least 20 nm, or at least 30 nm, or at least 40 nm, or at least 50 nm, or at least 100 nm, or at least 150 nm, or at least 200 nm, or at least 300 nm, or at least 400 nm, or at least 500 nm, or at least 600 nm, or at least 700 nm, or at least 800 nm, or at least 900 nm. The barrier coating or layer can be up to 1000 nm, or at most 900 nm, or at most 800 nm, or at most 700 nm, or at most 600 nm, or at most 500 nm, or at most 400 nm, or at most 300 nm, or at most 200 nm, or at most 100 nm, or at most 90 nm, or at most 80 nm, or at most 70 nm, or at most 60 nm, or at most 50 nm, or at most 40 nm, or at most 30 nm, or at most 20 nm, or at most 10 nm, or at most 5 nm thick. Ranges of 20-200 nm, optionally 20-30 nm, are contemplated. Specific thickness ranges composed of any one of the minimum thicknesses expressed above, plus any equal or greater one of the maximum thicknesses expressed above, are expressly contemplated.


The thickness of the SiOx or other barrier coating or layer can be measured, for example, by transmission electron microscopy (TEM), and its composition can be measured by X-ray photoelectron spectroscopy (XPS). The pH protective coating or layer described herein can be applied to a variety of pharmaceutical packages or other vessels made from plastic or glass, for example to plastic tubes, vessels, and syringes.


A barrier coating or layer 286 of SiOx, in which x is between 1.5 and 2.9, is applied by plasma enhanced chemical vapor deposition (PECVD) directly or indirectly to the thermoplastic wall 214 (for example a tie coating or layer 289 can be interposed between them) so that in the filled pharmaceutical package or other vessel 210 the barrier coating or layer 286 is located between the inner or interior surface 220 of the thermoplastic wall 214 and the fluid 218.


The barrier coating or layer 286 of SiOx is supported by the thermoplastic wall 214. The barrier coating or layer 286 as described elsewhere in this specification, or in U.S. Pat. No. 7,985,188, can be used in any embodiment.


Certain barrier coatings or layers 286 such as SiOx as defined here have been found to have the characteristic of being subject to being measurably diminished in barrier improvement factor in less than six months as a result of attack by certain relatively high pH contents of the coated vessel as described elsewhere in this specification, particularly where the barrier coating or layer directly contacts the contents. This issue can be addressed using a pH protective coating or layer as discussed in this specification.


pH Protective Coating or Layer


The inventors have found that barrier layers or coatings of SiOx are eroded or dissolved by some fluids, for example aqueous compositions having a pH above about 5. Since coatings applied by chemical vapor deposition can be very thin—tens to hundreds of nanometers thick—even a relatively slow rate of erosion can remove or reduce the effectiveness of the barrier layer in less time than the desired shelf life of a product package. This is particularly a problem for fluid pharmaceutical compositions, since many of them have a pH of roughly 7, or more broadly in the range of 5 to 9, similar to the pH of blood and other human or animal fluids. The higher the pH of the pharmaceutical preparation, the more quickly it erodes or dissolves the SiOx coating. Optionally, this problem can be addressed by protecting the barrier coating or layer 288, or other pH sensitive material, with a pH protective coating or layer 286.


Optionally, the pH protective coating or layer 286 can be composed of, comprise, or consist essentially of SiwOxCyHz (or its equivalent SiOxCy) or SiwNxCyHz or its equivalent SiNxCy), each as defined previously. The atomic ratio of Si:O:C or Si:N:C can be determined by XPS (X-ray photoelectron spectroscopy). Taking into account the H atoms, the pH protective coating or layer may thus in one aspect have the formula SiwOxCyHz, or its equivalent SiOxCy, for example where w is 1, x is from about 0.5 to about 2.4, y is from about 0.6 to about 3, and z is from about 2 to about 9.


Typically, expressed as the formula SiwOxCy, the atomic ratios of Si, O, and C are, as several options:

    • Si 100: O 50-150: C 90-200 (i.e. w=1, x=0.5 to 1.5, y=0.9 to 2);
    • Si 100: O 70-130: C 90-200 (i.e. w=1, x=0.7 to 1.3, y=0.9 to 2)
    • Si 100: O 80-120: C 90-150 (i.e. w=1, x=0.8 to 1.2, y=0.9 to 1.5)
    • Si 100: O 90-120: C 90-140 (i.e. w=1, x=0.9 to 1.2, y=0.9 to 1.4)
    • Si 100: O 92-107: C 116-133 (i.e. w=1, x=0.92 to 1.07, y=1.16 to 1.33), or
    • Si 100: O 80-130: C 90-150.


Alternatively, the pH protective coating or layer can have atomic concentrations normalized to 100% carbon, oxygen, and silicon, as determined by X-ray photoelectron spectroscopy (XPS) of less than 50% carbon and more than 25% silicon. Alternatively, the atomic concentrations are from 25 to 45% carbon, 25 to 65% silicon, and 10 to 35% oxygen. Alternatively, the atomic concentrations are from 30 to 40% carbon, 32 to 52% silicon, and 20 to 27% oxygen. Alternatively, the atomic concentrations are from 33 to 37% carbon, 37 to 47% silicon, and 22 to 26% oxygen.


The thickness of the pH protective coating or layer can be, for example:

    • from 10 nm to 1000 nm;
    • alternatively from 10 nm to 1000 nm;
    • alternatively from 10 nm to 900 nm;
    • alternatively from 10 nm to 800 nm;
    • alternatively from 10 nm to 700 nm;
    • alternatively from 10 nm to 600 nm;
    • alternatively from 10 nm to 500 nm;
    • alternatively from 10 nm to 400 nm;
    • alternatively from 10 nm to 300 nm;
    • alternatively from 10 nm to 200 nm;
    • alternatively from 10 nm to 100 nm;
    • alternatively from 10 nm to 50 nm;
    • alternatively from 20 nm to 1000 nm;
    • alternatively from 50 nm to 1000 nm;
    • alternatively from 10 nm to 1000 nm;
    • alternatively from 50 nm to 800 nm;
    • alternatively from 100 nm to 700 nm;
    • alternatively from 300 to 600 nm.


Optionally, the atomic concentration of carbon in the protective layer, normalized to 100% of carbon, oxygen, and silicon, as determined by X-ray photoelectron spectroscopy (XPS), can be greater than the atomic concentration of carbon in the atomic formula for the organosilicon precursor. For example, embodiments are contemplated in which the atomic concentration of carbon increases by from 1 to 80 atomic percent, alternatively from 10 to 70 atomic percent, alternatively from 20 to 60 atomic percent, alternatively from 30 to 50 atomic percent, alternatively from 35 to 45 atomic percent, alternatively from 37 to 41 atomic percent.


Optionally, the atomic ratio of carbon to oxygen in the pH protective coating or layer can be increased in comparison to the organosilicon precursor, and/or the atomic ratio of oxygen to silicon can be decreased in comparison to the organosilicon precursor.


Optionally, the pH protective coating or layer can have an atomic concentration of silicon, normalized to 100% of carbon, oxygen, and silicon, as determined by X-ray photoelectron spectroscopy (XPS), less than the atomic concentration of silicon in the atomic formula for the feed gas. For example, embodiments are contemplated in which the atomic concentration of silicon decreases by from 1 to 80 atomic percent, alternatively by from 10 to 70 atomic percent, alternatively by from 20 to 60 atomic percent, alternatively by from 30 to 55 atomic percent, alternatively by from 40 to 50 atomic percent, alternatively by from 42 to 46 atomic percent.


As another option, a pH protective coating or layer is contemplated that can be characterized by a sum formula wherein the atomic ratio C:O can be increased and/or the atomic ratio Si:O can be decreased in comparison to the sum formula of the organosilicon precursor.


The pH protective coating or layer 286 commonly is located between the barrier coating or layer 288 and the fluid 218 in the finished article such as the pharmaceutical package 210 shown in FIG. 23. In this instance, the pharmaceutical package 210 is a blood sample collection tube or other vessel 268, shown for example in FIG. 3, containing a reagent or other fluid 218 as shown in FIG. 23, and evacuated to facilitate its use for collecting an intravenous blood sample. One non-limiting example of a reagent is an aqueous sodium citrate reagent, which is suitable for preventing or reducing blood coagulation The pH protective coating or layer 286 is supported by the thermoplastic wall 214.


The pH protective coating or layer 286 optionally is effective to keep the barrier coating or layer 288 at least substantially undissolved as a result of attack by the fluid 218 for a period of at least six months.


The pH protective coating or layer can have a density between 1.25 and 1.65 g/cm3, alternatively between 1.35 and 1.55 g/cm3, alternatively between 1.4 and 1.5 g/cm3, alternatively between 1.4 and 1.5 g/cm3, alternatively between 1.44 and 1.48 g/cm3, as determined by X-ray reflectivity (XRR). Optionally, the organosilicon compound can be octamethylcyclotetrasiloxane and the pH protective coating or layer can have a density which can be higher than the density of a pH protective coating or layer made from HMDSO as the organosilicon compound under the same PECVD reaction conditions.


The pH protective coating or layer optionally can prevent or reduce the precipitation of a compound or component of a composition in contact with the pH protective coating or layer, in particular can prevent or reduce insulin precipitation or blood clotting, in comparison to the uncoated surface and/or to a barrier coated surface using HMDSO as precursor.


The interior surface of the pH protective coating or layer optionally can have a contact angle (with distilled water) of from 90° to 110°, optionally from 80° to 120°, optionally from 70° to 130°, as measured by Goniometer Angle measurement of a water droplet on the pH protective surface, per ASTM D7334-08 “Standard Practice for Surface Wettability of Coatings, Substrates and Pigments by Advancing Contact Angle Measurement.”


The passivation layer or pH protective coating or layer 286 optionally shows an O-Parameter measured with attenuated total reflection (ATR) of less than 0.4, measured as:







O


-


Parameter

=



Intensity





at





1253





cm

-
1



Maximum





intensity





in





the





range





1000





to





1100





cm

-
1






The O-Parameter is defined in U.S. Pat. No. 8,067,070, which claims an O-parameter value of most broadly from 0.4 to 0.9. It can be measured from physical analysis of an FTIR amplitude versus wave number plot to find the numerator and denominator of the above expression, as shown in FIG. 15, which is the same as FIG. 5 of U.S. Pat. No. 8,067,070, except annotated to show interpolation of the wave number and absorbance scales to arrive at an absorbance at 1253 cm−1 of 0.0424 and a maximum absorbance at 1000 to 1100 cm−1 of 0.08, resulting in a calculated O-parameter of 0.53. The O-Parameter can also be measured from digital wave number versus absorbance data.


U.S. Pat. No. 8,067,070 asserts that the claimed O-parameter range provides a superior pH protective coating or layer, relying on experiments only with HMDSO and HMDSN, which are both non-cyclic siloxanes. Surprisingly, it has been found by the present inventors that if the PECVD precursor is a cyclic siloxane, for example OMCTS, O-parameters outside the ranges claimed in U.S. Pat. No. 8,067,070, using OMCTS, provide even better results than are obtained in U.S. Pat. No. 8,067,070 with HMDSO.


Alternatively in any embodiment, the O-parameter has a value of from 0.1 to 0.39, or from 0.15 to 0.37, or from 0.17 to 0.35.


Even another aspect is a composite material according to any embodiment, wherein the passivation layer shows an N-Parameter measured with attenuated total reflection (ATR) of less than 0.7, measured as:







N


-


Parameter

=



Intensity





at





840






cm

-
1




Intensity





at





799






cm

-
1




.





The N-Parameter is also described in U.S. Pat. No. 8,067,070, and is measured analogously to the O-Parameter except that intensities at two specific wave numbers are used—neither of these wave numbers is a range. U.S. Pat. No. 8,067,070 claims a passivation layer with an N-Parameter of 0.7 to 1.6. Again, the present inventors have made better coatings employing a pH protective coating or layer 286 having an N-Parameter lower than 0.7, as described above. Alternatively, the N-parameter has a value of at least 0.3, or from 0.4 to 0.6, or at least 0.53.


The rate of erosion, dissolution, or leaching (different names for related concepts) of the pH protective coating or layer 286, if directly contacted by the fluid 218, is less than the rate of erosion of the barrier coating or layer 288, if directly contacted by the fluid 218.


The thickness of the pH protective coating or layer is contemplated to be from 50-500 nm, with a preferred range of 100-200 nm.


The pH protective coating or layer 286 is effective to isolate the fluid 218 from the barrier coating or layer 288, at least for sufficient time to allow the barrier coating to act as a barrier during the shelf life of the pharmaceutical package or other vessel 210.


The inventors have further found that certain pH protective coatings or layers of SiOxCy or SiNxCy formed from cyclic polysiloxane precursors, which pH protective coatings or layers have a substantial organic component, do not erode quickly when exposed to fluids, and in fact erode or dissolve more slowly when the fluids have higher pHs within the range of 5 to 9. For example, at pH 8, the dissolution rate of a pH protective coating or layer made from the precursor octamethylcyclotetrasiloxane, or OMCTS, is quite slow. These pH protective coatings or layers of SiOxCy or SiNxCy can therefore be used to cover a barrier layer of SiOx, retaining the benefits of the barrier layer by protecting it from the fluid in the pharmaceutical package. The protective layer is applied over at least a portion of the SiOx layer to protect the SiOx layer from contents stored in a vessel, where the contents otherwise would be in contact with the SiOx layer.


Although the present invention does not depend upon the accuracy of the following theory, it is further believed that effective pH protective coatings or layers for avoiding erosion can be made from cyclic siloxanes and silazanes as described in this disclosure. SiOxCy or SiNxCy coatings deposited from cyclic siloxane or linear silazane precursors, for example octamethylcyclotetrasiloxane (OMCTS), are believed to include intact cyclic siloxane rings and longer series of repeating units of the precursor structure. These coatings are believed to be nanoporous but structured and hydrophobic, and these properties are believed to contribute to their success as pH protective coatings or layers, and also protective coatings or layers. This is shown, for example, in U.S. Pat. No. 7,901,783.


SiOxCy or SiNxCy coatings also can be deposited from linear siloxane or linear silazane precursors, for example hexamethyldisiloxane (HMDSO) or tetramethyldisiloxane (TMDSO).


Optionally an FTIR absorbance spectrum of the pH protective coating or layer 286 of any embodiment has a ratio greater than 0.75 between the maximum amplitude of the Si—O—Si symmetrical stretch peak normally located between about 1000 and 1040 cm-1, and the maximum amplitude of the Si—O—Si assymmetric stretch peak normally located between about 1060 and about 1100 cm-1. Alternatively in any embodiment, this ratio can be at least 0.8, or at least 0.9, or at least 1.0, or at least 1.1, or at least 1.2. Alternatively in any embodiment, this ratio can be at most 1.7, or at most 1.6, or at most 1.5, or at most 1.4, or at most 1.3. Any minimum ratio stated here can be combined with any maximum ratio stated here, as an alternative embodiment.


Optionally, in any embodiment the pH protective coating or layer 286, in the absence of the medicament, has a non-oily appearance. This appearance has been observed in some instances to distinguish an effective pH protective coating or layer from a lubricity layer, which in some instances has been observed to have an oily (i.e. shiny) appearance.


Optionally, for the pH protective coating or layer 286 in any embodiment, the silicon dissolution rate by a 50 mM potassium phosphate buffer diluted in water for injection, adjusted to pH 8 with concentrated nitric acid, and containing 0.2 wt. % polysorbate-80 surfactant, (measured in the absence of the medicament, to avoid changing the dissolution reagent), at 40° C., is less than 170 ppb/day. (Polysorbate-80 is a common ingredient of pharmaceutical preparations, available for example as Tween®-80 from Uniqema Americas LLC, Wilmington Del.)


Optionally, for the pH protective coating or layer 286 in any embodiment, the silicon dissolution rate is less than 160 ppb/day, or less than 140 ppb/day, or less than 120 ppb/day, or less than 100 ppb/day, or less than 90 ppb/day, or less than 80 ppb/day. Optionally, in any embodiment the silicon dissolution rate is more than 10 ppb/day, or more than 20 ppb/day, or more than 30 ppb/day, or more than 40 ppb/day, or more than 50 ppb/day, or more than 60 ppb/day. Any minimum rate stated here can be combined with any maximum rate stated here for the pH protective coating or layer 286 in any embodiment.


Optionally, for the pH protective coating or layer 286 in any embodiment the total silicon content of the pH protective coating or layer and barrier coating, upon dissolution into a test composition with a pH of 8 from the vessel, is less than 66 ppm, or less than 60 ppm, or less than 50 ppm, or less than 40 ppm, or less than 30 ppm, or less than 20 ppm.


pH Protective Coating or Layer Properties of any Embodiment Theory of Operation


The inventors offer the following theory of operation of the pH protective coating or layer described here. The invention is not limited by the accuracy of this theory or to the embodiments predictable by use of this theory.


The dissolution rate of the SiOx barrier layer is believed to be dependent on SiO bonding within the layer. Oxygen bonding sites (silanols) are believed to increase the dissolution rate.


It is believed that the OMCTS-based pH protective coating or layer bonds with the silanol sites on the SiOx barrier layer to “heal” or passivate the SiOx surface and thus dramatically reduces the dissolution rate. In this hypothesis, the thickness of the OMCTS layer is not the primary means of protection—the primary means is passivation of the SiOx surface. It is contemplated that a pH protective coating or layer as described in this specification can be improved by increasing the crosslink density of the pH protective coating or layer.


Use of a coating or layer according to any described embodiment is contemplated as a pH protective coating or layer preventing dissolution of the barrier coating in contact with a fluid.


EXAMPLES
Example 1: Conditions for Production of pH Protective Layer

Some conditions optionally used for production of pH Protective Layers are shown in Table 1.









TABLE 1







OMCTS-BASED PLASMA PH PROTECTIVE COATING OR LAYER MADE WITH CARRIER GAS

















pH protective
protective
protective
Carrier
pH protective



pH protective

coating or
OMCTS
O2
Gas (Ar)
coating or


Example
coating or
PH protective
layer Time
Flow Rate
Flow Rate
Flow Rate
layer Power


1 run
layer Type
Monomer
(sec)
(sccm)
(sccm)
(sccm)
(Watts)





A
Uncoated
n/a
n/a
n/a
n/a
n/a
n/a


(Control)
COC


B
Silicon oil
n/a
n/a
n/a
n/a
n/a
n/a


(Industry
on COC


Standard)


C
L3 lubricity
OMCTS
10 sec
3
0
65
6


(without
coating or


Oxygen)
layer over



SiOx on COC


D
L2 pH
OMCTS
10 sec
3
1
65
6


(with
protective


Oxygen)
coating or



layer over



SiOx on COC









Examples 2-5

Vessel samples were produced as follows. A COC 8007 vessel was produced according to the Protocol for Forming COC Vessel. An SiOx barrier coating or layer was applied to the vessels according to the Protocol for Coating COC Vessel Interior with SiOx. A pH protective coating or layer was applied to the SiOx coated vessels according to the Protocol for Coating COC Vessel Interior with OMCTS, modified as follows. Argon carrier gas and oxygen were used where noted in Table 2.


The process conditions were set to the following, or as indicated in Table 2:

    • OMCTS—3 sccm (when used)
    • Argon gas—7.8 sccm (when used)
    • Oxygen 0.38 sccm (when used)
    • Power—3 watts
    • Power on time—10 seconds


      Vessels 2, 3, and 4 of the corresponding example numbers were tested to determine total extractable silicon levels (representing extraction of the organosilicon-based PECVD pH protective coating or layer) using the Protocol for Measuring Dissolved Silicon in a Vessel, modified and supplemented as shown in this example.


The silicon was extracted using saline water digestion. The vessel was filled with two milliliters of 0.9% aqueous saline solution and sealed. The vessel was set into a PTFE test stand and placed in an oven at 50° C. for 72 hours.


Then, the saline solution was removed from the vesseland the fluid obtained from each vessel was brought to a volume of 50 ml using 18.2M0-cm deionized water and further diluted 2× to minimize sodium background during analysis.


Next, the fluid recovered from each vessel was tested for extractable silicon using the Protocol for Measuring Dissolved Silicon in a Vessel. The instrument used was a Perkin Elmer Elan DRC II equipped with a Cetac ASX-520 autosampler. The following ICP-MS conditions were employed:

    • Nebulizer: Quartz Meinhardt
    • Spray Chamber: Cyclonic
    • RF (radio frequency) power: 1550 Watts
    • Argon (Ar) Flow: 15.0 L/min
    • Auxiliary Ar Flow: 1.2 L/min
    • Nebulizer Gas Flow: 0.88 L/min
    • Integration time: 80 sec
    • Scanning mode: Peak hopping
    • RPq (The RPq is a rejection parameter) for Cerium as CeO (m/z 156: <2%


Aliquots from aqueous dilutions obtained from vessels 2, 3, and 4 were injected and analyzed for Si in concentration units of micrograms per liter. The results of this test are shown in Table 2. While the results are not quantitative, they do indicate that extractables from the pH protective coating or layer are not clearly higher than the extractables for the SiOx barrier layer only.









TABLE 2







OMCTS PH PROTECTIVE COATING OR LAYER ((Ex. 2 and 3))












Example
OMCTS
O2
Ar



(Vessel)
(sccm)
(sccm)
(sccm)







2
3.0
0.38
7.8



3
3.0
0.38
7.8



4
n/a
n/a
n/a



(SiOxonly)



5
n/a
n/a
n/a



(silicon oil)










Examples 6-8

Vessel samples 6, 7, and 8, employing three different pH protective coatings or layers, were produced in the same manner as for Examples 2-5 except as otherwise indicated in Table 3:


Vessel 6 had a three-component pH protective coating or layer employing OMCTS, oxygen, and carrier gas. Vessel 7 had a two component pH protective coating or layer employing OMCTS and oxygen, but no carrier gas. Vessel 8 had a one-component pH protective coating or layer (OMCTS only). Vessels 6-8 were then tested for lubricity as described for Examples 2-5.


The pH protective coatings or layers produced according to these working examples are also contemplated to function as protective coatings or layers to increase the shelf life of the vessels, compared to similar vessels provided with a barrier coating or layer but no pH protective coating or layer.









TABLE 3





OMCTS pH PROTECTIVE COATING OR LAYER

















OMCTS - 2.5 sccm



Argon gas - 7.6 sccm (when used)



Oxygen 0.38 sccm (when used)



Power - 3 watts



Power on time - 10 seconds










Examples 9-11

Examples 6-8 using an OMCTS precursor gas were repeated in Examples 9-11, except that HMDSO was used as the precursor in Examples 9-11. The results are shown in Table 4. The coatings produced according to these working examples are contemplated to function as pH protective coatings or layers, and also as protective coatings or layers to increase the shelf life of the vessels, compared to similar vessels provided with a barrier coating or layer but no pH protective coating or layer.









TABLE 4







HMDSO pH PROTECTIVE COATING OR LAYER













HMDSO
O2
Ar



Example
(sccm)
(sccm)
(sccm)
















9
2.5
0.38
7.6



10
2.5
0.38




11
2.5












Example 12: PH Protective Coating or Layer Extractables

Silicon extractables from vessels were measured using ICP-MS analysis as described in the Protocol for Measuring Dissolved Silicon in a Vessel. The vessels were evaluated in both static and dynamic situations. The Protocol for Measuring Dissolved Silicon in a Vessel, modified as follows, describes the test procedure:

    • Vessel filled with 2 ml of 0.9% saline solution
    • Vessel placed in a stand—stored at 50° C. for 72 hours.
    • After 72 hours saline solution test for dissolved silicon
    • Dissolved silicon measured before and after saline solution expelled from vessel.


The extractable Silicon Levels from a silicon oil coated glass vessel and a protective coated and SiOx coated COC vessel are shown in Table 5. Precision of the ICP-MS total silicon measurement is +/−3%.









TABLE 5







Silicon Extractables Comparison of SiOxCyHz Coatings











Dynamic


Vessel Type
Static (ug/L)
(ug/L)












Cyclic olefin vessel with SiOxCyHz coating
70
81


Borosilicate glass vessel with silicone oil
825
835










Summary of Lubricity and/or Protective Measurements


Table 6 shows a summary of the above OMCTS coatings or layers









TABLE 6







Summary Table of OMCTS PH PROTECTIVE COATING OR LAYER


From Selected Previous Examples













OMCTS


Power
Dep Time


Example
(sccm)
O2 (sccm)
Ar (sccm)
(Watt)
(sec)















1C
3.0
0.00
65
6
10


1D
3.0
1.00
65
6
10


2
3.0
0.38
7.8
6
10


3
3.0
0.38
7.8
6
10


6
2.5
0.38
7.6
6
10


7
2.5
0.38
0.0
6
10


8
2.5
0.00
0.0
6
10









Comparative Example 13: Dissolution of SiOx Coating Versus pH

The Protocol for Measuring Dissolved Silicon in a Vessel is followed, except as modified here. Test solutions—50 mM buffer solutions at pH 3, 6, 7, 8, 9, and 12 are prepared. Buffers are selected having appropriate pKa values to provide the pH values being studied. A potassium phosphate buffer is selected for pH 3, 7, 8 and 12, a sodium citrate buffer is utilized for pH 6 and tris buffer is selected for pH 9. 3 ml of each test solution is placed in borosilicate glass 5 ml pharmaceutical vessels and SiOx coated 5 ml thermoplastic pharmaceutical vessels. The vessels are all closed with standard coated stoppers and crimped. The vessels are placed in storage at 20-25° C. and pulled at various time points for inductively coupled plasma spectrometer (ICP) analysis of Si content in the solutions contained in the vessels, in parts per billion (ppb) by weight, for different storage times.


The Protocol for Determining Average Dissolution Rate Si content is used to monitor the rate of glass dissolution, except as modified here. The data is plotted to determine an average rate of dissolution of borosilicate glass or SiOx coating at each pH condition. Representative plots at pH 6 through 8 are FIGS. 4-6.


The rate of Si dissolution in ppb is converted to a predicted thickness (nm) rate of Si dissolution by determining the total weight of Si removed, then using a surface area calculation of the amount of vessel surface (11.65 cm2) exposed to the solution and a density of SiOx of 2.2 g/cm3. FIG. 7 shows the predicted initial thickness of the SiOx coating required, based on the conditions and assumptions of this example (assuming a residual SiOx coating of at least 30 nm at the end of the desired shelf life of two years, and assuming storage at 20 to 25° C.). As FIG. 7 shows, the predicted initial thickness of the coating is about 36 nm at pH 5, about 80 nm at pH 6, about 230 nm at pH 7, about 400 nm at pH 7.5, about 750 nm at pH 8, and about 2600 nm at pH 9.


The coating thicknesses in FIG. 7 represent atypically harsh case scenarios for pharma and biotech products. As a general rule of thumb, storage at a lower temperature reduces the thickness required, all other conditions being equivalent.


The following conclusions are reached, based on this test. First, the amount of dissolved Si in the SiOx coating or glass increases exponentially with increasing pH. Second, the SiOx coating dissolves more slowly than borosilicate glass at a pH lower than 8. The SiOx coating shows a linear, monophasic dissolution over time, whereas borosilicate glass tends to show a more rapid dissolution in the early hours of exposure to solutions, followed by a slower linear dissolution. This may be due to surface accumulation of some salts and elements on borosilicate during the forming process relative to the uniform composition of the SiOx coating. This result incidentally suggests the utility of an SiOx coating on the wall of a borosilicate glass vessel to reduce dissolution of the glass at a pH lower than 8. Third, PECVD applied barrier coatings for vessels in which pharmaceutical preparations are stored will need to be adapted to the specific pharmaceutical preparation and proposed storage conditions (or vice versa), at least in some instances in which the pharmaceutical preparation interacts with the barrier coating significantly.


Example 14

An experiment is conducted with vessels coated with SiOx coating+OMCTS pH protective coating or layer, to test the pH protective coating or layer for its functionality as a protective coating or layer. The vessels are 5 mL vessels (the vessels are normally filled with product to 5 mL; their capacity without headspace, when capped, is about 7.5 mL) composed of cyclic olefin co-polymer (COC, Topas® 6013M-07).


Sixty vessels are coated on their interior surfaces with an SiOx coating produced in a plasma enhanced chemical vapor deposition (PECVD) process using a HMDSO precursor gas according to the Protocol for Coating Tube Interior with SiOx set forth above, except that equipment suitable for coating a vessel is used. The following conditions are used.

    • HMDSO flow rate: 0.47 sccm
    • Oxygen flow rate: 7.5 sccm
    • RF power: 70 Watts
    • Coating time: 12 seconds (includes a 2-sec RF power ramp-up time)


Next the SiOx coated vessels are coated over the SiOx with an SiOxCy coating produced in a PECVD process using an OMCTS precursor gas according to the Protocol for Coating COC Vessel Interior with OMCTS Lubricity Coating set forth above, except that the same coating equipment is used as for the SiOx coating. The following conditions are used.

    • OMCTS flow rate: 2.5 sccm
    • Argon flow rate: 10 sccm
    • Oxygen flow rate: 0.7 sccm
    • RF power: 3.4 Watts
    • Coating time: 5 seconds


Eight vessels are selected and the total deposited quantity of PECVD coating (SiOx+SiOxCy) is determined with a Perkin Elmer Optima Model 7300DV ICP-OES instrument, using the Protocol for Total Silicon Measurement set forth above. This measurement determines the total amount of silicon in both coatings, and does not distinguish between the respective SiOx and SiOxCy coatings. The results are shown below.
















Example, Vessel
Total Silicon ug/L



















14-1
13844



14-2
14878



14-3
14387



14-4
13731



14-5
15260



14-6
15017



14-7
15118



14-8
12736



Mean
14371



StdDev
877







Quantity of SiOx + Lubricity layer on Vessels






In the following work, except as indicated otherwise in this example, the Protocol for Determining Average Dissolution Rate is followed. Two buffered pH test solutions are used in the remainder of the experiment, respectively at pH 4 and pH 8 to test the effect of pH on dissolution rate. Both test solutions are 50 mM buffers using potassium phosphate as the buffer, diluted in water for injection (WFI) (0.1 um sterilized, filtered). The pH is adjusted to pH 4 or 8, respectively, with concentrated nitric acid.


25 vessels are filled with 7.5 ml per vessel of pH 4 buffered test solution and 25 other vessels are filled with 7.5 ml per vessel of pH 4 buffered test solution (note the fill level is to the top of the vessel—no head space). The vessels are closed using prewashed butyl stoppers and aluminum crimps. The vessels at each pH are split into two groups. One group at each pH containing 12 vessels is stored at 4° C. and the second group of 13 vessels is stored at 23° C.


The vessels are sampled at Days 1, 3, 6, and 8. The Protocol for Measuring Dissolved Silicon in a Vessel is used, except as otherwise indicated in this example. The analytical result is reported on the basis of parts per billion of silicon in the buffered test solutions of each vessel. A dissolution rate is calculated in terms of parts per billion per day as described above in the Protocol for Determining Average Dissolution Rate. The results at the respective storage temperatures follow:

















Shelf Life Conditions 23° C.










Vessel SiOx +
Vessel SiOx +



Lubricity Coating at
Lubricity Coating at



pH 4
pH 8





Si Dissolution Rate
31
7


(PPB/day)












Shelf Life Conditions 4° C.










Vessel SiOx +




Lubricity Coating at
Vessel SiOx + Lubricity



pH 4
Coating at pH 8





Si Dissolution Rate
7
11


(PPB/day)









The observations of Si dissolution versus time for the OMCTS-based coating at pH8 and pH 4 indicate the pH 4 rates are higher at ambient conditions. Thus, the pH 4 rates are used to determine how much material would need to be initially applied to leave a coating of adequate thickness at the end of the shelf life, taking account of the amount of the initial coating that would be dissolved. The results of this calculation are:















Vessel SiOx + Lubricity



Coating at pH 4

















Si Dissolution Rate (PPB/day)
31


Mass of Coating Tested (Total Si)
14,371


Shelf Life (days) at 23° C.
464


Shelf Life (years) at 23° C.
1.3


Required Mass of Coating (Total Si) - 2 years
22,630


Required Mass of Coating (Total Si) - 3 years
33,945


Shelf Life Calculation









Based on this calculation, the OMCTS protective layer needs to be about 2.5 times thicker—resulting in dissolution of 33945 ppb versus the 14,371 ppb representing the entire mass of coating tested—to achieve a 3-year calculated shelf life.


Example 15

The results of Comparative Example 13 and Example 14 above can be compared as follows, where the “pH protective coating or layer” is the coating of SiOxCy referred to in Example BB.















Shelf Life Conditions - pH 8 and 23° C.











Vessel SiOx + Lubricity



Vessel SiOx
Coating













Si Dissolution Rate (PPB/day)
1,250
7









This data shows that the silicon dissolution rate of SiOx alone is reduced by more than 2 orders of magnitude at pH 8 in vessels also coated with SiOxCy coatings.


Another comparison is shown by the following data from several different experiments carried out under similar accelerated dissolution conditions.















Silicon Dissolution with pH 8 at 40° C.



(ug/L)














Vessel Coating
1
2
3
4
7
10
15


Description
day
days
days
days
days
days
days

















A. SiOx made with HMDSO
165
211
226
252
435
850
1,364


Plasma + SiwOxCy or its


equivalent SiOxCy made


with OMCTS Plasma


B. SiwOxCy or its
109
107
76
69
74
158
198


equivalent SiOxCy made


with OMCTS Plasma


C. SiOx made with HMDSO
2,504
4,228
5,226
5,650
9,292
10,177
9,551


Plasma


D. SiOx made with HMDSO
1,607
1,341
3,927
10,182
18,148
20,446
21,889


Plasma + SiwOxCy or its


equivalent SiOxCy made


with HMDSO Plasma


E. SiwOxCy or its
1,515
1,731
1,813
1,743
2,890
3,241
3,812


equivalent SiOxCy made


with HMDSO Plasma









Row A (SiOx with OMCTS coating) versus C (SiOx without OMCTS coating) show that the OMCTS pH protective coating or layer is also an effective protective coating or layer to the SiOx coating at pH 8. The OMCTS coating reduced the one-day dissolution rate from 2504 ug/L (“u” or μ or the Greek letter “mu” as used herein are identical, and are abbreviations for “micro”) to 165 ug/L.


Example 16

Samples 1-6 as listed in Table 7 were prepared as described in Example 13, with further details as follows.


A cyclic olefin copolymer (COC) resin was injection molded to form a batch of 5 ml vessels. Silicon chips were adhered with double-sided adhesive tape to the internal walls of the vessels. The vessels and chips were coated with a two layer coating by plasma enhanced chemical vapor deposition (PECVD). The first layer was composed of SiOx with barrier properties as defined in the present disclosure, and the second layer was an SiOxCy pH protective coating or layer.


A precursor gas mixture comprising OMCTS, argon, and oxygen was introduced inside each vessel. The gas inside the vessel was excited between capacitively coupled electrodes by a radio-frequency (13.56 MHz) power source. The monomer flow rate (Fm) in units of sccm, oxygen flow rate (Fo) in units of sccm, argon flowrate in sccm, and power (W) in units of watts are shown in Table 7.


A composite parameter, W/FM in units of kJ/kg, was calculated from process parameters W, Fm, Fo and the molecular weight, M in g/mol, of the individual gas species. W/FM is defined as the energy input per unit mass of polymerizing gases. Polymerizing gases are defined as those species that are incorporated into the growing coating such as, but not limited to, the monomer and oxygen. Non-polymerizing gases, by contrast, are those species that are not incorporated into the growing coating, such as but not limited to argon, helium and neon.


In this test, PECVD processing at high W/FM is believed to have resulted in higher monomer fragmentation, producing organosiloxane coatings with higher cross-link density. PECVD processing at low W/FM, by comparison, is believed to have resulted in lower monomer fragmentation producing organosiloxane coatings with a relatively lower cross-link density.


The relative cross-link density of samples 5, 6, 2, and 3 was compared between different coatings by measuring FTIR absorbance spectra. The spectra of samples 5, 6, 2, and 3 are provided in FIGS. 11-14. In each spectrum, the ratio of the peak absorbance at the symmetric stretching mode (1000-1040 cm-1) versus the peak absorbance at the asymmetric stretching mode (1060-1100 cm-1) of the Si—O—Si bond was measured, and the ratio of these two measurements was calculated, all as shown in Table 7. The respective ratios were found to have a linear correlation to the composite parameter W/FM as shown in FIGS. 9-10.


A qualitative relation—whether the coating appeared oily (shiny, often with irridescence) or non-oily (non-shiny) when applied on the silicon chips—was also found to correlate with the W/FM values in Table 7. Oily appearing coatings deposited at lower W/FM values, as confirmed by Table 7, are believed to have a lower crosslink density, as determined by their lower sym/asym ratio, relative to the non-oily coatings that were deposited at higher W/FM and a higher cross-link density. The only exception to this general rule of thumb was sample 2 in Table 7. It is believed that the coating of sample 2 exhibited a non-oily appearance because it was was too thin to see. Thus, an oilyness observation was not reported in Table 7 for sample 2. The chips were analyzed by FTIR in transmission mode, with the infrared spectrum transmitted through the chip and sample coating, and the transmission through an uncoated null chip subtracted.


Non-oily organosiloxane layers produced at higher W/FM values, which protect the underlying SiOx coating from aqueous solutions at elevated pH and temperature, were preferred because they provided lower Si dissolution and a longer shelf life, as confirmed by Table 7. For example, the calculated silicon dissolution by contents of the vessel at a pH of 8 and 40° C. was reduced for the non-oily coatings, and the resulting shelf life was 1381 days in one case and 1147 days in another, as opposed to the much shorter shelf lives and higher rates of dissolution for oily coatings. Calculated shelf life was determined as shown for Example 13. The calculated shelf life also correlated linearly to the ratio of symmetric to asymmetric stretching modes of the Si—O—Si bond in organosiloxane pH protective coatings or layers.


Sample 6 can be particularly compared to Sample 5. An organosiloxane, pH protective coating or layer was deposited according to the process conditions of sample 6 in Table 7. The coating was deposited at a high W/FM. This resulted in a non-oily coating with a high Si—O—Si sym/asym ratio of 0.958, which resulted in a low rate of dissolution of 84.1 ppb/day (measured by the Protocol for Determining Average Dissolution Rate) and long shelf life of 1147 days (measured by the Protocol for Determining Calculated Shelf Life). The FTIR spectra of this coating exhibits a relatively similar asymmetric Si—O—Si peak absorbance compared to the symmetric Si—O—Si peak absorbance. This is an indication of a higher cross-link density coating, which is a preferred characteristic for pH protection and long shelf life.


An organosiloxane pH protective coating or layer was deposited according to the process conditions of sample 5 in Table 7. The coating was deposited at a moderate W/FM. This resulted in an oily coating with a low Si—O—Si sym/asym ratio of 0.673, which resulted in a high rate of dissolution of 236.7 ppb/day (following the Protocol for Determining Average Dissolution Rate) and shorter shelf life of 271 days (following the Protocol for Determining Calculated Shelf Life). The FTIR spectrum of this coating exhibits a relatively high asymmetric Si—O—Si peak absorbance compared to the symmetric Si—O—Si peak absorbance. This is an indication of a lower cross-link density coating, which is contemplated to be an unfavorable characteristic for pH protection and long shelf life.


Sample 2 can be particularly compared to Sample 3. A pH protective coating or layer was deposited according to the process conditions of sample 2 in Table 7. The coating was deposited at a low W/FM. This resulted in a coating that exhibited a low Si—O—Si sym/asym ratio of 0.582, which resulted in a high rate of dissolution of 174 ppb/day and short shelf life of 107 days. The FTIR spectrum of this coating exhibits a relatively high asymmetric Si—O—Si peak absorbance compared to the symmetric Si—O—Si peak absorbance. This is an indication of a lower cross-link density coating, which is an unfavorable characteristic for pH protection and long shelf life.


An organosiloxane, pH protective coating or layer was deposited according to the process conditions of sample 3 in Table 7. The coating was deposited at a high W/FM. This resulted in a non-oily coating with a high Si—O—Si sym/asym ratio of 0.947, which resulted in a low rate of Si dissolution of 79.5 ppb/day (following the Protocol for Determining Average Dissolution Rate) and long shelf life of 1381 days (following the Protocol for Determining Calculated Shelf Life). The FTIR spectrum of this coating exhibits a relatively similar asymmetric Si—O—Si peak absorbance compared to the symmetric Si—O—Si peak absorbance. This is an indication of a higher cross-link density coating, which is a preferred characteristic for pH protection and long shelf life.












TABLE 7









FTIR Absorbance














Process Parameters
Si Dissoution @ pH 8/40° C.
Si—O—Si
Si—O—Si



















Flow

O2


Total
Shelf
Rate of
sym stretch
asym stretch
Ratio



Rate

Flow
Power
W/FM
Si
life
Dissolution
(1000-
(1160-
Si—O—Si



















Samples
OMCTS
Ar
Rate
(W)
(kJ/kg)
(ppb)
(days)
(ppb/day)
1040 cm−1)
1100 cm−1)
(sym/asym)
Oilyness






















1
3
10
0.5
14
21613
43464
385
293.18
0.153
0.219
0.700
YES


2
3
20
0.5
2
3088
7180
107
174.08
0.011
0.020
0.582
NA


3
1
20
0.5
14
62533
42252.17
1381
79.53
0.093
0.098
0.947
NO


4
2
15
0.5
8
18356
27398
380
187.63
0.106
0.141
0.748
YES


5
3
20
0.5
14
21613
24699
271
236.73
0.135
0.201
0.673
YES


6
1
10
0.5
14
62533
37094
1147
84.1
0.134
0.140
0.958
NO









Example 17

An experiment similar to Example 14 was carried out, modified as indicated in this example and in Table 8 (where the results are tabulated). 100 5 mL COP vessels were made and coated with an SiOx barrier layer and an OMCTS-based pH protective coating or layer as described previously, except that for Sample PC194 only the pH protective coating or layer was applied. The coating quantity was again measured in parts per billion extracted from the surfaces of the vessels to remove the entire pH protective coating or layer, as reported in Table 8.


In this example, several different coating dissolution conditions were employed. The test solutions used for dissolution contained either 0.02 or 0.2 wt. % polysorbate-80 surfactant, as well as a buffer to maintain a pH of 8. Dissolution tests were carried out at either 23° C. or 40° C.


Multiple vessels were filled with each test solution, stored at the indicated temperature, and analyzed at several intervals to determine the extraction profile and the amount of silicon extracted. An average dissolution rate for protracted storage times was then calculated by extrapolating the data obtained according to the Protocol for Determining Average Dissolution Rate. The results were calculated as described previously and are shown in Table 8. Of particular note, as shown on Table 8, were the very long calculated shelf lives of the filled packages provided with a PC 194 pH protective coating or layer:


21045 days (over 57 years) based on storage at a pH of 8, 0.02 wt. % polysorbate-80 surfactant, at 23° C.;


38768 days (over 100 years) based on storage at a pH of 8, 0.2 wt. % polysorbate-80 surfactant, at 23° C.;


8184 days (over 22 years) based on storage at a pH of 8, 0.02 wt. % polysorbate-80 surfactant, at 40° C.; and


14732 days (over 40 years) based on storage at a pH of 8, 0.2 wt. % polysorbate-80 surfactant, at 40° C.


Referring to Table 8, the longest calculated shelf lives corresponded with the use of an RF power level of 150 Watts and a corresponding high W/FM value. It is believed that the use of a higher power level causes higher cross-link density of the pH protective coating or layer.


















TABLE 8






OMCTS
Argon
O2

Plasma

Total Si
Calculated
Average Rate



Flow Rate
Flow Rate
Flow Rate
Power
Duration
W/FM
(ppb) (OMCTS)
Shelf-life
of Dissolution


Sample
(sccm)
(sccm)
(sccm)
(W)
(sec)
(kJ/kg)
layer)
(days)
(ppb/day)


















Process Parameters
Si Dissolution @ pH 8/23° C./0.02% Tween ®-80




















PC194
0.5
20
0.5
150
20
1223335
73660
21045
3.5


018
1.0
20
0.5
18
15
77157
42982
1330
32.3













Process Parameters
Si Dissolution @ pH 8/23° C./0.2% Tween ®-80




















PC194
0.5
20
0.5
150
20
1223335
73660
38768
1.9


018
1.0
20
0.5
18
15
77157
42982
665
64.6


048
4
80
2
35
20
37507
56520
1074
52.62













Process Parameters
Si Dissolution @ pH 8/40° C./0.02% Tween ®-80




















PC194
0.5
20
0.5
150
20
1223335
73660
8184
9


018
1.0
20
0.5
18
15
77157
42982
511
84













Process Parameters
Si Dissolution @ pH 8/40° C./0.2% Tween ®-80




















PC194
0.5
20
0.5
150
20
1223335
73660
14732
5


018
1.0
20
0.5
18
15
77157
42982
255
168









Example 18

Another series of experiments similar to those of Example 17 are run, showing the effect of progressively increasing the RF power level on the FTIR absorbance spectrum of the pH protective coating or layer. The results are tabulated in Table 9, which in each instance shows a symmetric/assymmetric ratio greater than 0.75 between the maximum amplitude of the Si—O—Si symmetrical stretch peak normally located between about 1000 and 1040 cm-1, and the maximum amplitude of the Si—O—Si assymmetric stretch peak normally located between about 1060 and about 1100 cm-1. Thus, the symmetric/assymmetric ratio is 0.79 at a power level of 20 W, 1.21 or 1.22 at power levels of 40, 60, or 80 W, and 1.26 at 100 Watts under otherwise comparable conditions.


The 150 Watt data in Table 9 is taken under somewhat different conditions than the other data, so it is not directly comparable with the 20-100 Watt data discussed above. The FTIR data of samples 6 and 8 of Table 9 was taken from the upper portion of the vessel and the FTIR data of samples 7 and 9 of Table 9 was taken from the lower portion of the vessel. Also, the amount of OMCTS was cut in half for samples 8 and 9 of Table 9, compared to samples 6 and 7. Reducing the oxygen level while maintaining a power level of 150 W raised the symmetric/asymmetric ratio still further, as shown by comparing samples 6 and 7 to samples 8 and 9 in Table 9.


It is believed that, other conditions being equal, increasing the symmetric/asymmetric ratio increases the shelf life of a vessel filled with a material having a pH exceeding 5.


Table 10 shows the calculated O-Parameters and N-Parameters (as defined in U.S. Pat. No. 8,067,070) for the experiments summarized in Table 9. As Table 10 shows, the O-Parameters ranged from 0.134 to 0.343, and the N-Parameters ranged from 0.408 to 0.623—all outside the ranges claimed in U.S. Pat. No. 8,067,070.


















TABLE 9








OMCTS
Argon
O2

Plasma

Symmetric
Assymetric
Symmetric/



Flow Rate
Flow Rate
Flow Rate
Power
Duration
W/FM
Stretch Peak
Stretch Peak
Assymetric


Samples
(sccm)
(sccm)
(sccm)
(W)
(sec)
(kJ/kg)
at 1000-1040 cm−1
at 1060-1100 cm−1
Ratio









ID
Process Parameters
FTIR Results



















1
1
20
0.5
20
20
85,730
0.0793
0.1007
0.79


2
1
20
0.5
40
20
171,460
0.0619
0.0507
1.22


3
1
20
0.5
60
20
257,190
0.1092
0.0904
1.21


4
1
20
0.5
80
20
342,919
0.1358
0.1116
1.22


5
1
20
0.5
100
20
428,649
0.209
0.1658
1.26


6
1
20
0.5
150
20
642,973
0.2312
0.1905
1.21


7
1
20
0.5
150
20
642,973
0.2324
0.1897
1.23


8
0.5
20
0.5
150
20
1,223,335
0.1713
0.1353
1.27


9
0.5
20
0.5
150
20
1,223,335
0.1475
0.1151
1.28
























TABLE 10








OMCTS
Argon
O2

Plasma





Samples
Flow Rate
Flow Rate
Flow Rate
Power
Duration
W/FM
O-
N-


ID
(sccm)
(sccm)
(sccm)
(W)
(sec)
(kJ/kg)
Parameter
Parameter







Process Parameters


















1
1
20
0.5
20
20
85,730
0.343
0.436


2
1
20
0.5
40
20
171,460
0.267
0.408


3
1
20
0.5
60
20
257,190
0.311
0.457


4
1
20
0.5
80
20
342,919
0.270
0.421


5
1
20
0.5
100
20
428,649
0.177
0.406


6
1
20
0.5
150
20
642,973
0.151
0.453


7
1
20
0.5
150
20
642,973
0.151
0.448


8
0.5
20
0.5
150
20
1,223,335
0.134
0.623


9
0.5
20
0.5
150
20
1,223,335
0.167
0.609









Optionally in any embodiment of the vessel, the barrier coating or layer comprises SiOx, where x is from 1.5 to 2.9.


Optionally in any embodiment of the vessel, the barrier coating or layer consists essentially of SiOx, where x is from 1.5 to 2.9.


Optionally in any embodiment of the vessel, the barrier coating or layer is deposited by vapor deposition.


Optionally in any embodiment of the vessel, the barrier coating or layer is deposited by chemical vapor deposition.


Optionally in any embodiment of the vessel, the barrier coating or layer is deposited by plasma enhanced chemical vapor deposition.


Optionally in any embodiment of the vessel, the pH protective coating or layer is deposited by vapor deposition.


Optionally in any embodiment of the vessel, the pH protective coating or layer is deposited by chemical vapor deposition.


Optionally in any embodiment of the vessel, the pH protective coating or layer is deposited by plasma enhanced chemical vapor deposition. Graded Composite Layer


Another expedient contemplated here, for adjacent layers of SiOx and a pH protective coating or layer, is a graded composite of any two or more adjacent PECVD layers, for example the barrier coating or layer 288 and a pH protective coating or layer 286. A graded composite can be separate layers of a pH protective and/or barrier layer or coating with a transition or interface of intermediate composition between them, or separate layers of a protective and/or hydrophobic layer and SiOx with an intermediate distinct pH protective coating or layer of intermediate composition between them, or a single coating or layer that changes continuously or in steps from a composition of a protective and/or hydrophobic layer to a composition more like SiOx, going through the pH protective coating or layer in a normal direction.


The grade in the graded composite can go in either direction. For example, the composition of SiOx can be applied directly to the substrate and graduate to a composition further from the surface of a pH protective coating or layer, and optionally can further graduate to another type of coating or layer, such as a hydrophobic coating or layer or a lubricity coating or layer. Additionally, in any embodiment an adhesion coating or layer, for example SiwOxCy, or its equivalent SiOxCy, optionally can be applied directly to the substrate before applying the barrier layer. A graduated pH protective coating or layer is particularly contemplated if a layer of one composition is better for adhering to the substrate than another, in which case the better-adhering composition can, for example, be applied directly to the substrate. It is contemplated that the more distant portions of the graded pH protective coating or layer can be less compatible with the substrate than the adjacent portions of the graded pH protective coating or layer, since at any point the pH protective coating or layer is changing gradually in properties, so adjacent portions at nearly the same depth of the pH protective coating or layer have nearly identical composition, and more widely physically separated portions at substantially different depths can have more diverse properties. It is also contemplated that a pH protective coating or layer portion that forms a better barrier against transfer of material to or from the substrate can be directly against the substrate, to prevent the more remote pH protective coating or layer portion that forms a poorer barrier from being contaminated with the material intended to be barred or impeded by the barrier.


The applied coatings or layers, instead of being graded, optionally can have sharp transitions between one layer and the next, without a substantial gradient of composition. Such pH protective coating or layer can be made, for example, by providing the gases to produce a layer as a steady state flow in a non-plasma state, then energizing the system with a brief plasma discharge to form a coating or layer on the substrate. If a subsequent coating or layer is to be applied, the gases for the previous coating or layer are cleared out and the gases for the next coating or layer are applied in a steady-state fashion before energizing the plasma and again forming a distinct layer on the surface of the substrate or its outermost previous coating or layer, with little if any gradual transition at the interface.


Common Conditions for All Embodiments


In any embodiment contemplated here, many common conditions can be used, for example any of the following, in any combination. For example, the low-pressure PECVD process described in U.S. Pat. No. 7,985,188 can be used. A brief synopsis of that process follows.


The organosilicon precursor for the protective layer can include any of the following precursors useful for PECVD. The precursor for the PECVD coating or layer of the present invention is broadly defined as an organometallic precursor. An organometallic precursor is defined in this specification as comprehending compounds of metal elements from Group III and/or Group IV of the Periodic Table having organic residues, for example hydrocarbon, aminocarbon or oxycarbon residues. Organometallic compounds as presently defined include any precursor having organic moieties bonded to silicon or other Group III/IV metal atoms directly, or optionally bonded through oxygen or nitrogen atoms. The relevant elements of Group III of the Periodic Table are Boron, Aluminum, Gallium, Indium, Thallium, Scandium, Yttrium, and Lanthanum, Aluminum and Boron being preferred. The relevant elements of Group IV of the Periodic Table are Silicon, Germanium, Tin, Lead, Titanium, Zirconium, Hafnium, and Thorium, with Silicon and Tin being preferred. Other volatile organic compounds can also be contemplated. However, organosilicon compounds are preferred for performing present invention.


An organosilicon precursor is contemplated, where an “organosilicon precursor” is defined throughout this specification most broadly as a compound having the linkage:




embedded image


The structure immediately above is a tetravalent silicon atom connected to an oxygen atom and an organic carbon atom (an organic carbon atom being a carbon atom bonded to at least one hydrogen atom). Optionally, the organosilicon precursor is selected from the group consisting of a linear siloxane, a monocyclic siloxane, a polycyclic siloxane, a polysilsesquioxane, a linear silazane, a monocyclic silazane, a polycyclic silazane, a polysilsesquiazane, and a combination of any two or more of these precursors. Also contemplated as a precursor, though not within the two formulas immediately above, is an alkyl trimethoxysilane.


If an oxygen-containing precursor (for example a siloxane) is used, a representative predicted empirical composition resulting from PECVD under conditions forming a coating or layer would be SiwOxCyHz or its equivalent SiOxCy as defined in the Definition Section, while a representative predicted empirical composition resulting from PECVD under conditions forming a barrier coating or layer would be SiOx, where x in this formula is from about 1.5 to about 2.9.


One type of precursor starting material having the above empirical formula is a linear siloxane, for example a material having the following formula:




embedded image



in which each R is independently selected from alkyl, for example methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, vinyl, alkyne, or others, and n is 1, 2, 3, 4, or greater, optionally two or greater. Several examples of contemplated linear siloxanes are


hexamethyldisiloxane (HMDSO),


octamethyltrisiloxane,


decamethyltetrasiloxane,


dodecamethylpentasiloxane,


or combinations of two or more of these.


Another type of precursor starting material, among the preferred starting materials in the present context, is a monocyclic siloxane, for example a material having the following structural formula:




embedded image



in which R is defined as for the linear structure and “a” is from 3 to about 10, or the analogous monocyclic silazanes. Several examples of contemplated hetero-substituted and unsubstituted monocyclic siloxanes and silazanes include

  • 1,3,5-trimethyl-1,3,5-tris(3,3,3-trifluoropropyl)methyl]cyclotrisiloxane
  • 2,4,6,8-tetramethyl-2,4,6,8-tetravinylcyclotetrasiloxane,
  • pentamethylcyclopentasiloxane,
  • pentavinylpentamethylcyclopentasiloxane,
  • hexamethylcyclotrisiloxane,
  • hexaphenylcyclotrisiloxane,
  • octamethylcyclotetrasiloxane (OMCTS),
  • octaphenylcyclotetrasiloxane,
  • decamethylcyclopentasiloxane
  • dodecamethylcyclohexasiloxane,
  • methyl(3,3,3-trifluoropropl)cyclosiloxane,
  • or combinations of any two or more of these.


Another type of precursor starting material, among the preferred starting materials in the present context, is a polycyclic siloxane, for example a material having one of the following structural formulas:




embedded image



in which Y can be oxygen or nitrogen, E is silicon, and Z is a hydrogen atom or an organic substituent, for example alkyl such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, vinyl, alkyne, or others. When each Y is oxygen, the respective structures, from left to right, are a Silatrane, a Silquasilatrane, and a Silproatrane.


Another type of polycyclic siloxane precursor starting material, among the preferred starting materials in the present context, is a polysilsesquioxane, with the empirical formula RSiO1.5 and the structural formula:




embedded image



in which each R is a hydrogen atom or an organic substituent, for example alkyl such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, vinyl, alkyne, or others. Two commercial materials of this sort are SST-eM01 poly(methylsilsesquioxane), in which each R is methyl, and SST-3MH1.1 poly(Methyl-Hydridosilsesquioxane), in which 90% of the R groups are methyl, 10% are hydrogen atoms. This material is available in a 10% solution in tetrahydrofuran, for example. Combinations of two or more of these are also contemplated. Other examples of a contemplated precursor are methylsilatrane, CAS No. 2288-13-3, in which each Y is oxygen and Z is methyl, poly(methylsilsesquioxane) (for example SST-eM01 poly(methylsilsesquioxane)), in which each R optionally can be methyl, SST-3MH1.1 poly(Methyl-Hydridosilsesquioxane) (for example SST-3MH1.1 poly(Methyl-Hydridosilsesquioxane)), in which 90% of the R groups are methyl and 10% are hydrogen atoms, or a combination of any two or more of these.


One particularly contemplated precursor for the barrier coating or layer according to the present invention is a linear siloxane, for example is HMDSO. One particularly contemplated precursor for the pH protective coating or layer according to the present invention is a cyclic siloxane, for example octamethylcyclotetrasiloxane (OMCTS).


It is believed that under certain conditions the OMCTS or other cyclic siloxane molecule provides several advantages over other siloxane materials. First, its ring structure results in a less dense coating or layer (as compared to a coating or layer prepared from HMDSO). The molecule also allows selective ionization so that the final structure and chemical composition of the coating or layer can be directly controlled through the application of the plasma power. Other organosilicon molecules are readily ionized (fractured) so that it is more difficult to retain the original structure of the molecule.


Under certain other conditions, acyclic siloxane molecules such as TMDSO or HMDSO can instead be used to provide a suitable tie coating or layer 289, barrier coating or layer 288, or pH protective coating or layer 286.


Optionally, the PECVD coating or layer can be formed by chemical vapor deposition of a precursor selected from a monocyclic siloxane, a polycyclic siloxane, a polysilsesquioxane, a silatrane, a silquasilatrane, a silproatrane, or a combination of any two or more of these precursors.


In any of the PECVD methods according to the present invention, the applying step optionally can be carried out by vaporizing the precursor and providing it in the vicinity of the substrate. For example, OMCTS is usually vaporized by heating it to about 50° C. before applying it to the PECVD apparatus.


The reaction gas or precursor can also include a hydrocarbon. The hydrocarbon can comprise methane, ethane, ethylene, propane, acetylene, or a combination of two or more of these.


The organosilicon precursor can be delivered at a rate of equal to or less than 10 sccm, optionally equal to or less than 6 sccm, optionally equal to or less than 2.5 sccm, optionally equal to or less than 1.5 sccm, optionally equal to or less than 1.25 sccm. Larger pharmaceutical packages or other vessels or other changes in conditions or scale may require more or less of the precursor. The precursor can be provided at less than 1 Torr absolute pressure.


Other Components of PECVD Reaction Mixture and Ratios of Components


Generally, for a tie coating or layer 289 or pH protective coating or layer 286, O2 can be present in an amount (which can, for example be expressed by the flow rate in sccm) which is less than, or less than one order of magnitude greater than, the organosilicon amount. In contrast, in order to achieve a barrier coating or layer, the amount of O2 typically is at least one order of magnitude higher than the amount of organosilicon precursor. In particular, the volume ratio (in sccm) of organosilicon precursor to O2 for a tie coating or layer 289 or pH protective coating or layer 286, can be in the range from 0.1:1 to 10:1, optionally in the range from 0.3:1 to 8:1, optionally in the range from 0.5:1 to 5:1, optionally from 1:1 to 3:1. The presence of the precursor and O2 in the volume ratios as given in the working examples is specifically suitable to achieve a tie coating or layer 289 or pH protective coating or layer 286. Carrier gas of any embodiment


The tie coating or layer 289 or pH protective coating or layer 286 optionally can be made using a carrier gas. The carrier gas, alternatively referred to as a diluent gas since it is not used to take up or entrain the precursor in the illustrated embodiments, can comprise or consist of an inert gas, for example argon, helium, xenon, neon, another gas that is inert to the other constituents of the process gas under the deposition conditions, or any combination of two or more of these.


In one aspect, a carrier gas is absent in the reaction mixture, in another aspect, it is present. Suitable carrier gases include Argon, Helium and other noble gases such as Neon and Xenon. When the carrier gas is present in the reaction mixture, it is typically present in a volume (in sccm) exceeding the volume of the organosilicon precursor. For example, the ratio of the organosilicon precursor to carrier gas can be from 1:1 to 1:50, optionally from 1:5 to 1:40, optionally from 1:10 to 1:30. One function of the carrier gas is to dilute the reactants in the plasma, encouraging the formation of a coating on the substrate instead of powdered reaction products that do not adhere to the substrate and are largely removed with the exhaust gases.


Since the addition of Argon gas improves the protective performance (see the working examples below), it is believed that additional ionization of the molecule in the presence of Argon contributes to providing a tie coating or layer 289 or pH protective coating or layer 286. The Si—O—Si bonds of the molecule have a high bond energy followed by the Si—C, with the C—H bonds being the weakest. A tie coating or layer 289 or pH protective coating or layer 286, appears to be achieved when a portion of the C—H bonds are broken. This allows the connecting (cross-linking) of the structure as it grows. Addition of oxygen (with the Argon) is understood to enhance this process. A small amount of oxygen can also provide C—O bonding to which other molecules can bond. The combination of breaking C—H bonds and adding oxygen all at low pressure and power leads to a chemical structure that is solid while providing a tie coating or layer 289 or pH protective coating or layer 286.


Oxidizing Gas of any Embodiment


The oxidizing gas can comprise or consist of oxygen (O2 and/or O3 (commonly known as ozone)), nitrous oxide, or any other gas that oxidizes the precursor during PECVD at the conditions employed. The oxidizing gas comprises about 1 standard volume of oxygen. The gaseous reactant or process gas can be at least substantially free of nitrogen.


In any of embodiments, one preferred combination of process gases includes octamethylcyclotetrasiloxane (OMCTS) or another cyclic siloxane as the precursor, in the presence of oxygen as an oxidizing gas and argon as a carrier gas. Without being bound to the accuracy of this theory, the inventors believe this particular combination is effective for the following reasons. The presence of O2, N2O, or another oxidizing gas and/or of a carrier gas, in particular of a carrier gas, for example a noble gas, for example Argon (Ar), is contemplated to improve the resulting pH protective coating or layer.


Some non-exhaustive alternative selections and suitable proportions of the precursor gas, oxygen, and a carrier gas are provided below.


OMCTS: 0.5-5.0 sccm


Oxygen: 0.1-5.0 sccm


Argon: 1.0-20 sccm


RF Power of any Embodiment


The precursor can be contacted with a plasma made by energizing the vicinity of the precursor with electrodes powered at a frequency of 10 kHz to 2.45 GHz, alternatively from about 13 to about 14 MHz.


The precursor can be contacted with a plasma made by energizing the vicinity of the precursor with electrodes powered at radio frequency, optionally at a frequency of from 10 kHz to less than 300 MHz, optionally from 1 to 50 MHz, even optionally from 10 to 15 MHz, optionally at 13.56 MHz.


The precursor can be contacted with a plasma made by energizing the vicinity of the precursor with electrodes supplied with electric power at from 0.1 to 25 W, optionally from 1 to 22 W, optionally from 1 to 10 W, even optionally from 1 to 5 W, optionally from 2 to 4 W, for example of 3 W, optionally from 3 to 17 W, even optionally from 5 to 14 W, for example 6 or 7.5 W, optionally from 7 to 11 W, for example of 8 W, from 0.1 to 500 W, optionally from 0.1 to 400 W, optionally from 0.1 to 300 W, optionally from 1 to 250 W, optionally from 1 to 200 W, even optionally from 10 to 150 W, optionally from 20 to 150 W, for example of 40 W, optionally from 40 to 150 W, even optionally from 60 to 150 W.


The precursor can be contacted with a plasma made by energizing the vicinity of the precursor with electrodes supplied with electric power density at less than 10 W/ml of plasma volume, alternatively from 6 W/ml to 0.1 W/ml of plasma volume, alternatively from 5 W/ml to 0.1 W/ml of plasma volume, alternatively from 4 W/ml to 0.1 W/ml of plasma volume, alternatively from 2 W/ml to 0.2 W/ml of plasma volume, alternatively from 10 W/ml to 50 W/ml, optionally from 20 W/ml to 40 W/ml.


The plasma can be formed by exciting the reaction mixture with electromagnetic energy, alternatively microwave energy.


Other Process Options of any Embodiment


The applying step for applying a coating or layer to the substrate can be carried out by vaporizing the precursor and providing it in the vicinity of the substrate.


The chemical vapor deposition employed can be PECVD and the deposition time can be from 1 to 30 sec, alternatively from 2 to 10 sec, alternatively from 3 to 9 sec. The purposes for optionally limiting deposition time can be to avoid overheating the substrate, to increase the rate of production, and to reduce the use of process gas and its constituents. The purposes for optionally extending deposition time can be to provide a thicker coating or layer for particular deposition conditions.


Gaseous Reactant or Process Gas Limitations of any Embodiment


The plasma for PECVD, if used, can be generated at reduced pressure and the reduced pressure can be less than 300 mTorr, optionally less than 200 mTorr, even optionally less than 100 mTorr. The physical and chemical properties of the tie coating or layer 289, the pH protective coating or layer 286, or a layer serving the function of more than one of these can be set by setting the ratio of O2 to the organosilicon precursor in the gaseous reactant, and/or by setting the electric power used for generating the plasma.


The plasma of any PECVD embodiment can be formed in the vicinity of the substrate. The plasma can in certain cases, especially when preparing a barrier coating or layer, be a non-hollow-cathode plasma. In other certain cases, especially when preparing the tie coating or layer 289, the pH protective coating or layer 286, or a layer serving the function of more than one of these a non-hollow-cathode plasma is not desired. The plasma can be formed from the gaseous reactant at reduced pressure. Sufficient plasma generation power input can be provided to induce coating or layer formation on the substrate.


Relative proportions of gases for producing the tie coating or layer 289 or the pH protective coating or layer 286.


The process gas can contain this ratio of gases for preparing the tie coating or layer 289, the pH protective coating or layer 286, or a layer serving the function of more than one of these:

    • from 0.5 to 10 standard volumes of the precursor;
    • from 1 to 100 standard volumes of a carrier gas,
    • from 0.1 to 10 standard volumes of an oxidizing agent.


      alternatively this ratio:
    • from 1 to 6 standard volumes of the precursor;
    • from 1 to 80 standard volumes of a carrier gas,
    • from 0.1 to 2 standard volumes of an oxidizing agent.


      alternatively this ratio:
    • from 2 to 4 standard volumes, of the precursor;
    • from 1 to 100 standard volumes of a carrier gas,
    • from 0.1 to 2 standard volumes of an oxidizing agent.


      alternatively this ratio:
    • from 1 to 6 standard volumes of the precursor;
    • from 3 to 70 standard volumes, of a carrier gas,
    • from 0.1 to 2 standard volumes of an oxidizing agent.


      alternatively this ratio:
    • from 2 to 4 standard volumes, of the precursor;
    • from 3 to 70 standard volumes of a carrier gas,
    • from 0.1 to 2 standard volumes of an oxidizing agent.


      alternatively this ratio:
    • from 1 to 6 standard volumes of the precursor;
    • from 1 to 100 standard volumes of a carrier gas,
    • from 0.2 to 1.5 standard volumes of an oxidizing agent.


      alternatively this ratio:
    • from 2 to 4 standard volumes, of the precursor;
    • from 1 to 100 standard volumes of a carrier gas,
    • from 0.2 to 1.5 standard volumes of an oxidizing agent.


      alternatively this ratio:
    • from 1 to 6 standard volumes of the precursor;
    • from 3 to 70 standard volumes of a carrier gas,
    • from 0.2 to 1.5 standard volumes of an oxidizing agent.


      alternatively this ratio:
    • from 2 to 4 standard volumes of the precursor;
    • from 3 to 70 standard volumes of a carrier gas,
    • from 0.2 to 1.5 standard volumes of an oxidizing agent.


      alternatively this ratio:
    • from 1 to 6 standard volumes of the precursor;
    • from 1 to 100 standard volumes of a carrier gas,
    • from 0.2 to 1 standard volumes of an oxidizing agent.


      alternatively this ratio:
    • from 2 to 4 standard volumes of the precursor;
    • from 1 to 100 standard volumes of a carrier gas,
    • from 0.2 to 1 standard volumes of an oxidizing agent.


      alternatively this ratio:
    • from 1 to 6 standard volumes of the precursor;
    • from 3 to 70 standard volumes of a carrier gas,
    • from 0.2 to 1 standard volumes of an oxidizing agent.


      alternatively this ratio:
    • 2 to 4 standard volumes, of the precursor;
    • from 3 to 70 standard volumes of a carrier gas,
    • from 0.2 to 1 standard volumes of an oxidizing agent.


      alternatively this ratio:
    • from 1 to 6 standard volumes of the precursor;
    • from 5 to 100 standard volumes of a carrier gas,
    • from 0.1 to 2 standard volumes of an oxidizing agent.


      alternatively this ratio:
    • from 2 to 4 standard volumes, of the precursor;
    • from 5 to 100 standard volumes of a carrier gas,
    • from 0.1 to 2 standard volumes
    • of an oxidizing agent.


      alternatively this ratio:
    • from 1 to 6 standard volumes of the precursor;
    • from 10 to 70 standard volumes, of a carrier gas,
    • from 0.1 to 2 standard volumes of an oxidizing agent.


      alternatively this ratio:
    • from 2 to 4 standard volumes, of the precursor;
    • from 10 to 70 standard volumes of a carrier gas,
    • from 0.1 to 2 standard volumes of an oxidizing agent.


      alternatively this ratio:
    • from 1 to 6 standard volumes of the precursor;
    • from 5 to 100 standard volumes of a carrier gas,
    • from 0.5 to 1.5 standard volumes of an oxidizing agent.


      alternatively this ratio:
    • from 2 to 4 standard volumes, of the precursor;
    • from 5 to 100 standard volumes of a carrier gas,
    • from 0.5 to 1.5 standard volumes of an oxidizing agent.


      alternatively this ratio:
    • from 1 to 6 standard volumes of the precursor;
    • from 10 to 70 standard volumes, of a carrier gas,
    • from 0.5 to 1.5 standard volumes of an oxidizing agent.


      alternatively this ratio:
    • from 2 to 4 standard volumes of the precursor;
    • from 10 to 70 standard volumes of a carrier gas,
    • from 0.5 to 1.5 standard volumes of an oxidizing agent.


      alternatively this ratio:
    • from 1 to 6 standard volumes of the precursor;
    • from 5 to 100 standard volumes of a carrier gas,
    • from 0.8 to 1.2 standard volumes of an oxidizing agent.


      alternatively this ratio:
    • from 2 to 4 standard volumes of the precursor;
    • from 5 to 100 standard volumes of a carrier gas,
    • from 0.8 to 1.2 standard volumes of an oxidizing agent.


      alternatively this ratio:
    • from 1 to 6 standard volumes of the precursor;
    • from 10 to 70 standard volumes of a carrier gas,
    • from 0.8 to 1.2 standard volumes of an oxidizing agent.


      alternatively this ratio:
    • 2 to 4 standard volumes, of the precursor;
    • from 10 to 70 standard volumes of a carrier gas,
    • from 0.8 to 1.2 standard volumes of an oxidizing agent.


      Additional Embodiments


The tie coating or layer 289, the pH protective coating or layer 286, or a layer serving the function of more than one of these described in this specification can be applied in many different ways. For one example, the low-pressure PECVD process described in U.S. Pat. No. 7,985,188 can be used. For another example, instead of using low-pressure PECVD, atmospheric PECVD can be employed to deposit the tie coating or layer 289, the pH protective coating or layer 286, or a layer serving the function of more than one of these. For another example, the coating can be simply evaporated and allowed to deposit on the SiOx layer to be protected. For another example, the coating can be sputtered on the SiOx layer to be protected.


Process for Applying Tie Coating or Layer 289


The general PECVD process described in this specification is used, for example as follows, to produce a tie or adhesion coating or layer 289 (several names for the same type of coating) on a 1 to 5 mL vessel such as a pharmaceutical vessel or prefilled syringe. A person skilled in the art will know from this description how to scale the process conditions to suit larger or smaller vessels.


The tie or adhesion coating or layer can be produced, for example, using as the precursor tetramethyldisiloxane (TMDSO) or hexamethyldisiloxane (HMDSO) at a flow rate of 0.5 to 10 sccm, preferably 1 to 5 sccm; oxygen flow of 0.25 to 5 sccm, preferably 0.5 to 2.5 sccm; and argon flow of 1 to 120 sccm, preferably in the upper part of this range for a 1 mL vessel and the lower part of this range for a 5 ml. vessel. The overall pressure in the vessel during PECVD can be from 0.01 to 10 Torr, preferably from 0.1 to 1.5 Torr. The power level applied can be from 5 to 100 Watts, preferably in the upper part of this range for a 1 mL vessel and the lower part of this range for a 5 ml. vessel. The deposition time (i.e. “on” time for RF power) is from 0.1 to 10 seconds, preferably 1 to 3 seconds. The power cycle optionally can be ramped or steadily increased from 0 Watts to full power over a short time period, such as 2 seconds, when the power is turned on, which may improve the plasma uniformity. The ramp up of power over a period of time is optional, however.


PECVD Process for Applying Barrier Layer


The PECVD processes described as suitable in U.S. Pat. No. 7,985,188, incorporated by reference here, can be used to apply an SiOx barrier coating or layer 288 as defined in this specification.


PECVD Process for pH Protective Layer


A tie coating or layer 289 or a pH protective coating or layer 286 can be a SiOxCy coating or layer applied as described in any embodiment of this specification. For example, the pH protective coating or layer 286 of any embodiment comprises or consists essentially of a coating or layer of SiOxCy optionally applied over the barrier coating or layer 288 to protect at least a portion of the barrier coating or layer from the pharmaceutical preparation such as 218. The pH protective coating or layer such as 286 is provided, for example, by applying one of the described precursors on or in the vicinity of a substrate in a PECVD process, providing a pH protective coating or layer. The coating can be applied, for example, at a thickness of 1 to 5000 nm, or 10 to 1000 nm, or 10 to 500 nm, or 10 to 200 nm, or 20 to 100 nm, or 30 to 1000 nm, or 30 to 500 nm thick, or 30 to 1000 nm, or 20 to 100 nm, or 80 to 150 nm, and crosslinking or polymerizing (or both) the protective layer, optionally in a PECVD process, to provide a protected surface.


Although not intending to be bound according to the accuracy of the following theory, the inventors contemplate that the pH protective coating or layer 286, applied over an SiOx barrier layer on a vessel wall, functions at least in part by passivating the SiOx barrier layer surface against attack by the contents of the vessel, as well as providing a more resistant or sacrificial independent layer to isolate the SiOx barrier layer from the contents of the vessel. It is thus contemplated that the pH protective coating or layer can be very thin, and even so improve the shelf life of the pharmaceutical package.


Exemplary reaction conditions for preparing a pH protective coating or layer 286 coating or layer according to the present invention in a 3 ml sample size vessel with a ⅛″ diameter tube (open at the end) are as follows:


Flow Rate Ranges:


OMCTS: 0.5-10 sccm


Oxygen: 0.1-10 sccm


Argon: 1.0-200 sccm


Power: 0.1-500 watts


Specific Flow Rates:


OMCTS: 2.0 sccm


Oxygen: 0.7 sccm


Argon: 7.0 sccm


Power: 3.5 watts


The pH protective coating or layer 286 and its application are described in more detail below. A method for applying the coating includes several steps. A vessel wall is provided, as is a reaction mixture comprising plasma forming gas, i.e. an organosilicon compound gas, optionally an oxidizing gas, and optionally a hydrocarbon gas.


Plasma is formed in the reaction mixture that is substantially free of hollow cathode plasma. The vessel wall is contacted with the reaction mixture, and the coating or layer of SiOx is deposited on at least a portion of the vessel wall.


It has been found that acyclic organosiloxanes, for example HMDSO and TMDSO, can be used to form the pH protective coating or layer, as described elsewhere in this specification.


In certain embodiments, the generation of a uniform plasma throughout the portion of the vessel to be coated is contemplated, as it has been found in certain instances to generate a better coating or layer. Uniform plasma means regular plasma that does not include a substantial amount of hollow cathode plasma (which has a higher emission intensity than regular plasma and is manifested as a localized area of higher intensity interrupting the more uniform intensity of the regular plasma).


Additional Embodiments


The pH protective coating or layer 286 described in this specification can be applied in many different ways. For one example, the low-pressure PECVD process described in U.S. Pat. No. 7,985,188 can be used. For another example, instead of using low-pressure PECVD, atmospheric PECVD can be employed to deposit the pH protective coating or layer. For another example, the coating can be simply evaporated and allowed to deposit on the SiOx layer to be protected. For another example, the coating can be sputtered on the SiOx layer to be protected. For still another example, the pH protective coating or layer 286 can be applied from a liquid medium used to rinse or wash the SiOx layer.


Other precursors and methods can be used to apply the pH protective coating or layer or passivating treatment. For example, hexamethylene disilazane (HMDZ) can be used as the precursor. HMDZ has the advantage of containing no oxygen in its molecular structure. This passivation treatment is contemplated to be a surface treatment of the SiOx barrier layer with HMDZ. To slow down and/or eliminate the decomposition of the silicon dioxide coatings at silanol bonding sites, the coating must be passivated. It is contemplated that passivation of the surface with HMDZ (and optionally application of a few mono layers of the HMDZ-derived coating) will result in a toughening of the surface against dissolution, resulting in reduced decomposition. It is contemplated that HMDZ will react with the —OH sites that are present in the silicon dioxide coating, resulting in the evolution of NH3 and bonding of S—(CH3)3 to the silicon (it is contemplated that hydrogen atoms will be evolved and bond with nitrogen from the HMDZ to produce NH3).


It is contemplated that this HMDZ passivation can be accomplished through several possible paths.


One contemplated path is dehydration/vaporization of the HMDZ at ambient temperature. First, an SiOx surface is deposited, for example using hexamethylene disiloxane (HMDSO). The as-coated silicon dioxide surface is then reacted with HMDZ vapor. In an embodiment, as soon as the SiOx surface is deposited onto the article of interest, the vacuum is maintained. The HMDSO and oxygen are pumped away and a base vacuum is achieved. Once base vacuum is achieved, HMDZ vapor is flowed over the surface of the silicon dioxide (as coated on the part of interest) at pressures from the mTorr range to many Torr. The HMDZ is then pumped away (with the resulting NH3 that is a byproduct of the reaction). The amount of NH3 in the gas stream can be monitored (with a residual gas analyzer—RGA—as an example) and when there is no more NH3 detected, the reaction is complete. The part is then vented to atmosphere (with a clean dry gas or nitrogen). The resulting surface is then found to have been passivated. It is contemplated that this method optionally can be accomplished without forming a plasma.


Alternatively, after formation of the SiOx barrier coating or layer, the vacuum can be broken before dehydration/vaporization of the HMDZ. Dehydration/vaporization of the HMDZ can then be carried out in either the same apparatus used for formation of the SiOx barrier coating or layer or different apparatus.


Dehydration/vaporization of HMDZ at an elevated temperature is also contemplated. The above process can alternatively be carried out at an elevated temperature exceeding room temperature up to about 150° C. The maximum temperature is determined by the material from which the coated part is constructed. An upper temperature should be selected that will not distort or otherwise damage the part being coated.


Dehydration/vaporization of HMDZ with a plasma assist is also contemplated. After carrying out any of the above embodiments of dehydration/vaporization, once the HMDZ vapor is admitted into the part, a plasma is generated. The plasma power can range from a few watts to 100+ watts (similar powers as used to deposit the SiOx). The above is not limited to HMDZ and could be applicable to any molecule that will react with hydrogen, for example any of the nitrogen-containing precursors described in this specification.


For depositing a pH protective coating or layer, a precursor feed or process gas can be employed having a standard volume ratio of, for example:


from 0.5 to 10 standard volumes, optionally from 1 to 6 standard volumes, optionally from 2 to 4 standard volumes, optionally equal to or less than 6 standard volumes, optionally equal to or less than 2.5 standard volumes, optionally equal to or less than 1.5 standard volumes, optionally equal to or less than 1.25 standard volumes of the precursor, for example OMCTS or one of the other precursors of any embodiment;


from 0 to 100 standard volumes, optionally from 1 to 80 standard volumes, optionally from 5 to 100 standard volumes, optionally from 10 to 70 standard volumes, of a carrier gas of any embodiment;


from 0.1 to 10 standard volumes, optionally from 0.1 to 2 standard volumes, optionally from 0.2 to 1.5 standard volumes, optionally from 0.2 to 1 standard volumes, optionally from 0.5 to 1.5 standard volumes, optionally from 0.8 to 1.2 standard volumes of an oxidizing agent.


Another embodiment is a pH protective coating or layer of the type made by the above process.


Another embodiment is a vessel such as the vessel 214 (FIG. 1) including a lumen defined by a surface defining a substrate. A pH protective coating or layer is present on at least a portion of the substrate, typically deposited over an SiOx barrier layer to protect the barrier layer from dissolution. The pH protective coating or layer is made by the previously defined process.


PECVD Process for Trilayer Coating


The PECVD trilayer coating described in this specification can be applied, for example, as follows for a 1 to 5 mL vessel. Two specific examples are 1 mL thermoplastic resin vessel and a 5 mL thermoplastic resin drug vessel. Larger or smaller vessels will call for adjustments in parameters that a person of ordinary skill can carry out in view of the teaching of this specification.


The apparatus used is the PECVD apparatus with rotating quadrupole magnets as described generally in this specification.


The general coating parameter ranges, with preferred ranges in parentheses, for a trilayer coating for a 1 mL vessel are shown in the PECVD Trilayer Process General Parameters Tables (1 mL vessel and 5 mL vessel).












PECVD Trilayer Process General Parameters Table (1 mL vessel)











Parameter
Units
Tie
Barrier
pH Protective














Power
W
40-90
140
40-90




(60-80)

(60-80)


TMDSO Flow
sccm
 1-10
None
 1-10




(3-5)

(3-5)


HMDSO Flow
sccm
None
1.56
None


O2 Flow
sccm
0.5-5  
20
0.5-5  




(1.5-2.5)

(1.5-2.5)


Argon Flow
sccm
 40-120
0
 40-120




(70-90)

(70-90)


Ramp Time
seconds
None
None
None


Deposition
seconds
0.1-10 
20
0.1-40 


Time

(1-3)

(15-25)


Tube Pressure
Torr
0.01-10  
0.59
0.01-10  




(0.1-1.5)

(0.1-1.5)



















PECVD Trilayer Process General Parameters Table (5 mL vessel)













Parameter
Units
Adhesion
Barrier
Protection

















Power
W
40-90
140
40-90





(60-80)

(60-80)



TMDSO
sccm
 1-10
None
 1-10



Flow

(3-5)

(3-5)



HMDSO
sccm
None
1.56
None



Flow



O2 Flow
sccm
0.5-5  
20
0.5-5  





(1.5-2.5)

(1.5-2.5)



Argon Flow
sccm
 40-120
0
 40-120





(70-90)

(70-90)



Ramp Time
seconds
None
None
None



Deposition
seconds
0.1-10 
20
0.1-40 



Time

(1-3)

(15-25)



Tube
Torr
0.01-10  
0.59
0.01-10  



Pressure

(0.1-1.5)

(0.1-1.5)











Trilayer Working Examples


Examples of specific coating parameters that have been used for a 1 mL vessel and 5 mL vessel are shown in the PECVD Trilayer Process Specific Parameters Tables (1 mL vessel and 5 mL vessel):












PECVD Trilayer Process


Specific Parameters Table (1 mL syringe)













Parameter
Units
Tie
Barrier
Protection

















Power
W
70
140
70



TMDSO
sccm
4
None
4



Flow



HMDSO
sccm
None
1.56
None



Flow



O2 Flow
sccm
2
20
2



Argon Flow
sccm
80
0
80



Ramp Time
seconds
None
None
None



Deposition
seconds
2.5
20
10



Time



Tube
Torr
1
0.59
1



Pressure




















PECVD Trilayer Process


Specific Parameters Table (5 mL vessel)













Parameter
Units
Adhesion
Barrier
Protection

















Power
W
20
40
20



TMDSO
sccm
2
0
2



Flow



HMDSO
sccm
0
3
0



Flow



O2 Flow
sccm
1
50
1



Argon Flow
sccm
20
0
20



Ramp Time
seconds
0
2
2



Deposition
seconds
2.5
10
10



Time



Tube
Torr
0.85
1.29
0.85



Pressure










The O-parameter and N-parameter values for the pH protective coating or layer applied to the 1 mL vessel as described above are 0.34 and 0.55, respectively.


The O-parameter and N-parameter values for the pH protective coating or layer applied to the 5 mL vessel are 0.24 and 0.63, respectively.


Referring to FIGS. 16-18, the thickness uniformity at four different points along the length of a 1 mL vessel with a staked needle as the vessel (present during PECVD deposition) and the indicated trilayer coating (avg. thicknesses: 38 nm adhesion or tie coating or layer; 55 nm barrier coating or layer, 273 nm pH protective coating or layer) is shown. The plot maps the coating thickness over the cylindrical inner surface of the barrel, as though unrolled to form a rectangle. The overall range is 572 plus or minus 89 nm. The table shows individual layer thicknesses at the four marked points, showing adequate thickness of each layer at each point along the high profile vessel.


A vessel having a coating similar to the trilayer coating of FIG. 18 is tested for shelf life, using the silicon dissolution and extrapolation method described in this specification, compared to vessels having a bilayer coating (similar to the trilayer coating except lacking the tie coating or layer) and a monolayer coating which is just the pH protective coating or layer directly applied to the thermoplastic barrel of the vessel, with no barrier layer. The test solution was a 0.2% Tween, pH 8 phosphate buffer. The extrapolated shelf lives of the monolayer and trilayer coatings were similar and very long—on the order of 14 years. The shelf life of the vessels having a bilayer coating were much lower—less than two years. In other words, the presence of a barrier layer under the pH protective layer shortened the shelf life of the coating substantially, but the shelf life was restored by providing a tie coating or layer under the barrier layer, sandwiching the barrier coating or layer with respective SiOxCy layers. The barrier layer is necessary to establish a gas barrier, so the monolayer coating would not be expected to provide adequate gas barrier properties by itself. Thus, only the trilayer coating had the combination of gas barrier properties and a long shelf life, even while in contact with a solution that would attack an exposed barrier coating or layer.



FIGS. 19-20 show the coating distribution for a 5 mL vessel—a vial similar to that of FIG. 21—showing very little variation in coating thickness, with the great majority of the surface coated between 150 and 250 nm thickness of the trilayer, with only a small proportion of the container coated with between 50 and 250 nm of the trilayer.


The Vessel Coating Distribution Table shows the breakdown of coating thickness (nm) by vessel location as shown in FIG. 21. The Vessel Coating Distribution Table shows the uniformity of coating.












Vessel Coating Distribution Table











Vessel



Total Trilayer,


Location
Adhesion
Barrier
Protection
nm














1
13
29
77
119


2
14
21
58
93


3
25
37
115
177


4
35
49
158
242


5
39
49
161
249


6
33
45
148
226


7
31
29
153
213


8
48
16
218
282


9
33
53
155
241


10 
31
29
150
210


Average
30
36
139
205










FIG. 22 is a visual test result showing the integrity of the trilayer vessel coating described above. The three 5 mL cyclic olefin polymer (COC) vessels of FIG. 22 were respectively:

    • uncoated (left vessel),
    • coated with the bilayer coating described in this specification (a barrier coating or layer plus a pH protective coating or layer—the second and third components of the trilayer coating) (center vessel); and
    • coated with the trilayer coating as described above (right vessel).


The three vessels were each exposed to 1 N potassium hydroxide for four hours, then exposed for 24 hours to a ruthenium oxide (RuO4) stain that darkens any exposed part of the thermoplastic vessel unprotected by the coatings. The high pH potassium hydroxide exposure erodes any exposed part of the barrier coating or layer at a substantial rate, greatly reduced, however by an intact pH protective coating or layer. In particular, the high pH exposure opens up any pinholes in the coating system. As FIG. 22 shows, the uncoated vessel is completely black, showing the absence of any effective coating. The bilayer coating (Center, FIG. 22, portion enlarged in FIG. 22A) was mostly intact under the treatment conditions, but on microscopic inspection has many pinholes where the ruthenium stain reached the thermoplastic substrate through the coating. The overall appearance of the bilayer coating clearly shows visible “soiled” areas where the stain penetrated. The trilayer coating, however (FIG. 22, Right), protected the entire vessel against penetration of the stain, and the illustrated vessel remains clear after treatment. This is believed to be the result of sandwiching the barrier coating or layer between two layers of SiOxCy, which both protects the barrier layer against direct etching and against undercutting and removal of flakes of the barrier layer.


The rate of erosion of the pH protective coating or layer 286, if directly contacted by the fluid 218, is less than the rate of erosion of the barrier coating 288, if directly contacted by the fluid 218.


The pH protective coating or layer 286 is effective to isolate the fluid 218 from the barrier coating 288.


Optionally for any of the embodiments, at least a portion of the wall 214 of the vessel 250 comprises or consists essentially of a polymer, for example a polyolefin (for example a cyclic olefin polymer, a cyclic olefin copolymer


Optionally for any of the embodiments, the fluid 218 in the lumen such as 212 or 274 has a pH between 5 and 6, optionally between 6 and 7, optionally between 7 and 8, optionally between 8 and 9, optionally between 6.5 and 7.5, optionally between 7.5 and 8.5, optionally between 8.5 and 9.


Optionally for any of the embodiments, the fluid 218 is a liquid at 20° C. and ambient pressure at sea level, which is defined as a pressure of 760 mm Hg.


Optionally for any of the embodiments, the fluid 218 is an aqueous liquid.


Optionally for any of the embodiments, the barrier coating 288 is from 4 nm to 500 nm thick, optionally from 7 nm to 400 nm thick, optionally from 10 nm to 300 nm thick, optionally from 20 nm to 200 nm thick, optionally from 30 nm to 100 nm thick.


Optionally for any of the embodiments, the pH protective coating or layer 286 comprises or consists essentially of SiOxCy. Optionally for any of the embodiments, the pH protective coating or layer 286 comprises or consists essentially of SiNxCy.


Optionally for any of the embodiments, the precursor comprises a monocyclic siloxane, a polycyclic siloxane, a polysilsesquioxane, a monocyclic silazane, a polycyclic silazane, a polysilsesquiazane, a silatrane, a silquasilatrane, a silproatrane, an azasilatrane, an azasilquasiatrane, an azasilproatrane, or a combination of any two or more of these precursors.


Optionally for any of the embodiments, the precursor comprises a monocyclic siloxane, a polycyclic siloxane, a polysilsesquioxane, a Silatrane, a Silquasilatrane, a Silproatrane, or a combination of any two or more of these precursors. Optionally for any of the embodiments, the precursor comprises octamethylcyclotetrasiloxane (OMCTS) or consists essentially of OMCTS. Other precursors described elsewhere in this specification or known in the art are also contemplated for use according to the invention.


Optionally for any of the embodiments, the pH protective coating or layer 286 as applied is between 10 and 1000 nm thick, optionally between 50 and 800 nm thick, optionally between 100 and 700 nm thick, optionally between 300 and 600 nm thick. The thickness does not need to be uniform throughout the vessel, and will typically vary from the preferred values in portions of a vessel.


Optionally for any of the embodiments, the pH protective coating or layer 286 contacting the fluid 218 is between 10 and 1000 nm thick, optionally between 50 and 500 nm thick, optionally between 100 and 400 nm thick, optionally between 150 and 300 nm thick two years after the pharmaceutical package 210 is assembled.


Optionally for any of the embodiments, the rate of erosion of the pH protective coating or layer 286, if directly contacted by a fluid 218 having a pH of 8, is less than 20%, optionally less than 15%, optionally less than 10%, optionally less than 7%, optionally from 5% to 20%, optionally 5% to 15%, optionally 5% to 10%, optionally 5% to 7%, of the rate of erosion of the barrier coating 288, if directly contacted by the same fluid 218 under the same conditions.


Optionally for any of the embodiments, the pH protective coating or layer 286 is at least coextensive with the barrier coating 288. The pH protective coating or layer 286 alternatively can be less extensive than the barrier coating, as when the fluid does not contact or seldom is in contact with certain parts of the barrier coating absent the pH protective coating or layer. The pH protective coating or layer 286 alternatively can be more extensive than the barrier coating, as it can cover areas that are not provided with a barrier coating.


Optionally for any of the embodiments, the pharmaceutical package 210 can have a shelf life, after the pharmaceutical package 210 is assembled, of at least one year, alternatively at least two years.


Optionally for any of the embodiments, the shelf life is measured at 3° C., alternatively at 4° C. or higher, alternatively at 20° C. or higher, alternatively at 23° C., alternatively at 40° C.


Optionally for any of the embodiments, the pH of the fluid 218 is between 5 and 6 and the thickness by TEM of the pH protective coating or layer 286 is at least 80 nm at the end of the shelf life. Alternatively, the pH of the fluid 218 is between 6 and 7 and the thickness by TEM of the pH protective coating or layer 286 is at least 80 nm at the end of the shelf life. Alternatively, the pH of the fluid 218 is between 7 and 8 and the thickness by TEM of the pH protective coating or layer 286 is at least 80 nm at the end of the shelf life. Alternatively, the pH of the fluid 218 is between 8 and 9 and the thickness by TEM of the pH protective coating or layer 286 is at least 80 nm at the end of the shelf life. Alternatively, the pH of the fluid 218 is between 5 and 6 and the thickness by TEM of the pH protective coating or layer 286 is at least 150 nm at the end of the shelf life. Alternatively, the pH of the fluid 218 is between 6 and 7 and the thickness by TEM of the pH protective coating or layer 286 is at least 150 nm at the end of the shelf life. Alternatively, the pH of the fluid 218 is between 7 and 8 and the thickness by TEM of the pH protective coating or layer 286 is at least 150 nm at the end of the shelf life. Alternatively, the pH of the fluid 218 is between 8 and 9 and the thickness by TEM of the pH protective coating or layer 286 is at least 150 nm at the end of the shelf life.


Optionally for any of the embodiments, the fluid 218 removes the pH protective coating or layer 286 at a rate of 1 nm or less of pH protective coating or layer thickness per 44 hours of contact with the fluid 218 (200 nm per year), alternatively 1 nm or less of pH protective coating or layer thickness per 88 hours of contact with the fluid 218 (100 nm per year), alternatively 1 nm or less of pH protective coating or layer thickness per 175 hours of contact with the fluid 218 (50 nm per year), alternatively 1 nm or less of pH protective coating or layer thickness per 250 hours of contact with the fluid 218 (35 nm per year), alternatively 1 nm or less of pH protective coating or layer thickness per 350 hours of contact with the fluid 218 (25 nm per year). The rate of removing the pH protective coating or layer can be determined by TEM from samples exposed to the fluid for known periods.


Optionally for any of the embodiments, the pH protective coating or layer 286 is effective to provide a lower frictional resistance than the uncoated article surface 254. Preferably the frictional resistance is reduced by at least 25%, more preferably by at least 45%, even more preferably by at least 60% in comparison to the uncoated article surface 254. For example, the pH protective coating or layer 286 preferably is effective to reduce the frictional resistance between a portion of the wall 214 contacted by the fluid 218 and a relatively sliding part 258 after the pharmaceutical package 210 is assembled. Preferably, the pH protective coating or layer 286 is effective to reduce the frictional resistance between the wall 214 and a relatively sliding part 258 at least two years after the pharmaceutical package 210 is assembled.


Optionally, in any embodiment the calculated shelf life of the package (total Si/Si dissolution rate) is more than six months, or more than 1 year, or more than 18 months, or more than 2 years, or more than 2½ years, or more than 3 years, or more than 4 years, or more than 5 years, or more than 10 years, or more than 20 years. Optionally, in any embodiment the calculated shelf life of the package (total Si/Si dissolution rate) is less than 60 years.


Any minimum time stated here can be combined with any maximum time stated here, as an alternative embodiment.


Even another embodiment is a medical or diagnostic kit including a vessel having a coating or layer as defined in any embodiment herein on a substrate as defined in any embodiment above. Optionally, the kit additionally includes a medicament or diagnostic agent which is contained in the vessel in contact with the coating or layer; and/or a hypodermic needle, double-ended needle, or other delivery conduit; and/or an instruction sheet.


The substrate can be a pharmaceutical package or other vessel, for protecting a compound or composition contained or received in the vessel with a coating or layer against mechanical and/or chemical effects of the surface of the uncoated substrate.


The substrate can be a pharmaceutical package or other vessel, for preventing or reducing precipitation and/or clotting of a compound or a component of the composition in contact with the inner or interior surface of the vessel. The compound or composition can be a biologically active compound or composition, for example a medicament, for example the compound or composition can comprise insulin, wherein insulin precipitation can be reduced or prevented. Alternatively, the compound or composition can be a biological fluid, for example a bodily fluid, for example blood or a blood fraction wherein blood clotting can be reduced or prevented.


A concern of converting from glass to plastic vessels centers around the potential for leachable materials from plastics. With plasma coating technology, the coatings or layers derived from non-metal gaseous precursors, for example HMDSO or OMCTS or other organosilicon compounds, will itself contain no trace metals and function as a barrier to inorganic, metals and organic solutes, preventing leaching of these species from the coated substrate into vessel fluids. In addition to leaching control of plastic vessels, the same plasma coating or layer technology offers potential to provide a solute barrier to the plunger tip, typically made of elastomeric plastic compositions containing even higher levels of leachable organic oligomers and catalysts.


Moreover, a critical factor in the conversion from glass to plastic vessels will be the improvement of plastic oxygen and moisture barrier performance. The plasma coating technology is suitable to maintain the SiOx barrier coating or layer for protection against oxygen and moisture over an extended shelf life.


Substrate


Vessels Generally


A vessel with a coating or layer as described herein and/or prepared according to a method described herein can be used for reception and/or storage and/or delivery of a compound or composition. The compound or composition can be sensitive, for example air-sensitive, oxygen-sensitive, sensitive to humidity and/or sensitive to mechanical influences. It can be a biologically active compound or composition, for example a pharmaceutical preparation or medicament like insulin or a composition comprising insulin. In another aspect, it can be a biological fluid, optionally a bodily fluid, for example blood or a blood fraction. In certain aspects of the present invention, the compound or composition can be a product to be administrated to a subject in need thereof, for example a product to be injected, like blood (as in transfusion of blood from a donor to a recipient or reintroduction of blood from a patient back to the patient) or insulin.


A vessel as described herein and/or prepared according to a method described herein can further be used for protecting a compound or composition contained in its interior space against mechanical and/or chemical effects of the surface of the vessel material. For example, it can be used for preventing or reducing precipitation and/or clotting or platelet activation of the compound or a component of the composition, for example insulin precipitation or blood clotting or platelet activation.


It can further be used for protecting a compound or composition contained in its interior against the environment outside of the vessel, for example by preventing or reducing the entry of one or more compounds from the environment surrounding the vessel into the interior space of the vessel. Such environmental compound can be a gas or liquid, for example an atmospheric gas or liquid containing oxygen, air, and/or water vapor.


A vessel with a trilayer coating as described herein can also be evacuated and stored in an evacuated state. For example, the trilayer coating or layer allows better maintenance of the vacuum in comparison to a corresponding vessel without a trilayer coating or layer. In one aspect of this embodiment, the vessel with a trilayer coating or layer is a blood collection tube. The tube can also contain an agent for preventing blood clotting or platelet activation, for example EDTA or heparin.


Basic Protocols for Forming and Coating Vessels


The vessels tested in the subsequent working examples were formed and coated according to the following exemplary protocols, except as otherwise indicated in individual examples. Particular parameter values given in the following basic protocols, for example the electric power and gaseous reactant or process gas flow, are typical values. When parameter values were changed in comparison to these typical values, this will be indicated in the subsequent working examples. The same applies to the type and composition of the gaseous reactant or process gas.


In some instances, the reference characters and Figures mentioned in the following protocols and additional details can be found in U.S. Pat. No. 7,985,188.


Protocol for Coating Vessel Interior with SiOx


The apparatus and protocol generally as found in U.S. Pat. No. 7,985,188 were used for coating vessel interiors with an SiOx barrier coating or layer, in some cases with minor variations. A similar apparatus and protocol were used for coating vessels with an SiOx barrier coating or layer, in some cases with minor variations. Protocol for Coating Vessel Interior with OMCTS pH Protective Coating or Layer


Vessels already interior coated with a barrier coating or layer of SiOx, as previously identified, are further interior coated with a pH protective coating or layer as previously identified, generally following the protocols of U.S. Pat. No. 7,985,188 for applying the lubricity coating or layer, except with modified conditions in certain instances as noted in the working examples. The conditions given here are for a COC vessel, and can be modified as appropriate for vessels made of other materials. The apparatus as generally shown in FIGS. 3 and 4 of U.S. Pat. No. 7,985,188 is used to hold a vessel with butt sealing at the base of the vessel. Additionally a cap is provided that seals the end of the vessel (illustrated in present FIG. 3).


The vessel is carefully moved into the sealing position over the extended probe or counter electrode 108 of U.S. Pat. No. 7,985,188 and pushed against a plasma screen. The plasma screen is fit snugly around the probe or counter electrode 108 insuring good electrical contact. The probe or counter electrode 108 is grounded to the casing of the RF matching network.


The gas delivery port 110 of U.S. Pat. No. 7,985,188 is connected to a manual ball valve or similar apparatus for venting, a thermocouple pressure gauge and a bypass valve connected to the vacuum pumping line. In addition, the gas system is connected to the gas delivery port 110 allowing the gaseous reactant or process gas, octamethylcyclotetrasiloxane (OMCTS) (or the specific gaseous reactant or process gas reported for a particular example) to be flowed through the gas delivery port 110 (under process pressures) into the interior of the vessel.


The gas system is comprised of a commercially available heated mass flow vaporization system that heats the OMCTS to about 100° C. The heated mass flow vaporization system is connected to liquid octamethylcyclotetrasiloxane (Alfa Aesar® Part Number A12540, 98%). The OMCTS flow rate is set to the specific organosilicon precursor flow reported for a particular example. To ensure no condensation of the vaporized OMCTS flow past this point, the gas stream is diverted to the pumping line when it is not flowing into the interior of the COC vessel for processing.


Once the vessel is installed, the vacuum pump valve is opened to the vessel holder 50 and the interior of the COC vessel of U.S. Pat. No. 7,985,188. A vacuum pump and blower comprise the vacuum pump system. The pumping system allows the interior of the COC vessel to be reduced to pressure(s) of less than 100 mTorr while the gaseous reactant or process gases is flowing at the indicated rates.


Once the base vacuum level is achieved, the vessel holder 50 assembly is moved into the electrode 160 assembly. The gas stream (OMCTS vapor) is flowed into the gas delivery port 110 (by adjusting the 3-way valve from the pumping line to the gas delivery port 110. Pressure inside the COC vessel is approximately 140 mTorr as measured by a capacitance manometer (MKS) installed on the pumping line near the valve that controls the vacuum. In addition to the COC vessel pressure, the pressure inside the gas delivery port 110 and gas system is also measured with the thermocouple vacuum gauge that is connected to the gas system. This pressure is typically less than 6 Torr.


Once the gas is flowing to the interior of the COC vessel, the RF power supply is turned on to its fixed power level. A 600 Watt RF power supply is used (at 13.56 MHz) at a fixed power level indicated in a specific example. The RF power supply is connected to an auto match which matches the complex impedance of the plasma (to be created in the vessel) to the output impedance of the RF power supply. The forward power is as stated and the reflected power is 0 Watts so that the stated power is delivered to the interior of the vessel. The RF power supply is controlled by a laboratory timer and the power on time set to 10 seconds (or a different time stated in a given example).


Upon initiation of the RF power, a uniform plasma is established inside the interior of the vessel. The plasma is maintained for the entire coating time, until the RF power is terminated by the timer. The plasma produces a pH protective coating or layer on the interior of the vessel.


After pH protective coating, the gas flow is diverted back to the vacuum line and the vacuum valve is closed. The vent valve is then opened, returning the interior of the COC vessel to atmospheric pressure (approximately 760 Torr). The treated vessel is then carefully removed from the vessel holder 50 assembly (after moving the vessel holder 50 assembly out of the electrode 160 assembly).


A similar protocol is used, except using apparatus generally like that of FIG. 1 of U.S. Pat. No. 7,985,188, for applying a pH protective coating or layer to vessels.


Protocol for Total Silicon Measurement


This protocol is used to determine the total amount of silicon coatings present on the entire vessel wall. A supply of 0.1 N potassium hydroxide (KOH) aqueous solution is prepared, taking care to avoid contact between the solution or ingredients and glass. The water used is purified water, 18 MΩ) quality. A Perkin Elmer Optima Model 7300DV ICP-OES instrument is used for the measurement except as otherwise indicated.


Each device (vessel, such as a vial, syringe, tube, or the like) to be tested and its closure (in the case of a vessel) or other closure are weighed empty to 0.001 g, then filled completely with the KOH solution (with no headspace), closed with the closure, and reweighed to 0.001 g. In a digestion step, each vessel is placed in an autoclave oven (liquid cycle) at 121° C. for 1 hour. The digestion step is carried out to quantitatively remove the silicon coatings from the vessel wall into the KOH solution. After this digestion step, the vessels are removed from the autoclave oven and allowed to cool to room temperature. The contents of the vessels are transferred into ICP tubes. The total Si concentration is run on each solution by ICP/OES following the operating procedure for the ICP/OES.


The total Si concentration is reported as parts per billion of Si in the KOH solution. This concentration represents the total amount of silicon coatings that were on the vessel wall before the digestion step was used to remove it.


The total Si concentration can also be determined for fewer than all the silicon layers on the vessel, as when an SiOx barrier layer is applied, an SiOxCy second layer (for example, a pH protective coating or layer) is then applied, and it is desired to know the total silicon concentration of just the SiOxCy layer. This determination is made by preparing two sets of vessels, one set to which only the SiOx layer is applied and the other set to which the same SiOx layer is applied, followed by the SiOxCy layer or other layers of interest. The total Si concentration for each set of vessels is determined in the same manner as described above. The difference between the two Si concentrations is the total Si concentration of the SiOxCy second layer.


Protocol for Measuring Dissolved Silicon in a Vessel


In some of the working examples, the amount of silicon dissolved from the wall of the vessel by a test solution is determined, in parts per billion (ppb), for example to evaluate the dissolution rate of the test solution. This determination of dissolved silicon is made by storing the test solution in a vessel provided with an SiOx and/or SiOxCy coating or layer under test conditions, then removing a sample of the solution from the vessel and testing the Si concentration of the sample. The test is done in the same manner as the Protocol for Total Silicon Measurement, except that the digestion step of that protocol is replaced by storage of the test solution in the vessel as described in this protocol. The total Si concentration is reported as parts per billion of Si in the test solution


Protocol for Determining Average Dissolution Rate


The average dissolution rates reported in the working examples are determined as follows. A series of test vessels having a known total silicon measurement are filled with the desired test solution analogous to the manner of filling the vessels with the KOH solution in the Protocol for Total Silicon Measurement. (The test solution can be a physiologically inactive test solution as employed in the present working examples or a physiologically active pharmaceutical preparation intended to be stored in the vessels to form a pharmaceutical package). The test solution is stored in respective vessels for several different amounts of time, then analyzed for the Si concentration in parts per billion in the test solution for each storage time. The respective storage times and Si concentrations are then plotted. The plots are studied to find a series of substantially linear points having the steepest slope.


The plot of dissolution amount (ppb Si) versus days decreases in slope with time, even though it does not appear that the Si layer has been fully digested by the test solution.


For the PC194 test data in Table 10 below, linear plots of dissolution versus time data are prepared by using a least squares linear regression program to find a linear plot corresponding to the first five data points of each of the experimental plots. The slope of each linear plot is then determined and reported as representing the average dissolution rate applicable to the test, measured in parts per billion of Si dissolved in the test solution per unit of time.


Protocol for Determining Calculated Shelf Life


The calculated shelf life values reported in the working examples below are determined by extrapolation of the total silicon measurements and average dissolution rates, respectively determined as described in the Protocol for Total Silicon Measurement and the Protocol for Determining Average Dissolution Rate. The assumption is made that under the indicated storage conditions the SiOxCy pH protective coating or layer will be removed at the average dissolution rate until the coating is entirely removed. Thus, the total silicon measurement for the vessel, divided by the dissolution rate, gives the period of time required for the test solution to totally dissolve the SiOxCy coating. This period of time is reported as the calculated shelf life. Unlike commercial shelf life calculations, no safety factor is calculated. Instead, the calculated shelf life is the calculated time to failure.


It should be understood that because the plot of ppb Si versus hours decreases in slope with time, an extrapolation from relatively short measurement times to relatively long calculated shelf lives is believed to be a “worst case” test that tends to underestimate the calculated shelf life actually obtainable.


Test Methods


Barrier Improvement Factor


The barrier improvement factor (BIF) of a barrier coating or layer can be determined by providing two groups of identical containers, adding a barrier layer to one group of containers, testing a barrier property (such as the rate of outgassing in micrograms per minute or another suitable measure) on containers having a barrier, doing the same test on containers lacking a barrier, and taking a ratio of the properties of the materials with versus without a barrier. For example, if the rate of outgassing through the barrier is one-third the rate of outgassing without a barrier, the barrier has a BIF of 3.


Measurement of Coating Thickness


The thickness of a PECVD coating or layer such as the pH protective coating or layer, the barrier coating or layer, the lubricity coating or layer, and/or a composite of any two or more of these layers can be measured, for example, by transmission electron microscopy (TEM). An exemplary TEM image for a pH protective coating or layer is shown in FIG. 18. An exemplary TEM image for an SiOx barrier coating or layer also is shown in FIG. 18.


The TEM can be carried out, for example, as follows. Samples can be prepared for Focused Ion Beam (FIB) cross-sectioning in two ways. Either the samples can be first coated with a thin layer of carbon (50-100 nm thick) and then coated with a sputtered coating or layer of platinum (50-100 nm thick) using a K575X Emitech primer coating or layer system, or the samples can be coated directly with the protective sputtered Pt layer. The coated samples can be placed in an FEI FIB200 FIB system. An additional coating or layer of platinum can be FIB-deposited by injection of an organometallic gas while rastering the 30 kV gallium ion beam over the area of interest. The area of interest for each sample can be chosen to be a location half way down the length of the vessel. Thin cross sections measuring approximately 15 μm (“micrometers”) long, 2 μm wide and 15 μm deep can be extracted from the die surface using an in-situ FIB lift-out technique. The cross sections can be attached to a 200 mesh copper TEM grid using FIB-deposited platinum. One or two windows in each section, measuring about 8 μm wide, can be thinned to electron transparency using the gallium ion beam of the FEI FIB.


Cross-sectional image analysis of the prepared samples can be performed utilizing either a Transmission Electron Microscope (TEM), or a Scanning Transmission Electron Microscope (STEM), or both. All imaging data can be recorded digitally. For STEM imaging, the grid with the thinned foils can be transferred to a Hitachi HD2300 dedicated STEM. Scanning transmitted electron images can be acquired at appropriate magnifications in atomic number contrast mode (ZC) and transmitted electron mode (TE). The following instrument settings can be used.














Scanning Transmission Electron


Instrument
Microscope







Manufacturer/Model
Hitachi HD2300


Accelerating Voltage
200 kV


Objective Aperture
2


Condenser Lens 1 Setting
1.672


Condenser Lens 2 Setting
1.747


Approximate Objective Lens Setting
5.86


ZC Mode Projector Lens
1.149


TE Mode Projector Lens
0.7


Image Acquisition


Pixel Resolution
1280 × 960


Acquisition Time
20 sec.(x4









For TEM analysis the sample grids can be transferred to a Hitachi HF2000 transmission electron microscope. Transmitted electron images can be acquired at appropriate magnifications. The relevant instrument settings used during image acquisition can be those given below.
















Instrument
Transmission Electron Microscope









Manufacturer/Model
Hitachi HF2000



Accelerating Voltage
200 kV



Condenser Lens 1
0.78



Condenser Lens 2
0



Objective Lens
6.34



Condenser Lens Aperture
1



Objective Lens Aperture
3



for imaging



Selective Area Aperture
N/A



for SAD











SEM Procedure


SEM Sample Preparation: Each vessel sample was cut in half along its length (to expose the inner or interior surface). The top of the vessel (Luer end) was cut off to make the sample smaller.


The sample was mounted onto the sample holder with conductive graphite adhesive, then put into a Denton Desk IV SEM Sample Preparation System, and a thin (approximately 50 Å) gold coating was sputtered onto the inner or interior surface of the vessel. The gold coating is used to eliminate charging of the surface during measurement.


The sample was removed from the sputter system and mounted onto the sample stage of a Jeol JSM 6390 SEM (Scanning Electron Microscope). The sample was pumped down to at least 1×10-6 Torr in the sample compartment. Once the sample reached the required vacuum level, the slit valve was opened and the sample was moved into the analysis station.


The sample was imaged at a coarse resolution first, then higher magnification images were accumulated. The SEM images can be, for example, 5 m edge-to-edge (horizontal and vertical).


XPS


The composition of the SiOx or other barrier coating or layer can be measured, for example, by X-ray photoelectron spectroscopy (XPS).


Silicon Dissolution Rate


As shown in the working examples, the silicon dissolution rate is measured by determining the total silicon leached from the vessel into its contents, and does not distinguish between the silicon derived from the pH protective coating or layer 286, the barrier coating or layer 288, or other materials present.

Claims
  • 1. A blood sample collection tube comprising: a wall having a surface and a coating set on the surface comprising a tie coating or layer, a barrier coating or layer, and a pH protective coating or layer; the tie coating or layer comprising SiOxCy or SiNxCy wherein x is from about 0.5 to about 2.4 and y is from about 0.6 to about 3, the tie coating or layer having an outer surface facing the wall surface and the tie coating or layer having an interior surface;the barrier coating or layer comprising SiOx, wherein x is from 1.5 to 2.9, from 2 to 1000 nm thick, the barrier coating or layer of SiOx having an outer surface facing the interior surface of the tie coating or layer and the barrier coating or layer of SiOx having an interior surface, the barrier coating or layer being effective to reduce the ingress of atmospheric gas through the wall compared to an uncoated wall; andthe pH protective coating or layer comprising SiOxCy or SiNxCy wherein x is from about 0.5 to about 2.4 and y is from about 0.6 to about 3, on the barrier coating or layer, the pH protective coating or layer being formed by chemical vapor deposition of a precursor selected from an acyclic siloxane, a monocyclic siloxane, a polycyclic siloxane, a polysilsesquioxane, a monocyclic silazane, a polycyclic silazane, a polysilsesquiazane, a silatrane, a silquasilatrane, a silproatrane, an azasilatrane, an azasilquasiatrane, an azasilproatrane, or a combination of any two or more of these precursors; andin which the rate of erosion of the pH protective coating or layer, if directly contacted by a fluid composition having a pH at some point between 5 and 9, is less than the rate of erosion of the barrier coating or layer, if directly contacted by the fluid composition.
  • 2. The blood sample collection tube of claim 1, in which the pH protective coating or layer as applied is between 100 and 700 nm thick.
  • 3. The blood sample collection tube of claim 1, in which the rate of erosion of the pH protective coating or layer, if directly contacted by a fluid composition having a pH of 8, is less than 20% of the rate of erosion of the barrier coating or layer, if directly contacted by the same fluid composition under the same conditions.
  • 4. The blood sample collection tube of claim 1, in which the rate of erosion of the pH protective coating or layer, if directly contacted by a fluid composition having a pH of 8, is from 5% to 20% of the rate of erosion of the barrier coating or layer, if directly contacted by the same fluid composition under the same conditions.
  • 5. The blood sample collection tube of claim 1, in which the silicon dissolution rate by a 50 mM potassium phosphate buffer diluted in water for injection, adjusted to pH 8 with concentrated nitric acid, and containing 0.2 wt. % polysorbate-80 surfactant from the vessel is less than 170 ppb/day.
  • 6. The blood sample collection tube of claim 1, in which x is between 0.5 and 1.5 and y is between 0.9 and 2.
  • 7. The blood sample collection tube of claim 1, in which the tie coating or layer on average is between 10 and 100 nm thick.
  • 8. The blood sample collection tube of claim 1 in which the barrier coating or layer on average is between 10 and 100 nm thick.
  • 9. The blood sample collection tube of claim 1 in which the range of thickness of the pH protective coating or layer is between 50 and 400 nm thick.
  • 10. The blood sample collection tube of claim 1, in which an FTIR absorbance spectrum of the pH protective coating or layer has a ratio greater than 0.75 between: the maximum amplitude of the Si—O—Si symmetrical stretch peak between about 1000 and 1040 cm−1, andthe maximum amplitude of the Si—O—Si asymmetric stretch peak between about 1060 and about 1100 cm−1.
  • 11. The blood sample collection tube of claim 10, in which the ratio is at most 1.7.
  • 12. The blood sample collection tube of claim 1, wherein the pH protective coating or layer shows an O-Parameter measured with attenuated total reflection (ATR) of less than 0.4, measured as:
  • 13. The blood sample collection tube of claim 12, in which the O-parameter has a value of from 0.15 to 0.37.
  • 14. The blood sample collection tube of claim 1, wherein the pH protective coating or layer shows an N-Parameter measured with attenuated total reflection (ATR) of less than 0.7, measured as:
  • 15. The blood sample collection tube of claim 14, in which the N-parameter has a value of 0.4 to 0.6.
  • 16. A blood sample collection tube comprising: a vessel having a lumen defined at least in part by a wall, the wall having an interior surface facing the lumen, an outer surface, and a coating set on the interior surface comprising a tie coating or layer, a barrier coating or layer, and a pH protective coating or layer; the tie coating or layer comprising SiOxCy or SiNxCy wherein x is from about 0.5 to about 2.4 and y is from about 0.6 to about 3, the tie coating or layer having an interior surface facing the lumen and an outer surface facing the wall interior surface;the barrier coating or layer comprising SiOx, wherein x is from 1.5 to 2.9, from 2 to 1000 nm thick, the barrier coating or layer of SiOx having an interior surface facing the lumen and an outer surface facing the interior surface of the tie coating or layer, the barrier coating or layer being effective to reduce the ingress of atmospheric gas into the lumen compared to an vessel without a barrier coating or layer;the pH protective coating or layer comprising SiOxCy or SiNxCy wherein x is from about 0.5 to about 2.4 and y is from about 0.6 to about 3, the pH protective coating or layer having an interior surface facing the lumen and an outer surface facing the interior surface of the barrier coating or layer,the combination of the tie coating or layer and the pH protective coating or layer being effective to increase the calculated shelf life of the package (total Si/Si dissolution rate); anda fluid composition contained in the lumen and having a pH between 5 and 9; wherein the calculated shelf life of the blood sample collection tube more than six months at a storage temperature of 4° C.
  • 17. A blood sample collection tube comprising: a thermoplastic wall having an interior surface enclosing a lumen;a fluid contained in the lumen having a pH greater than 5 disposed in the lumen;a tie coating or layer comprising SiOxCy or SiNxCy wherein x is from about 0.5 to about 2.4 and y is from about 0.6 to about 3, the tie coating or layer having an outer surface facing the wall surface and the tie coating or layer having an interior surface;a barrier coating or layer of SiOx, in which x is between 1.5 and 2.9, the barrier coating or layer applied by PECVD, positioned between the interior surface of the tie coating or layer and the fluid, and supported by the thermoplastic wall, the barrier coating or layer having the characteristic of being subject to being measurably diminished in barrier improvement factor in less than six months as a result of attack by the fluid; anda pH protective coating or layer of SiOxCy, in which x is between 0.5 and 2.4 and y is between 0.6 and 3, the pH protective coating or layer applied by PECVD, positioned between the barrier coating or layer and the fluid and supported by the thermoplastic wall, the pH protective coating or layer and tie coating or layer together being effective to keep the barrier coating or layer at least substantially undissolved as a result of attack by the fluid for a period of at least six months.
  • 18. The blood sample collection tube of claim 17, in which the fluid composition has a pH between 5 and 6.
  • 19. The blood sample collection tube of claim 17, in which the fluid composition has a pH between 6 and 7.
  • 20. The blood sample collection tube of claim 17, in which the fluid composition has a pH between 7 and 8.
  • 21. The blood sample collection tube of claim 17, in which the fluid composition has a pH between 8 and 9.
  • 22. The blood sample collection tube of claim 17, in which the pH protective coating or layer contacting the fluid composition is between 50 and 500 nm thick two years after the invention is assembled.
  • 23. The blood sample collection tube of claim 17, in which the calculated shelf life (total Si/Si dissolution rate) is more than 18 months.
  • 24. The blood sample collection tube of claim 17, in which the calculated shelf life (total Si/Si dissolution rate) is more than 2 years.
  • 25. The blood sample collection tube of claim 17, having a shelf life, after the invention is assembled, of at least two years.
  • 26. The blood sample collection tube of claim 25, in which the shelf life is determined at 20° C.
Parent Case Info

This application is a continuation-in-part of U.S. Ser. No. 16/029,923, filed Jul. 9, 2018, now pending, which is a continuation of U.S. Ser. No. 15/385,150, filed Dec. 20, 2016, now U.S. patent Ser. No. 10/016,338, which is a continuation of U.S. Ser. No. 14/205,329, filed Mar. 11, 2014, now U.S. Pat. No. 9,554,968, which claims the priority of U.S. Provisional Applications 61/776,733, filed Mar. 11, 2013, and 61/800,746, filed Mar. 15, 2013. This application is also a continuation-in-part of U.S. Ser. No. 14/357,418, filed Nov. 9, 2012, now U.S. patent Ser. No. 10/189,603, which is the U.S. National Stage of International Application No. PCT/US2012/064489, which claims priority to U.S. Ser. No. 61/645,003, filed May 9, 2012, U.S. Ser. No. 61/636,377, filed Apr. 20, 2012, and U.S. Ser. No. 61/558,885, filed Nov. 11, 2011. The entire specification and all the drawings of each application mentioned in this paragraph is incorporated here by reference to provide continuity of disclosure. The specification and drawings of U.S. Ser. No. 12/779,007, filed May 12, 2010, now U.S. Pat. No. 7,985,188, is also incorporated here by reference in its entirety.

US Referenced Citations (935)
Number Name Date Kind
3274267 Chow Sep 1966 A
3297465 Connell Jan 1967 A
3355947 Karlby Dec 1967 A
3442686 Jones May 1969 A
3448614 Muger Jun 1969 A
3590634 Pasternak Jul 1971 A
3838598 Tomkins Oct 1974 A
3957653 Blecher May 1976 A
4111326 Percarpio Sep 1978 A
4134832 Heimreid Jan 1979 A
4136794 Percapio Jan 1979 A
4162528 Maldonado Jul 1979 A
4168330 Kaganowicz Sep 1979 A
4186840 Percarpio Feb 1980 A
4187952 Percarpio Feb 1980 A
4226333 Percarpio Oct 1980 A
4289726 Potoczky Sep 1981 A
4290534 Percarpio Sep 1981 A
4293078 Percarpio Oct 1981 A
4338764 Percarpio Jul 1982 A
4391128 McWorter Jul 1983 A
4392218 Plunkett, Jr. Jul 1983 A
4422896 Class Dec 1983 A
4452679 Dunn Jun 1984 A
4478873 Masso Oct 1984 A
4481229 Suzuki Nov 1984 A
4483737 Mantel Nov 1984 A
4484479 Eckhardt Nov 1984 A
4486378 Hirata Dec 1984 A
4522510 Rosencwaig Jun 1985 A
4524089 Haque Jun 1985 A
4524616 Drexel Jun 1985 A
4552791 Hahn Nov 1985 A
4576204 Smallborn Mar 1986 A
4609428 Fujimura Sep 1986 A
4610770 Saito Sep 1986 A
4648107 Latter Mar 1987 A
4648281 Morita Mar 1987 A
4652429 Konrad Mar 1987 A
4664279 Obrist May 1987 A
4667620 White May 1987 A
4668365 Foster May 1987 A
4683838 Kimura Aug 1987 A
4697717 Grippi Oct 1987 A
4703187 Hofling Oct 1987 A
4716491 Ohno Dec 1987 A
4721553 Saito Jan 1988 A
4725481 Ostapchenko Feb 1988 A
4741446 Miller May 1988 A
4756964 Kincaid Jul 1988 A
4767414 Williams Aug 1988 A
4778721 Sliemers Oct 1988 A
4799246 Fischer Jan 1989 A
4808453 Romberg Feb 1989 A
4809876 Tomaswick Mar 1989 A
4824444 Nomura Apr 1989 A
4841776 Kawachi Jun 1989 A
4842704 Collins Jun 1989 A
4844986 Karakelle Jul 1989 A
4846101 Montgomery Jul 1989 A
4853102 Tateishi Aug 1989 A
4869203 Pinkhasov Sep 1989 A
4872758 Miyazaki Oct 1989 A
4874497 Matsuoka Oct 1989 A
4880675 Mehta Nov 1989 A
4883686 Doehler Nov 1989 A
4886086 Etchells Dec 1989 A
4894256 Gartner Jan 1990 A
4894510 Nakanishi Jan 1990 A
4897285 Wilhelm Jan 1990 A
4926791 Hirose May 1990 A
4948628 Montgomery Aug 1990 A
4973504 Romberg Nov 1990 A
4991104 Miller Feb 1991 A
4999014 Gold Mar 1991 A
5000994 Romberg Mar 1991 A
5016564 Nakamura May 1991 A
5021114 Saito Jun 1991 A
5028566 Lagendijk Jul 1991 A
5030475 Ackermann Jul 1991 A
5032202 Tsai Jul 1991 A
5039548 Hirose Aug 1991 A
5041303 Wertheimer Aug 1991 A
5042951 Gold Aug 1991 A
5044199 Drexel Sep 1991 A
5064083 Alexander Nov 1991 A
5067491 Taylor Nov 1991 A
5079481 Moslehi Jan 1992 A
5082542 Moslehi Jan 1992 A
5084356 Deak Jan 1992 A
5085904 Deak Feb 1992 A
5099881 Nakajima Mar 1992 A
5113790 Geisler May 1992 A
5120966 Kondo Jun 1992 A
5131752 Yu Jul 1992 A
5144196 Gegenwart Sep 1992 A
5147678 Foerch Sep 1992 A
5154943 Etzkorn Oct 1992 A
5189446 Barnes Feb 1993 A
5192849 Moslehi Mar 1993 A
5198725 Chen Mar 1993 A
5203959 Hirose Apr 1993 A
5204141 Roberts Apr 1993 A
5209882 Hattori May 1993 A
5216329 Pelleteir Jun 1993 A
5224441 Felts Jul 1993 A
5225024 Hanley Jul 1993 A
5232111 Burns Aug 1993 A
5252178 Moslehi Oct 1993 A
5260095 Aftinito Nov 1993 A
5266398 Hioki Nov 1993 A
5271274 Khuri-Yakub Dec 1993 A
5272417 Ohmi Dec 1993 A
5272735 Bryan Dec 1993 A
5275299 Konrad Jan 1994 A
5286297 Moslehi Feb 1994 A
5292370 Tsai Mar 1994 A
5294011 Konrad Mar 1994 A
5294464 Geisler Mar 1994 A
5297561 Hulon Mar 1994 A
5298587 Hu Mar 1994 A
5300901 Krummel Apr 1994 A
5302266 Grabarz Apr 1994 A
5308649 Babacz May 1994 A
5314561 Komiya May 1994 A
5320875 Hu Jun 1994 A
5321634 Obata Jun 1994 A
5330578 Sakama Jul 1994 A
5333049 Ledger Jul 1994 A
5338579 Ogawa et al. Aug 1994 A
5346579 Cook Sep 1994 A
5354286 Mesa Oct 1994 A
5356029 Hogan Oct 1994 A
5361921 Burns Nov 1994 A
5364665 Felts Nov 1994 A
5364666 Williams Nov 1994 A
5372851 Ogawa et al. Dec 1994 A
5374314 Babacz Dec 1994 A
5378510 Thomas Jan 1995 A
5381228 Brace Jan 1995 A
5395644 Affinito Mar 1995 A
5396080 Hannotiau Mar 1995 A
5397956 Araki Mar 1995 A
5409782 Murayama Apr 1995 A
5413813 Cruse May 1995 A
5423915 Murata Jun 1995 A
5429070 Campbell Jul 1995 A
5433786 Hu Jul 1995 A
5434008 Felts Jul 1995 A
5439736 Nomura Aug 1995 A
5440446 Shaw Aug 1995 A
5443645 Otoshi Aug 1995 A
5444207 Sekine Aug 1995 A
5449432 Hanawa Sep 1995 A
5452082 Sanger Sep 1995 A
5468520 Williams Nov 1995 A
5470388 Goedicke Nov 1995 A
5472660 Fortin Dec 1995 A
5485091 Verkuil Jan 1996 A
5486701 Norton Jan 1996 A
5494170 Burns Feb 1996 A
5494712 Hu Feb 1996 A
5495958 Konrad Mar 1996 A
5508075 Roulin Apr 1996 A
5510155 Williams Apr 1996 A
5513515 Mayer May 1996 A
5514276 Babock May 1996 A
5521351 Mahoney May 1996 A
5522518 Konrad Jun 1996 A
5531060 Fayet Jul 1996 A
5531683 Kriesel Jul 1996 A
5536253 Haber Jul 1996 A
5543919 Mumola Aug 1996 A
5545375 Tropsha Aug 1996 A
5547508 Affinito Aug 1996 A
5547723 Williams Aug 1996 A
5554223 Imahashi Sep 1996 A
5555471 Xu Sep 1996 A
5565248 Piester Oct 1996 A
5569810 Tsuji Oct 1996 A
5571366 Ishii Nov 1996 A
5578103 Araujo Nov 1996 A
5591898 Mayer Jan 1997 A
5593550 Stewart Jan 1997 A
5597456 Maruyama Jan 1997 A
5616369 Williams Apr 1997 A
5620523 Maeda Apr 1997 A
5632396 Burns May 1997 A
5633711 Nelson May 1997 A
5643638 Otto Jul 1997 A
5652030 Delperier Jul 1997 A
5654054 Tropsha Aug 1997 A
5656141 Betz Aug 1997 A
5658438 Givens Aug 1997 A
5665280 Tropsha Sep 1997 A
5667840 Tingey Sep 1997 A
5674321 Pu Oct 1997 A
5677010 Esser Oct 1997 A
5679412 Kuehnle Oct 1997 A
5679413 Petrmichl Oct 1997 A
5683771 Tropsha Nov 1997 A
5686157 Harvey Nov 1997 A
5690745 Grunwald Nov 1997 A
5691007 Montgomery Nov 1997 A
5693196 Stewart Dec 1997 A
5699923 Burns Dec 1997 A
5702770 Martin Dec 1997 A
5704983 Thomas et al. Jan 1998 A
5716683 Harvey Feb 1998 A
5718967 Hu Feb 1998 A
5725909 Shaw Mar 1998 A
5733405 Taki Mar 1998 A
5736207 Walther Apr 1998 A
5737179 Shaw Apr 1998 A
5738233 Burns Apr 1998 A
5738920 Knors Apr 1998 A
5744360 Hu Apr 1998 A
5750892 Huang May 1998 A
5763033 Tropsha Jun 1998 A
5766362 Montgomery Jun 1998 A
5769273 Sasaki Jun 1998 A
5779074 Burns Jul 1998 A
5779716 Cano Jul 1998 A
5779802 Borghs Jul 1998 A
5779849 Blalock Jul 1998 A
5788670 Reinhard Aug 1998 A
5792940 Ghandhi Aug 1998 A
5798027 Lefebvre Aug 1998 A
5800880 Laurent Sep 1998 A
5807343 Tucker Sep 1998 A
5807605 Tingey Sep 1998 A
5812261 Nelson Sep 1998 A
5814257 Kawata Sep 1998 A
5814738 Pinkerton Sep 1998 A
5820603 Tucker Oct 1998 A
5823373 Sudo Oct 1998 A
5824198 Williams Oct 1998 A
5824607 Trow Oct 1998 A
5833752 Martin Nov 1998 A
5837888 Mayer Nov 1998 A
5837903 Weingand Nov 1998 A
5840167 Kim Nov 1998 A
5849368 Hostettler Dec 1998 A
5853833 Sudo Dec 1998 A
5855686 Rust Jan 1999 A
5861546 Sagi Jan 1999 A
5871700 Konrad Feb 1999 A
5877895 Shaw Mar 1999 A
5880034 Keller Mar 1999 A
5888414 Collins Mar 1999 A
5888591 Gleason Mar 1999 A
5897508 Konrad Apr 1999 A
5900284 Hu May 1999 A
5900285 Walther May 1999 A
5902461 Xu May 1999 A
5904952 Lopata May 1999 A
5913140 Roche Jun 1999 A
5914189 Hasz Jun 1999 A
5919328 Tropsha Jul 1999 A
5919420 Niermann Jul 1999 A
5935391 Nakahigashi Aug 1999 A
5945187 Buch-Rasmussen Aug 1999 A
5951527 Sudo Sep 1999 A
5952069 Tropsha Sep 1999 A
5955161 Tropsha Sep 1999 A
5961911 Hwang Oct 1999 A
5968620 Harvey Oct 1999 A
5972297 Niermann Oct 1999 A
5972436 Walther Oct 1999 A
5985103 Givens Nov 1999 A
6001429 Martin Dec 1999 A
6009743 Mayer Jan 2000 A
6013337 Knors Jan 2000 A
6017317 Newby Jan 2000 A
6018987 Mayer Feb 2000 A
6020196 Hu Feb 2000 A
6027619 Cathey Feb 2000 A
6032813 Niermann Mar 2000 A
6035717 Carodiskey Mar 2000 A
6050400 Taskis Apr 2000 A
6051151 Keller Apr 2000 A
6054016 Tuda Apr 2000 A
6054188 Tropsha Apr 2000 A
6068884 Rose May 2000 A
6077403 Kobayashi Jun 2000 A
6081330 Nelson Jun 2000 A
6082295 Lee Jul 2000 A
6083313 Venkatraman et al. Jul 2000 A
6085927 Kusz Jul 2000 A
6090081 Sudo Jul 2000 A
6106678 Shufflebotham Aug 2000 A
6110395 Gibson, Jr. Aug 2000 A
6110544 Yang Aug 2000 A
6112695 Felts Sep 2000 A
6116081 Ghandhi Sep 2000 A
6117243 Walther Sep 2000 A
6118844 Fischer Sep 2000 A
6124212 Fan Sep 2000 A
6125687 McClelland Oct 2000 A
6126640 Tucker Oct 2000 A
6136275 Niermann Oct 2000 A
6139802 Niermann Oct 2000 A
6143140 Wang Nov 2000 A
6149982 Plester Nov 2000 A
6153269 Gleason Nov 2000 A
6156152 Ogino Dec 2000 A
6156399 Spallek Dec 2000 A
6156435 Gleason Dec 2000 A
6160350 Sakemi Dec 2000 A
6161712 Savitz Dec 2000 A
6163006 Doughty Dec 2000 A
6165138 Miller Dec 2000 A
6165542 Jaworowski Dec 2000 A
6165566 Tropsha Dec 2000 A
6171670 Sudo Jan 2001 B1
6175612 Sato Jan 2001 B1
6177142 Felts Jan 2001 B1
6180185 Felts Jan 2001 B1
6180191 Felts Jan 2001 B1
6188079 Juvinall Feb 2001 B1
6189484 Yin Feb 2001 B1
6190992 Sandhu Feb 2001 B1
6193853 Yumshtyk Feb 2001 B1
6196155 Setoyama Mar 2001 B1
6197166 Moslehi Mar 2001 B1
6200658 Walther Mar 2001 B1
6200675 Neerinck Mar 2001 B1
6204922 Chalmers Mar 2001 B1
6210791 Skoog Apr 2001 B1
6213985 Niedospial Apr 2001 B1
6214422 Yializis Apr 2001 B1
6217716 Fai Lai Apr 2001 B1
6223683 Plester May 2001 B1
6236459 Negandaripour May 2001 B1
6245190 Masuda Jun 2001 B1
6248219 Wellerdieck Jun 2001 B1
6248397 Ye Jun 2001 B1
6251792 Collins Jun 2001 B1
6254983 Namiki Jul 2001 B1
6261643 Hasz Jul 2001 B1
6263249 Stewart Jul 2001 B1
6271047 Ushio Aug 2001 B1
6276296 Plester Aug 2001 B1
6277331 Konrad Aug 2001 B1
6279505 Plester Aug 2001 B1
6284986 Dietze Sep 2001 B1
6306132 Moorman Oct 2001 B1
6308556 Sagi Oct 2001 B1
6322661 Bailey, III Nov 2001 B1
6331174 Reinhard et al. Dec 2001 B1
6346596 Mallen Feb 2002 B1
6348967 Nelson Feb 2002 B1
6350415 Niermann Feb 2002 B1
6351075 Barankova Feb 2002 B1
6352629 Wang Mar 2002 B1
6354452 DeSalvo Mar 2002 B1
6355033 Moorman Mar 2002 B1
6365013 Beele Apr 2002 B1
6375022 Zurcher Apr 2002 B1
6376028 Laurent Apr 2002 B1
6379757 Iacovangelo Apr 2002 B1
6382441 Carano May 2002 B1
6394979 Sharp May 2002 B1
6396024 Doughty May 2002 B1
6399944 Vasilyev Jun 2002 B1
6402885 Loewenhardt Jun 2002 B2
6410926 Munro Jun 2002 B1
6413645 Graff Jul 2002 B1
6432494 Yang Aug 2002 B1
6432510 Kim Aug 2002 B1
6470650 Lohwasser Oct 2002 B1
6471822 Yin Oct 2002 B1
6475622 Namiki Nov 2002 B2
6482509 Buch-Rasmussen et al. Nov 2002 B2
6486081 Ishikawa Nov 2002 B1
6500500 Okamura Dec 2002 B1
6503579 Murakami Jan 2003 B1
6518195 Collins Feb 2003 B1
6524448 Brinkmann Feb 2003 B2
6539890 Felts Apr 2003 B1
6544610 Minami Apr 2003 B1
6551267 Cohen Apr 2003 B1
6558679 Flament-Garcia et al. May 2003 B2
6562189 Quiles May 2003 B1
6565791 Laurent May 2003 B1
6582426 Moorman Jun 2003 B2
6582823 Sakhrani et al. Jun 2003 B1
6584828 Sagi Jul 2003 B2
6595961 Hetzler Jul 2003 B2
6597193 Lagowski Jul 2003 B2
6599569 Humele Jul 2003 B1
6599594 Walther Jul 2003 B1
6602206 Niermann Aug 2003 B1
6616632 Sharp Sep 2003 B2
6620139 Plicchi Sep 2003 B1
6620334 Kanno Sep 2003 B2
6623861 Martin Sep 2003 B2
6638403 Inaba Oct 2003 B1
6638876 Levy Oct 2003 B2
6645354 Gorokhovsky Nov 2003 B1
6651835 Iskra Nov 2003 B2
6652520 Moorman Nov 2003 B2
6656540 Sakamoto Dec 2003 B2
6658919 Chatard Dec 2003 B2
6662957 Zurcher Dec 2003 B2
6663601 Hetzler Dec 2003 B2
6670200 Ushio Dec 2003 B2
6673199 Yamartino Jan 2004 B1
6680091 Buch-Rasmussen et al. Jan 2004 B2
6680621 Savtchouk Jan 2004 B2
6683308 Itagaki Jan 2004 B2
6684683 Potyrailo Feb 2004 B2
6702898 Hosoi Mar 2004 B2
6706412 Yializis Mar 2004 B2
6746430 Lubrecht Jun 2004 B2
6749078 Iskra Jun 2004 B2
6752899 Singh Jun 2004 B1
6753972 Hirose Jun 2004 B1
6757056 Meeks Jun 2004 B1
6764714 Wei Jul 2004 B2
6765466 Miyata Jul 2004 B2
6766682 Engle Jul 2004 B2
6774018 Mikhael Aug 2004 B2
6796780 Chatard Sep 2004 B1
6800852 Larson Oct 2004 B2
6808753 Rule Oct 2004 B2
6810106 Sato Oct 2004 B2
6815014 Gabelnick Nov 2004 B2
6818310 Namiki Nov 2004 B2
6827972 Darras Dec 2004 B2
6837954 Carano Jan 2005 B2
6844075 Saak Jan 2005 B1
6853141 Hoffman Feb 2005 B2
6858259 Affinito Feb 2005 B2
6863731 Elsayed-Ali Mar 2005 B2
6864773 Perrin Mar 2005 B2
6866656 Tingey Mar 2005 B2
6872428 Yang Mar 2005 B2
6876154 Appleyard Apr 2005 B2
6885727 Tamura Apr 2005 B2
6887578 Gleason May 2005 B2
6891158 Larson May 2005 B2
6892567 Morrow May 2005 B1
6899054 Bardos May 2005 B1
6905769 Komada Jun 2005 B2
6910597 Iskra Jun 2005 B2
6911779 Madocks Jun 2005 B2
6919107 Schwarzenbach Jul 2005 B2
6919114 Darras Jul 2005 B1
6933460 Vanden Brande Aug 2005 B2
6946164 Huang Sep 2005 B2
6952949 Moore Oct 2005 B2
6960393 Yializis Nov 2005 B2
6962671 Martin Nov 2005 B2
6965221 Lipcsei Nov 2005 B2
6981403 Ascheman Jan 2006 B2
6989675 Kesil Jan 2006 B2
6995377 Darr Feb 2006 B2
7029755 Terry Apr 2006 B2
7029803 Becker Apr 2006 B2
7039158 Janik May 2006 B1
7052736 Wei May 2006 B2
7052920 Ushio May 2006 B2
7059268 Russell Jun 2006 B2
7067034 Bailey, III Jun 2006 B2
7074501 Czeremuszkin Jul 2006 B2
7098453 Ando Aug 2006 B2
7109070 Behle Sep 2006 B2
7112352 Schaepkens Sep 2006 B2
7112541 Xia Sep 2006 B2
7115310 Jacoud Oct 2006 B2
7118538 Konrad Oct 2006 B2
7119908 Nomoto Oct 2006 B2
7121135 Moore Oct 2006 B2
7130373 Omote Oct 2006 B2
7150299 Hertzler Dec 2006 B2
7160292 Moorman Jan 2007 B2
7180849 Hirokane Feb 2007 B2
7183197 Won Feb 2007 B2
7188734 Konrad Mar 2007 B2
7189218 Lichtenberg Mar 2007 B2
7189290 Hama Mar 2007 B2
7193724 Isei Mar 2007 B2
7198685 Hetzler Apr 2007 B2
7206074 Fujimoto Apr 2007 B2
7244381 Chatard Jul 2007 B2
7253892 Semersky Aug 2007 B2
7286242 Kim Oct 2007 B2
7288293 Koulik Oct 2007 B2
7297216 Hetzler Nov 2007 B2
7297640 Xie Nov 2007 B2
7300684 Boardman Nov 2007 B2
7303789 Saito Dec 2007 B2
7303790 Delaunay Dec 2007 B2
7306852 Komada Dec 2007 B2
7332227 Hardman Feb 2008 B2
7338576 Ono Mar 2008 B2
7339682 Aiyer Mar 2008 B2
7344766 Sorensen Mar 2008 B1
7348055 Chappa Mar 2008 B2
7348192 Mikami Mar 2008 B2
7362425 Meeks Apr 2008 B2
7381469 Moelle Jun 2008 B2
7390573 Korevaar Jun 2008 B2
7399500 Bicker Jul 2008 B2
7404278 Wittland Jul 2008 B2
7405008 Domine Jul 2008 B2
7409313 Ringermacher Aug 2008 B2
7411685 Takashima Aug 2008 B2
RE40531 Graff Oct 2008 E
7431989 Sakhrani Oct 2008 B2
7438783 Miyata Oct 2008 B2
7444955 Boardman Nov 2008 B2
7455892 Goodwin Nov 2008 B2
7480363 Lasiuk Jan 2009 B2
7488683 Kobayashi Feb 2009 B2
7494941 Kasahara Feb 2009 B2
7507378 Reichenbach Mar 2009 B2
7513953 Felts Apr 2009 B1
7520965 Wei Apr 2009 B2
7521022 Konrad Apr 2009 B2
7534615 Havens May 2009 B2
7534733 Bookbinder May 2009 B2
RE40787 Martin Jun 2009 E
7541069 Tudhope Jun 2009 B2
7552620 DeRoos Jun 2009 B2
7553529 Sakhrani Jun 2009 B2
7555934 DeRoos Jul 2009 B2
7569035 Wilmot Aug 2009 B1
7571122 Howes Aug 2009 B2
7579056 Brown Aug 2009 B2
7586824 Hirokane Aug 2009 B2
7582868 Jiang Sep 2009 B2
7595097 Iacovangelo Sep 2009 B2
7608151 Tudhope Oct 2009 B2
7609605 Hirokane Oct 2009 B2
7618686 Colpo Nov 2009 B2
7624622 Mayer Dec 2009 B1
7625494 Honda Dec 2009 B2
7641636 Moesli Jan 2010 B2
7645696 Dulkin Jan 2010 B1
7648481 Geiger Jan 2010 B2
7648762 Sohn Jan 2010 B2
7682816 Kim Mar 2010 B2
7694403 Moulton Apr 2010 B2
7699933 Lizenberg Apr 2010 B2
7704683 Wittenberg Apr 2010 B2
7713638 Moelle May 2010 B2
7736689 Chappa Jun 2010 B2
7740610 Moh Jun 2010 B2
7744567 Glowacki Jun 2010 B2
7744790 Behle Jun 2010 B2
7745228 Schwind Jun 2010 B2
7745547 Auerbach Jun 2010 B1
7749914 Honda Jul 2010 B2
7754302 Yamaski Jul 2010 B2
7766882 Sudo Aug 2010 B2
7780866 Miller Aug 2010 B2
7785862 Kim Aug 2010 B2
7790475 Galbraith Sep 2010 B2
7798993 Lim Sep 2010 B2
7803305 Ahem Sep 2010 B2
7807242 Sorensen Oct 2010 B2
7810448 Behle Oct 2010 B2
7815922 Chaney Oct 2010 B2
7846293 Iwasaki Dec 2010 B2
7854889 Perot Dec 2010 B2
7867366 McFarland Jan 2011 B1
7901783 Rose Mar 2011 B2
7905866 Haider Mar 2011 B2
7922880 Pradhan Apr 2011 B1
7922958 D'Arrigo Apr 2011 B2
7926446 Behle Apr 2011 B2
7931955 Behle Apr 2011 B2
7932678 Madocks Apr 2011 B2
7934613 Sudo May 2011 B2
7943205 Schaepkens May 2011 B2
7947337 Kuepper May 2011 B2
7955986 Hoffman Jun 2011 B2
7960043 Harris Jun 2011 B2
7964438 Roca I Cabarrocas Jun 2011 B2
7967945 Glukhoy Jun 2011 B2
7975646 Rius Jul 2011 B2
7985188 Felts Jul 2011 B2
8025915 Haines Sep 2011 B2
8038858 Bures Oct 2011 B1
8039524 Chappa Oct 2011 B2
8056719 Porret Nov 2011 B2
8062266 McKinnon Nov 2011 B2
8066854 Storey Nov 2011 B2
8067070 Klein Nov 2011 B2
8070917 Tsukamoto Dec 2011 B2
8075995 Zhao Dec 2011 B2
8092605 Shannon Jan 2012 B2
8101246 Fayet Jan 2012 B2
8197452 Harding Jun 2012 B2
8277025 Lewis Jul 2012 B2
8258486 Avnery Sep 2012 B2
8268410 Moelle Sep 2012 B2
8273222 Wei Sep 2012 B2
8313455 DiGregorio Nov 2012 B2
8323166 Haines Dec 2012 B2
8389958 Vo-Dinh Mar 2013 B2
8397667 Behle Mar 2013 B2
8409441 Wilt Apr 2013 B2
8418650 Goto Apr 2013 B2
8435605 Aitken et al. May 2013 B2
8450113 Luepke May 2013 B2
8475886 Chen et al. Jul 2013 B2
8512796 Felts Aug 2013 B2
8524331 Honda Sep 2013 B2
8592015 Bicker Nov 2013 B2
8603638 Liu Dec 2013 B2
8618509 Vo-Dinh Dec 2013 B2
8623324 Diwu Jan 2014 B2
8633034 Trotter Jan 2014 B2
8747962 Bicker Jun 2014 B2
8802603 D'Souza Aug 2014 B2
8816022 Zhao Aug 2014 B2
9067706 Joergensen Jun 2015 B2
9068565 Alarcon Jun 2015 B2
20010000279 Daniels Apr 2001 A1
20010021356 Konrad Sep 2001 A1
20010038894 Komada Nov 2001 A1
20010042510 Plester Nov 2001 A1
20010043997 Uddin Nov 2001 A1
20020006487 O'Connor Jan 2002 A1
20020007796 Gorokhovsky Jan 2002 A1
20020070647 Ginovker Jun 2002 A1
20020117114 Ikenaga Aug 2002 A1
20020125900 Savtchouk Sep 2002 A1
20020130100 Smith Sep 2002 A1
20020130674 Logowski Sep 2002 A1
20020141477 Akahori Oct 2002 A1
20020153103 Madocks Oct 2002 A1
20020155218 Meyer Oct 2002 A1
20020170495 Nakamura Nov 2002 A1
20020176947 Darras Nov 2002 A1
20020182101 Koulik Dec 2002 A1
20020185226 Lea Dec 2002 A1
20020190207 Levy Dec 2002 A1
20030010454 Bailey, III Jan 2003 A1
20030013818 Hakuta Jan 2003 A1
20030029837 Trow Feb 2003 A1
20030031806 Jinks Feb 2003 A1
20030046982 Chartard Mar 2003 A1
20030058413 Barnhurst Mar 2003 A1
20030102087 Ito Jun 2003 A1
20030119193 Hess Jun 2003 A1
20030148028 Kimura et al. Aug 2003 A1
20030159654 Arnold Aug 2003 A1
20030215652 O'Connor Nov 2003 A1
20030219547 Arnold Nov 2003 A1
20030232150 Arnold Dec 2003 A1
20040024371 Plicchi Feb 2004 A1
20040039401 Chow Feb 2004 A1
20040040372 Plester Mar 2004 A1
20040045811 Wang Mar 2004 A1
20040050744 Hama Mar 2004 A1
20040055538 Gorokhovsky Mar 2004 A1
20040071960 Weber Apr 2004 A1
20040082917 Hetzler Apr 2004 A1
20040084151 Kim May 2004 A1
20040125913 Larson Jul 2004 A1
20040135081 Larson Jul 2004 A1
20040149225 Weikart Aug 2004 A1
20040175961 Olsen Sep 2004 A1
20040177676 Moore Sep 2004 A1
20040195960 Czeremuszkin Oct 2004 A1
20040206309 Bera Oct 2004 A1
20040217081 Konrad Nov 2004 A1
20040247948 Behle Dec 2004 A1
20040267194 Sano Dec 2004 A1
20050000962 Crawford Jan 2005 A1
20050010175 Beedon Jan 2005 A1
20050019503 Komada Jan 2005 A1
20050037165 Ahem Feb 2005 A1
20050039854 Matsuyama Feb 2005 A1
20050045472 Nagata Mar 2005 A1
20050057754 Smith Mar 2005 A1
20050073323 Kohno Apr 2005 A1
20050075611 Heltzer Apr 2005 A1
20050075612 Lee Apr 2005 A1
20050161149 Yokota Jul 2005 A1
20050169803 Betz Aug 2005 A1
20050190450 Becker Sep 2005 A1
20050196629 Bariatinsky Sep 2005 A1
20050199571 Geisler Sep 2005 A1
20050206907 Fujimoto Sep 2005 A1
20050211383 Miyata Sep 2005 A1
20050223988 Behle Oct 2005 A1
20050227002 Lizenberg Oct 2005 A1
20050227022 Domine Oct 2005 A1
20050229850 Behle Oct 2005 A1
20050233077 Lizenberg Oct 2005 A1
20050233091 Kumar Oct 2005 A1
20050236346 Whitney Oct 2005 A1
20050260504 Becker Nov 2005 A1
20050284550 Bicker Dec 2005 A1
20060005608 Kutzhoffer Jan 2006 A1
20060013997 Kuepper Jan 2006 A1
20060014309 Sachdev Jan 2006 A1
20060024849 Zhu Feb 2006 A1
20060042755 Holmberg Mar 2006 A1
20060046006 Bastion Mar 2006 A1
20060051252 Yuan Mar 2006 A1
20060051520 Behle Mar 2006 A1
20060076231 Wei Apr 2006 A1
20060086320 Lizenberg Apr 2006 A1
20060099340 Behle May 2006 A1
20060121222 Audrich Jun 2006 A1
20060121613 Havens Jun 2006 A1
20060121623 He Jun 2006 A1
20060127699 Moelle Jun 2006 A1
20060135945 Bankiewicz Jun 2006 A1
20060138326 Jiang Jun 2006 A1
20060150909 Behle Jul 2006 A1
20060169026 Kage Aug 2006 A1
20060178627 Geiger Aug 2006 A1
20060183345 Nguyen Aug 2006 A1
20060192973 Aiyer Aug 2006 A1
20060196419 Tudhope Sep 2006 A1
20060198903 Storey Sep 2006 A1
20060198965 Tudhope Sep 2006 A1
20060200078 Konrad Sep 2006 A1
20060200084 Ito Sep 2006 A1
20060210425 Mirkarimi Sep 2006 A1
20060228497 Kumar Oct 2006 A1
20060260360 Dick Nov 2006 A1
20070003441 Wohleb Jan 2007 A1
20070009673 Fukazawa et al. Jan 2007 A1
20070017870 Belov Jan 2007 A1
20070048456 Keshner Mar 2007 A1
20070049048 Rauf Mar 2007 A1
20070051629 Donlik Mar 2007 A1
20070065680 Schultheis Mar 2007 A1
20070076833 Becker Apr 2007 A1
20070102344 Konrad May 2007 A1
20070110907 Brown May 2007 A1
20070123920 Inokuti May 2007 A1
20070148326 Hatings Jun 2007 A1
20070166187 Song Jul 2007 A1
20070184657 Iijima Aug 2007 A1
20070187229 Aksenov Aug 2007 A1
20070187280 Haines Aug 2007 A1
20070205096 Nagashima Sep 2007 A1
20070215009 Shimazu Sep 2007 A1
20070215046 Lupke Sep 2007 A1
20070218265 Harris Sep 2007 A1
20070224236 Boden Sep 2007 A1
20070229844 Holz Oct 2007 A1
20070231655 Ha Oct 2007 A1
20070232066 Bicker Oct 2007 A1
20070235890 Lewis Oct 2007 A1
20070243618 Hatchett Oct 2007 A1
20070251458 Mund Nov 2007 A1
20070258894 Melker et al. Nov 2007 A1
20070259184 Martin Nov 2007 A1
20070281108 Weikart Dec 2007 A1
20070281117 Kaplan Dec 2007 A1
20070287950 Kjeken Dec 2007 A1
20070287954 Zhao Dec 2007 A1
20070298189 Straemke Dec 2007 A1
20080011232 Ruis Jan 2008 A1
20080017113 Goto Jan 2008 A1
20080023414 Konrad Jan 2008 A1
20080027400 Harding Jan 2008 A1
20080045880 Kjeken Feb 2008 A1
20080050567 Kawashima Feb 2008 A1
20080050932 Lakshmanan Feb 2008 A1
20080053373 Mund Mar 2008 A1
20080069970 Wu Mar 2008 A1
20080071228 Wu Mar 2008 A1
20080081184 Kubo Apr 2008 A1
20080090039 Klein Apr 2008 A1
20080093245 Periasamy Apr 2008 A1
20080102206 Wagner May 2008 A1
20080109017 Herweck May 2008 A1
20080110852 Kuroda May 2008 A1
20080113109 Moelle May 2008 A1
20080118734 Goodwin May 2008 A1
20080131628 Abensour Jun 2008 A1
20080131638 Hutton Jun 2008 A1
20080139003 Pirzada Jun 2008 A1
20080144185 Wang et al. Jun 2008 A1
20080145271 Kidambi Jun 2008 A1
20080187681 Hofrichter Aug 2008 A1
20080202414 Yan Aug 2008 A1
20080206477 Leontaris Aug 2008 A1
20080210550 Walther Sep 2008 A1
20080220164 Bauch Sep 2008 A1
20080223815 Konrad Sep 2008 A1
20080233355 Henze Sep 2008 A1
20080260966 Hanawa Oct 2008 A1
20080277332 Liu Nov 2008 A1
20080289957 Takigawa Nov 2008 A1
20080292806 Wei Nov 2008 A1
20080295772 Park Dec 2008 A1
20080303131 McElrea Dec 2008 A1
20080312607 Delmotte Dec 2008 A1
20080314318 Han Dec 2008 A1
20090004091 Kang Jan 2009 A1
20090004363 Keshner Jan 2009 A1
20090017217 Hass Jan 2009 A1
20090022981 Yoshida Jan 2009 A1
20090029402 Papkovsky Jan 2009 A1
20090031953 Ingle Feb 2009 A1
20090032393 Madocks Feb 2009 A1
20090039240 Van Nijnatten Feb 2009 A1
20090053491 Laboda Feb 2009 A1
20090061237 Gates Mar 2009 A1
20090065485 O'Neill Mar 2009 A1
20090069790 Yokley Mar 2009 A1
20090081797 Fadeev Mar 2009 A1
20090099512 Digregorio Apr 2009 A1
20090104392 Takada Apr 2009 A1
20090117268 Lewis May 2009 A1
20090117389 Amberg-Schwab May 2009 A1
20090122832 Feist May 2009 A1
20090134884 Bosselmann May 2009 A1
20090137966 Rueckert May 2009 A1
20090142227 Fuchs Jun 2009 A1
20090142514 O'Neill Jun 2009 A1
20090147719 Rak Jun 2009 A1
20090149816 Hetzler Jun 2009 A1
20090155490 Bicker Jun 2009 A1
20090162571 Haines Jun 2009 A1
20090166312 Giraud Jul 2009 A1
20090176031 Armellin Jul 2009 A1
20090214801 Higashi Aug 2009 A1
20090220948 Oviso et al. Sep 2009 A1
20090263668 David Oct 2009 A1
20090274851 Goudar Nov 2009 A1
20090280268 Glukhoy Nov 2009 A1
20090297730 Glukhoy Dec 2009 A1
20090306595 Shih Dec 2009 A1
20090326517 Bork Dec 2009 A1
20100021998 Sanyal Jan 2010 A1
20100028238 Maschwitz Feb 2010 A1
20100034985 Krueger Feb 2010 A1
20100075077 Bicker et al. Mar 2010 A1
20100086808 Nagata Apr 2010 A1
20100089097 Brack Apr 2010 A1
20100104770 Goudar Apr 2010 A1
20100105208 Winniczek Apr 2010 A1
20100132762 Graham, Jr. Jun 2010 A1
20100145284 Togashi Jun 2010 A1
20100149540 Boukherroub Jun 2010 A1
20100174239 Yodfat Jul 2010 A1
20100174245 Halverson Jul 2010 A1
20100178490 Cerny Jul 2010 A1
20100186740 Lewis Jul 2010 A1
20100190036 Komvopoulos Jul 2010 A1
20100193461 Boutroy Aug 2010 A1
20100195471 Hirokane Aug 2010 A1
20100204648 Stout Aug 2010 A1
20100230281 Park Sep 2010 A1
20100231194 Bauch Sep 2010 A1
20100237545 Haury Sep 2010 A1
20100273261 Chen Oct 2010 A1
20100275847 Yamasaki Nov 2010 A1
20100279397 Crawford Nov 2010 A1
20100298738 Felts Nov 2010 A1
20100298779 Hetzler Nov 2010 A1
20110037159 McElrea Feb 2011 A1
20110046570 Stout Feb 2011 A1
20110056912 Magsuyama Mar 2011 A1
20110065798 Hoang Mar 2011 A1
20110079582 Yonesu Apr 2011 A1
20110093056 Kaplan Apr 2011 A1
20110111132 Wei May 2011 A1
20110117202 Bourke, Jr. May 2011 A1
20110117288 Honda May 2011 A1
20110137263 Ashmead Jun 2011 A1
20110152820 Chattaraj Jun 2011 A1
20110159101 Kurdyumov et al. Jun 2011 A1
20110160662 Stout Jun 2011 A1
20110160663 Stout Jun 2011 A1
20110174220 Laure Jul 2011 A1
20110186537 Rodriguez San Juan Aug 2011 A1
20110220490 Wei Sep 2011 A1
20110253674 Chung Oct 2011 A1
20110313363 D'Souza Dec 2011 A1
20110319758 Wang Dec 2011 A1
20110319813 Kamen Dec 2011 A1
20120003497 Handy Jan 2012 A1
20120004339 Chappa Jan 2012 A1
20120021136 Dzengeleski Jan 2012 A1
20120031070 Slough Feb 2012 A1
20120035543 Kamen Feb 2012 A1
20120052123 Kurdyumov et al. Mar 2012 A9
20120053530 Zhao Mar 2012 A1
20120058351 Zhao Mar 2012 A1
20120065612 Stout Mar 2012 A1
20120097527 Kodaira Apr 2012 A1
20120097870 Leray Apr 2012 A1
20120108058 Ha May 2012 A1
20120123345 Felts May 2012 A1
20120141913 Lee Jun 2012 A1
20120143148 Zhao Jun 2012 A1
20120149871 Saxena Jun 2012 A1
20120171386 Bicker Jul 2012 A1
20120175384 Greter Jul 2012 A1
20120183954 Diwu Jul 2012 A1
20120205374 Klumpen Aug 2012 A1
20120231182 Stevens Sep 2012 A1
20120234720 Digregorio Sep 2012 A1
20120252709 Felts Oct 2012 A1
20130041241 Felts Feb 2013 A1
20130046375 Chen Feb 2013 A1
20130057677 Weil Mar 2013 A1
20130072025 Singh Mar 2013 A1
20130081953 Bruna et al. Apr 2013 A1
20130190695 Wu Jul 2013 A1
20130209704 Krueger Aug 2013 A1
20130264303 Andersen Oct 2013 A1
20130296235 Alarcon Nov 2013 A1
20140010969 Bicker Jan 2014 A1
20140052076 Zhao Feb 2014 A1
20140054803 Chen Feb 2014 A1
20140099455 Stanley Apr 2014 A1
20140110297 Trotter Apr 2014 A1
20140147654 Walthe May 2014 A1
20140151320 Chang Jun 2014 A1
20140151370 Chang Jun 2014 A1
20140187666 Aizenberg Jul 2014 A1
20140190846 Belt Jul 2014 A1
20140221934 Janvier Aug 2014 A1
20140251856 Larsson Sep 2014 A1
20140251859 Weikart et al. Sep 2014 A1
20140305830 Bicker Oct 2014 A1
20150105734 Bryant Apr 2015 A1
20150165125 Foucher Jun 2015 A1
20150224263 Dugand Aug 2015 A1
20160186009 Goto Jun 2016 A1
Foreign Referenced Citations (355)
Number Date Country
414209 Oct 2006 AT
504533 Jun 2008 AT
2002354470 May 2007 AU
2085805 Dec 1992 CA
2277679 Jul 1997 CA
2355681 Jul 2000 CA
2571380 Jul 2006 CA
2718253 Sep 2009 CA
2268719 Aug 2010 CA
2879732 Jan 2014 CA
1245439 Feb 2000 CN
2546041 Apr 2003 CN
1436104 Aug 2003 CN
1639775 Jul 2005 CN
1711310 Dec 2005 CN
2766863 Mar 2006 CN
1898172 Jan 2007 CN
101035630 Sep 2007 CN
201002786 Jan 2008 CN
101147813 Mar 2008 CN
201056331 May 2008 CN
102027159 Apr 2011 CN
102036814 Apr 2011 CN
102414343 Apr 2012 CN
102581274 Jul 2012 CN
102917805 Feb 2013 CN
1147836 Apr 1969 DE
1147838 Apr 1969 DE
3632748 Apr 1988 DE
3908418 Sep 1990 DE
4214401 Mar 1993 DE
4204082 Aug 1993 DE
4316349 Nov 1994 DE
4438359 May 1996 DE
19707645 Aug 1998 DE
19830794 Jan 2000 DE
19912737 Jun 2000 DE
10010831 Sep 2001 DE
10154404 Jun 2003 DE
10201110 Oct 2003 DE
10242698 Mar 2004 DE
10246181 Apr 2004 DE
10353540 May 2004 DE
102004017236 Oct 2005 DE
102006061585 Feb 2008 DE
102008023027 Nov 2009 DE
0121340 Oct 1984 EP
0221005 May 1987 EP
0275965 Jul 1988 EP
0284867 Oct 1988 EP
0306307 Mar 1989 EP
0329041 Aug 1989 EP
0343017 Nov 1989 EP
0396919 Nov 1990 EP
0482613 Oct 1991 EP
0484746 Oct 1991 EP
0495447 Jul 1992 EP
0520519 Dec 1992 EP
0535810 Apr 1993 EP
0375778 Sep 1993 EP
0571116 Nov 1993 EP
0580094 Jan 1994 EP
0603717 Jun 1994 EP
0619178 Oct 1994 EP
0645470 Mar 1995 EP
0697378 Feb 1996 EP
0709485 May 1996 EP
0719877 Jul 1996 EP
0728676 Aug 1996 EP
0787824 Aug 1997 EP
0787828 Aug 1997 EP
0814114 Dec 1997 EP
0251812 Jan 1998 EP
0833366 Apr 1998 EP
0879611 Nov 1998 EP
0940183 Sep 1999 EP
0962229 Dec 1999 EP
0992610 Apr 2000 EP
1119034 Jul 2001 EP
0954272 Mar 2002 EP
1245694 Oct 2002 EP
1388594 Jan 2003 EP
1317937 Jun 2003 EP
1365043 Nov 2003 EP
1367145 Dec 2003 EP
1388593 Feb 2004 EP
1439241 Jul 2004 EP
1447459 Aug 2004 EP
1990639 Feb 2005 EP
1510595 Mar 2005 EP
1522403 Apr 2005 EP
1901067 Aug 2005 EP
1507894 Dec 2005 EP
1507723 Mar 2006 EP
1653192 May 2006 EP
1810758 Jul 2007 EP
1356260 Dec 2007 EP
1870117 Dec 2007 EP
1881088 Jan 2008 EP
1507887 Jul 2008 EP
1415018 Oct 2008 EP
1756565 Jul 2009 EP
2199264 Nov 2009 EP
1388594 Jan 2010 EP
2178109 Apr 2010 EP
1507895 Jul 2010 EP
2218465 Aug 2010 EP
2243751 Oct 2010 EP
2251671 Nov 2010 EP
2261185 Dec 2010 EP
2369038 Sep 2011 EP
1960279 Oct 2011 EP
2444771 Apr 2012 EP
2602354 Jun 2013 EP
2639330 Sep 2013 EP
3381444 Oct 2018 EP
891892 Nov 1942 FR
752822 Jul 1956 GB
1363762 Aug 1974 GB
1513426 Jun 1978 GB
1566251 Apr 1980 GB
2210826 Jun 1989 GB
2231197 Nov 1990 GB
2246794 Feb 1992 GB
2246795 Feb 1992 GB
2387964 Oct 2003 GB
1304783 Mar 2001 IT
1310330 Feb 2002 IT
56027330 Mar 1981 JP
58154602 Sep 1983 JP
59087307 May 1984 JP
59154029 Sep 1984 JP
S61183462 Aug 1986 JP
S62180069 Aug 1987 JP
S62290866 Dec 1987 JP
63124521 May 1988 JP
1023105 Jan 1989 JP
H01225775 Sep 1989 JP
1279745 Nov 1989 JP
2501490 May 1990 JP
3183759 Aug 1991 JP
H03260065 Nov 1991 JP
H03271374 Dec 1991 JP
4000373 Jan 1992 JP
4000374 Jan 1992 JP
4000375 Jan 1992 JP
4014440 Jan 1992 JP
H04124273 Apr 1992 JP
H0578844 Mar 1993 JP
05-006688 Apr 1993 JP
H05263223 Oct 1993 JP
6010132 Jan 1994 JP
6289401 Oct 1994 JP
7041579 Feb 1995 JP
7068614 Mar 1995 JP
7126419 May 1995 JP
7-304127 Nov 1995 JP
8025244 Jan 1996 JP
8084773 Apr 1996 JP
H08296038 Nov 1996 JP
9005038 Jan 1997 JP
10008254 Jan 1998 JP
10-130844 May 1998 JP
11-108833 Apr 1999 JP
11106920 Apr 1999 JP
H11256331 Sep 1999 JP
11344316 Dec 1999 JP
2000064040 Feb 2000 JP
2000109076 Apr 2000 JP
2001033398 Feb 2001 JP
2001231841 Aug 2001 JP
2002177364 Jun 2002 JP
2002206167 Jul 2002 JP
2002371364 Dec 2002 JP
2003171771 Jun 2003 JP
2003-268550 Sep 2003 JP
2003294431 Oct 2003 JP
2003305121 Oct 2003 JP
2004002928 Jan 2004 JP
2004008509 Jan 2004 JP
2004043789 Feb 2004 JP
2004100036 Apr 2004 JP
2004156444 Jun 2004 JP
2004168359 Jun 2004 JP
2004169087 Jun 2004 JP
2004203682 Jul 2004 JP
2004-253683 Sep 2004 JP
2004307935 Nov 2004 JP
2005035597 Feb 2005 JP
2005043285 Feb 2005 JP
2005132416 May 2005 JP
2005160888 Jun 2005 JP
2005-200044 Jul 2005 JP
2005200044 Jul 2005 JP
2005-241524 Sep 2005 JP
2005271997 Oct 2005 JP
2005290561 Oct 2005 JP
2006-064416 Mar 2006 JP
2006111967 Apr 2006 JP
2006160268 Jun 2006 JP
2006-224992 Aug 2006 JP
2006249577 Sep 2006 JP
2007050898 Mar 2007 JP
2007231386 Sep 2007 JP
2007246974 Sep 2007 JP
2008174793 Jul 2008 JP
2009-062620 Mar 2009 JP
2009062620 Mar 2009 JP
2009079298 Apr 2009 JP
2009084203 Apr 2009 JP
2009185330 Aug 2009 JP
2010155134 Jul 2010 JP
2010270117 Dec 2010 JP
2012149278 Aug 2012 JP
2012210315 Nov 2012 JP
2012526921 Nov 2012 JP
2013233716 Nov 2013 JP
5362941 Dec 2013 JP
10-2005-0100367 Oct 2005 KR
10-2006-0029694 Apr 2006 KR
10-0685594 Feb 2007 KR
1530913 Dec 1989 SU
200703536 Jan 2007 TW
WO9324243 Dec 1993 WO
WO9400247 Jan 1994 WO
WO9426497 Nov 1994 WO
WO9524275 Sep 1995 WO
WO9711482 Mar 1997 WO
WO9713802 Apr 1997 WO
WO98-27926 Jul 1998 WO
WO9845871 Oct 1998 WO
WO9917334 Apr 1999 WO
WO9941425 Aug 1999 WO
WO9945984 Sep 1999 WO
WO9945985 Sep 1999 WO
WO9947192 Sep 1999 WO
WO9950471 Oct 1999 WO
WO0038566 Jul 2000 WO
WO0104668 Jan 2001 WO
WO0125788 Apr 2001 WO
WO0154816 Aug 2001 WO
WO0156706 Aug 2001 WO
WO0170403 Sep 2001 WO
WO0222192 Mar 2002 WO
WO03033426 Apr 2002 WO
WO0243116 May 2002 WO
WO0249925 Jun 2002 WO
WO02056333 Jul 2002 WO
WO02072914 Sep 2002 WO
WO02076709 Oct 2002 WO
02100928 Dec 2002 WO
WO03014415 Feb 2003 WO
WO03038143 May 2003 WO
WO03040649 May 2003 WO
WO03044240 May 2003 WO
2004044039 May 2004 WO
WO2005035147 Apr 2005 WO
WO2005052555 Jun 2005 WO
WO2005051525 Jun 2005 WO
WO2005094214 Oct 2005 WO
WO2005103605 Nov 2005 WO
WO2006012281 Feb 2006 WO
WO2006017186 Feb 2006 WO
WO2006027568 Mar 2006 WO
WO2006029743 Mar 2006 WO
WO2006044254 Apr 2006 WO
WO2006048650 May 2006 WO
WO2006048276 May 2006 WO
WO2006048277 May 2006 WO
WO2006069774 Jul 2006 WO
2006121556 Nov 2006 WO
WO2006135755 Dec 2006 WO
WO2007028061 Mar 2007 WO
WO2007035741 Mar 2007 WO
WO2007036544 Apr 2007 WO
WO2007081814 Jul 2007 WO
WO2007089216 Aug 2007 WO
WO2007112328 Oct 2007 WO
WO2007120507 Oct 2007 WO
WO2007133378 Nov 2007 WO
WO2007134347 Nov 2007 WO
WO2008014438 Jan 2008 WO
WO2008024566 Feb 2008 WO
WO2008040531 Apr 2008 WO
WO2008047541 Apr 2008 WO
WO2008067574 Jun 2008 WO
WO2008071458 Jun 2008 WO
WO2008093335 Aug 2008 WO
2008121478 Oct 2008 WO
WO2009015862 Feb 2009 WO
WO2009020550 Feb 2009 WO
WO2009021257 Feb 2009 WO
WO2009030974 Mar 2009 WO
WO2009030975 Mar 2009 WO
WO2009030976 Mar 2009 WO
WO2009031838 Mar 2009 WO
WO2009040109 Apr 2009 WO
WO2009053947 Apr 2009 WO
WO2009112053 Sep 2009 WO
WO2009117032 Sep 2009 WO
WO2009118361 Oct 2009 WO
WO2009158613 Dec 2009 WO
WO2010047825 Apr 2010 WO
WO2010095011 Aug 2010 WO
WO2010132579 Nov 2010 WO
WO2010132581 Nov 2010 WO
WO2010132584 Nov 2010 WO
WO2010132585 Nov 2010 WO
WO2010132589 Nov 2010 WO
WO2010132591 Nov 2010 WO
WO2010034004 Nov 2010 WO
WO2010132579 Nov 2010 WO
WO2010132579 Nov 2010 WO
WO2010132589 Nov 2010 WO
WO2010132591 Nov 2010 WO
WO2011029628 Mar 2011 WO
WO2011059823 May 2011 WO
WO2011007055 Jun 2011 WO
WO2011080543 Jul 2011 WO
WO2011082296 Jul 2011 WO
WO2011090717 Jul 2011 WO
WO2011143329 Nov 2011 WO
WO2011143509 Nov 2011 WO
WO2011143509 Nov 2011 WO
WO2011137437 Nov 2011 WO
WO2011143329 Nov 2011 WO
WO2011159975 Dec 2011 WO
WO2012003221 Jan 2012 WO
WO2012009653 Jan 2012 WO
WO2012166515 Dec 2012 WO
WO2013045671 Apr 2013 WO
WO2013071138 May 2013 WO
WO2013071138 May 2013 WO
WO2013106588 Jul 2013 WO
WO2013170044 Nov 2013 WO
WO2013170052 Nov 2013 WO
2014-005728 Jan 2014 WO
WO2014008138 Jan 2014 WO
WO2014012039 Jan 2014 WO
WO2014012052 Jan 2014 WO
WO2014012072 Jan 2014 WO
WO2014012078 Jan 2014 WO
WO2014012079 Jan 2014 WO
WO2014014641 Jan 2014 WO
WO2014059012 Apr 2014 WO
WO2014071061 May 2014 WO
WO2014078666 May 2014 WO
WO2014085346 Jun 2014 WO
WO2014085348 Jun 2014 WO
WO2014134577 Sep 2014 WO
WO2014144926 Sep 2014 WO
WO2014164928 Oct 2014 WO
WO2015049972 Apr 2015 WO
WO2016057068 Apr 2016 WO
WO2016094387 Jun 2016 WO
Non-Patent Literature Citations (201)
Entry
US 5,645,643 A, 07/1997, Thomas (withdrawn)
PCT, Written Opinion of the International Preliminary Examining Authority, in International application No. PCT/USUS13/048709, dated Sep. 30, 2014 (4 pages).
PCT, Notification of Transmittal of the International Preliminary Report on Patentability, in International application No. PCT/USUS13/048709, dated Oct. 15, 2014 (7 pages).
PCT, Written Opinion of the International Preliminary Examining Authority, in International application No. PCT/USUS13/064121, dated Nov. 19, 2014 (8 pages).
PCT, Written Opinion of the International Preliminary Examining Authority, in International application No. PCT/USUS13/064121, dated Nov. 21, 2014 (7 pages).
Intellectual Property Corporation of Malaysia, Substantive Examintion Adverse Report (section 30(1)/30(2)), in Application No. PI 2011005486, dated Oct. 31, 2014 (3 pages).
Patent Office of the Russian Federation, Official Action, in Application No. 2011150499, dated Sep. 25, 2014 (4 pages).
Instituto Mexicano de la Propiedad Indutrial, Official Action, in Appilcation No. MX/a/2012/013129, dated Sep. 22, 2014 (5 pages).
Australian Government, Patent Examination Report No. 2 in Application No. 2010249031 dated Apr. 21, 2015.
Japanese Patent Office, Notice of Reasons for Refusal in application No. 2013-510276, dated Mar. 31, 2015.
Bose, Sagarika and Constable, Kevin, Advanced Delivery Devices, Design & Evaluation of a Polymer-Based Prefillable Syringe for Biopharmaceuticals With Improved Functionality & Performance, JR Automation Technologies, May 2015.
Hopwood J ED—CRC Press: “Plasma-assisted deposition”, Aug. 17, 1997 (Aug. 17, 1997), Handbook of Nanophase Materials, Chapter 6, pp. 141-197, XP008107730, ISBN: 978-0-8247-9469-9.
PCT, Written Opinion of the International Preliminary Examining Authority, International application No. PCT/SU2013/071752, dated May 6, 2015.
Hlobik, Plastic Pre-Fillable Syringe Systems (http://www.healthcarepackaging.com/package-type/Containers/plastic-prefillablesyringe-systems, Jun. 8, 2010).
PCT, Written Opinion of the International Preliminary Examining Authority, in International application No. PCT/US2013/071750, dated Jan. 20, 2015 (9 pages).
PCT, Written Opinion of the International Preliminary Examining Authority, in International application No. PCT/US2013/064121, dated Nov. 21, 2014 (7 pages).
Japanese Patent Office, Decision of Rejection in Application No. 2012-510983, dated Jan. 20, 2015 (4 pages).
Australian Government, IP Australia, Patent Examination Report No. 1, in Application No. 2010249033, dated Dec. 19, 2014 (7 pages).
Australian Government, IP Australia, Patent Examination Report No. 1, in Application No. 2011252925, dated Dec. 2, 2014 (3 pages).
State Intellectual Property Office of the People's Republic of China, Notification of the Fourth Office Action in Application No. 201080029199.0, dated Mar. 18, 2015 (15 pages).
Reh, et al., Evaluation of stationary phases for 2-dimensional HPLC of Proteins—Validation of commercial RP-columns, Published by Elsevier B.V., 2000.
Sahagian, Khoren; Larner, Mikki; Kaplan, Stephen L., “Altering Biological Interfaces with Gas Plasma: Example Applications”, Plasma Technology Systems, Belmont, CA, In SurFACTS in Biomaterials, Surfaces in Biomaterials Foundation, Summer 2013, 18(3), p. 1-5.
Daikyo Cyrystal Zenith Insert Needle Syringe System, West Delivering Innovative Services, West Pharmaceutical Services, Inc., 2010.
Daikyo Crystal Zenigh Syringes, West Pharmaceutical Services, Inc., www. WestPFSsolutions.com, #5659, 2011.
Zhang, Yongchao and Heller, Adam, Reduction of the Nonspecific Binding of a Target Antibody and of Its Enzyme-Labeled Detection Probe Enabling Electrochemical Immunoassay of Antibody through the 7 pg/mL-100 ng/ML (40 fM-400 pM) Range, Department of Chemical Engineering and Texas Materials Institute, University of Texas at Austin, Anal. Chem. 2005, 7, 7758-7762. (6 pages).
Principles and Applications of Liquid Scintillation Counting, LSC Concepts—Fundamentals of Liquid Scintillation Counting, National Diagnostics, 2004, pp. 1-15.
Chikkaveeraiah, Bhaskara V. and Rusling, Dr. James, Non Specific Binding (NSB) in Antigen-Antibody Assays, University of Connecticut, Spring 2007. (13 pages).
Sahagian, Khoren; Larner, Mikki; Kaplan, Stephen L., “Cold Gas Plasma in Surface Modification of Medical Plastics”, Plasma Technology Systems, Belmont, CA, Publication pending. Presented at SPE Antec Medical Plastics Division, Apr. 23, 2013, Ohio.
Lipman, Melissa, “Jury Orders Becton to Pay $114M in Syringe Antitrust Case”, © 2003-2013, Portfolio Media, Inc., Law360, New York (Sep. 20, 2013, 2:53 PM ET), http://www.law360.com/articles/474334/print?section=ip, [retrieved Sep. 23, 2013].
Wikipedia, the free encyclopedia, http://en.wikipedia.org/wiki/Birefringence, page last modified Sep. 18, 2013 at 11:39. [retrieved on Oct. 8, 2013]. (5 pages).
Wikipedia, the free encyclopedia, http://en.wikipedia.org/wiki/Confocal_microscopy, page last modified Aug. 28, 2013 at 11:12. [retrieved on Oct. 8, 2013]. (4 pages).
Wang, Jun et al., “Fluorocarbon thin film with superhydrophobic property prepared by pyrolysis of hexafluoropropylene oxide”, Applied Surface Science, vol. 258, 2012, pp. 9782-9784 (4 pages).
Wang, Hong et al., “Ozone-Initiated Secondary Emission Rates of Aldehydes from Indoor surfaces in Four Homes”, American Chemical Society, Environmental Science & Technology, vol. 40, No. 17, 2006, pp. 5263-5268 (6 pages).
Lewis, Hilton G. Pryce, et al., “HWCVD of Polymers: Commercialization and Scale-Up”, Thin Solid Films 517, 2009, pp. 3551-3554.
Wolgemuth, Lonny, “Challenges With Prefilled Syringes: The Parylene Solution”, Frederick Furness Publishing, www.ongrugdelivery.com, 2012, pp. 44-45.
History of Parylene (12 pages).
SCS Parylene HTX brochure, Stratamet Thin Film Corporation, Fremont, CA, 2012, retrieved from the Internet Feb. 13, 2013, http://www.stratametthinfilm.com/parylenes/htx. (2 pages).
SCS Parylene Properties, Specialty Coating Systems, Inc., Indianapolis, IN, 2011. (12 pages).
Werthheimer, M.R., Studies of the earliest stages of plasma-enhanced chemical vapor deposition of SiO2 on polymeric substrates, Thin Solid Films 382 (2001) 1-3, and references therein, United States Pharmacopeia 34. In General Chapters <1>, 2001.
Gibbins, Bruce and Warner, Lenna, The Role of Antimicrobial Silver Nanotechnology, Medical Device & Diagnostic Industry, Aug. 205, pp. 2-6.
MTI CVD Tube Furnace w Gas Delivery & Vacuum Pump, http://mtixtl.com/MiniCVDTubeFurnace2ChannelsGasVacuum-OTF-1200X-S50-2F.aspx (2 pages).
Lab-Built HFPO CVD Coater, HFPO Decomp to Give Thin Fluorocarbon Films, Applied Surface Science 2012 258 (24) 9782.
Technical Report No. 10, Journal of Parenteral Science and Technology, 42, Supplement 1988, Parenteral Formulation of Proteins and Peptides: Stability and Stabilizers, Parenteral Drug Association, 1988.
Technical Report No. 12, Journal of Parenteral Science and Technology, 42, Supplement 1988, Siliconization of Parenteral Drug Packaging Components, Parenteral Drug Association, 1988.
European Patent Office, Communication under Rule 71(3) EPC, in Application No. 10 162 760.2-1353, dated Oct. 25, 2013. (366 pages).
Wikipedia, the free encyclopedia, http://en.wikipedia.org/wiki/Difluorocarbene, page last modified Feb. 20, 2012 at 14:41. [retrieved on Sep. 7, 2012]. (4 pages).
O'Shaughnessy, W.S., et al., “Initiated Chemical Vapor Deposition of a Siloxane Coating for Insulation of Neutral Probes”, Thin Solid Films 517 (2008) 3612-3614. (3 pages).
Denler, et al., Investigations of SiOx-polymer “interphases” by glancing angle RBS with Li+ and Be+ ions, Nuclear Instruments and Methods in Physical Research B 208 (2003) 176-180, United States Pharmacopeia 34. In General chapters <1>, 2003.
PCT, Invitation to Pay Additional Fees and Annex to Form PCT/ISA/206 Communication relating to the results of the partial international search in International application No. PCT/US2013/071750, dated Feb. 14, 2014. (6 pages).
PCT, Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration, in International application No. PCT/US2013/62247, dated Dec. 30, 2013. (13 pages).
PCT, Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration, in International application No. PCT/US2013/043642, dated Dec. 5, 2013. (21 pages).
Japanese Patent Office, Notice of Reason(s) for Rejection in Patent application No. 2012-510983, dated Jan. 7, 2014. (6 pages).
Chinese Patent Office, Notification of the Second Office Action in Application No. 201080029199.0, dated Jan. 6, 2014. (26 pages).
Chinese Patent Office, Notification of the First Office Action in Application No. 201180023474.2, dated Dec. 23, 2013. (18 pages).
PCT, Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration, in International application No. PCT/US2013/067852, dated Jan. 22, 2014. (9 pages).
PCT, Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration, in International application No. PCT/US2013/064121, dated Mar. 24, 2014. (8 pages).
PCT, Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration, in International application No. PCT/US2013/070325, dated Mar. 24, 2014. (16 pages).
Hanlon, Adriene Lepiane, Pak, Chung K., Pawlikowski, Beverly A., Decision on Appeal, Appeal No. 2005-1693, U.S. Appl. No. 10/192,333, dated Sep. 30, 2005.
Arganguren, Mirta I., Macosko, Christopher W., Thakkar, Bimal, and Tirrel, Matthew, “Interfacial Interactions in Silica Reinforced Silicones,” Materials Research Society Symposium Proceedings, vol. 170, 1990, pp. 303-308.
Patent Cooperation Treaty, International Preliminary Examining Authority, Notification of Transmittal of International Preliminary Report on Patentability, in international application No. PCT/US2011/036097, dated Nov. 13, 2012.
Patent Cooperation Treaty, Notification of Transmittal of International Preliminary Report on Patentability, in Application No. PCT/US2010/034576, dated Sep. 14, 2011.
Patent Cooperation Treaty, Notification of Transmittal of International Preliminary Report on Patentability, in Application No. PCT/US2010/034568, dated Sep. 14, 2011.
Patent Cooperation Treaty, International Search Report and Written Opinion, in Application No. PCT/US2011/036358, dated Sep. 9, 2011.
Patent Cooperation Treaty, International Search Report and Written Opinion, in Application No. PCT/US2011/036340, dated Aug. 1, 2011.
MacDonald, Gareth, “West and Daikyo Seiko Launch Ready Pack”, http://www.in-pharmatechnologist.com/Packaging/West-and-Daikyo-Seiko-launch-Ready-Pack, 2 pages, retrieved from the internet Sep. 22, 2011.
Kumer, Vijai, “Development of Terminal Sterilization Cycle for Pre-Filled Cyclic Olefin Polymer (COP) Syringes”, http://abstracts.aapspharmaceutica.com/ExpoAAPS09/CC/forms/attendee/index.aspx?content=sessionInfo&sessionId=401, 1 page, retrieved from the internet Sep. 22, 2011.
Quinn, F.J., “Biotech Lights Up the Glass Packaging Picture”, http://www.pharmaceuticalcommerce.com/frontEnd/main.php?idSeccion=840, 4 pages, retrieved from the internet Sep. 21, 2011.
Wen, Zai-Qing et al., Distribution of Silicone Oil in Prefilled Glass Syringes Probed with Optical and Spectroscopic Methods, PDA Journal of Pharmaceutical Science and Technology 2009, 63, pp. 149-158.
ZebraSci—Intelligent Inspection Products, webpage, http://zebrasci.com/index.html, retrieved from the internet Sep. 30, 2011.
Google search re “cyclic olefin polymer resin” syringe OR vial, http://www.google.com/search?sclient=psy-ab&hl=en&lr=&source=hp&q=%22cyclic+olefin+polymer+resin%22+syringe+OR+vial&btnG=Search&pbx=1&oq=%22cyclic+olefin+polymer+resin%22+syringe+OR+vial&aq, 1 page, retrieved from the internet Sep. 22, 2011.
Taylor, Nick, “West to Add CZ Vials as Glass QC Issues Drive Interest”, ttp://twitter.com/WestPharma/status/98804071674281986, 2 pages, retrieved from the Internet Sep. 22, 2011.
Patent Cooperation Treaty, International Preliminary Examining Authority, Notification of Transmittal of International Preliminary Report on Patentability, in international application No. PCT/US2010/034571, dated Jun. 13, 2011.
Patent Cooperation Treaty, International Preliminary Examining Authority, Written Opinion of the International Preliminary Examining Authority, in international application No. PCT/US2010/034586, dated Aug. 23, 2011.
Patent Cooperation Treaty, International Preliminary Examining Authority, Written Opinion of the International Preliminary Examining Authority, in international application No. PCT/US2010/034568, dated May 30, 2011.
Silicone Oil Layer, Contract Testing, webpage, http://www.siliconization.com/downloads/siliconeoillayercontracttesting.pdf, retrieved from the internet Oct. 28, 2011.
Patent Cooperation Treaty, Notification of Transmittal of International Preliminary Report on Patentability, in PCT/US2010/034577, dated Nov. 24, 2011.
Patent Cooperation Treaty, Notification of Transmittal of International Preliminary Report on Patentability, in PCT/US2010/034582, dated Nov. 24, 2011.
Patent Cooperation Treaty, Notification of Transmittal of International Preliminary Report on Patentability, in PCT/US2010/034586, dated Dec. 20, 2011.
Patent Cooperation Treaty, Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, in PCT/US2011/036097, dated Dec. 29, 2011.
“Oxford instruments plasmalab 80plus”, XP55015205, retrieved from the Internet on Dec. 20, 2011, URL:http://www.oxfordplasma.de/pdf_inst/plas_80.pdf.
Patent Cooperation Treaty, Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, in PCT/US2011/044215, dated Dec. 29, 2011.
European Patent Office, Communication pursuant to Article 94(3) EPC, in Application No. 10 162 758.6-1234, dated May 8, 2012 (6 pages).
P.G. Pai, S.S. Chao, and Y Takagi, “Infrared Spectroscopic Study of SiOx Films Produced by Plasma Enhanced Chemical Vapor Deposition”,Journal of Vacuum Science & Technology A: Vacuum Surfaces and Films, Jun. 1986, p. 689-694; retrieved on Jun. 1, 2014 (7 pages).
C. Weikart and T. Smith, The Dow Chemical Company, “Microwave Plasma Barrier Coating Technology or PET Beverages Containers”, Society of Vacuum Coaters, 46th Annual Technical Conference Proceedings, ISSN 0737-5921, pp. 486-490, 2003 (5 pages).
C. Weikart, T. Fisk, and M. Larive, The Dow Chemical Company; T. Glass, H. Pham, and A. Taha, The Dow Chemical Company, J. Felts, Nano Scale Surface Systems, Inc.; “Advances in PECVD Banier Coating Development for ISBM PP Containers”, Society of Vacuum Coaters, 51st Annual Technical Conference Proceedings, ISSN 0737-5921, pp. 569-573, Apr. 19-24, 2008 (5 pages).
C. Weikart, H. Yasuda, “Modification, Degradation, and Stability of Polymeric Surfaces Treated with Reactive Plasmas”, Journal of Polymer Science: Part A: Polymer Chemistry, vol. 38, 3028-3042, John Wiley & Sons, Inc., 2000 (15 pages).
Australian Government, IP Australia, Patent Examination Report No. 1, in Application No. 2010249031, dated Mar. 13, 2014. (4 pages).
Australian Government, IP Australia, Patent Examination Report No. 1, in Application No. 2013202893, dated Mar. 13, 2014. (4 pages).
European Patent Office, Communication pursuant to Article 93(3) EPC, in Application No. 11 731 554.9 dated Apr. 15, 2014. (7 pages).
PCT, Notification Concerning Transmittal of International Preliminary Report on Patentability, in International application No. PCT/US2012/064489, dated May 22, 2014. (10 pages).
PCT, Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration, in International application No. PCT/US2013/071750, dated Apr. 4, 2014. (13 pages).
PCT, Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration, in International application No. PCT/US2014/019684, dated May 23, 2014. (16 pages).
PCT, Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration, in International application No. PCT/US2014/023813, dated May 22, 2014. (11 pages).
European Patent Office, Communication pursuant to Article 94(3) EPC, in Application No. 11 736 511.4, dated Mar. 28, 2014.
PCT, Notification Concerning Transmittal of International Preliminary Report on Patentability, in International application No. PCT/US2011/042387, dated Jan. 17, 2013. (7 pages).
State Intellectual Property Office of the People's Republic of China, Notification of the First Office Action, in Application No. 201180032145.4, dated Jan. 30, 2014. (16 pages).
PCT, Notification Concerning Transmittal of International Preliminary Report on Patentability, in International application No. PCT/US2011/044215, dated Jan. 31, 2013. (14 pages).
Da Silva Sobrinho A S et al., “Transparent barrier coatings on polyethylene terephthalate by single-and dual-frequency plasma-enhanced chemical vapor deposition”, Journal of Vacuum Science and Technology; Part A, AVS/AIP, Melville, NY, US, vol. 16, No. 6, Nov. 1, 1998 (Nov. 1, 1998), pp. 3190-3198, XP01200471, ISSN: 0734-2101, DOI: 10.1116/1.581519 (9 pages).
State Intellectual Property Office of the People's Republic of China, Notification of the Third Office Action, in Application No. 201080029201.4, dated Jul. 7, 2014 (15 pages).
PCT, Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration, in International application No. PCT/US2014/029531, dated Jun. 20, 2014 (12 pages).
State Intellectual Property Office of the People's Republic of China, Notification of the Third Office Action, with translation, in Application No. 201080029199.0, dated Jun. 27, 2014 (19 pages).
Intellectual Property Office of Singapore, Invitation to Respond to Written Opinion, in Application No. 2012083077, dated Jun. 30, 2014 (12 pages).
PCT, Notification of Transmittal of International Preliminary Report on Patentability, in International application No. PCT/US13/40368, dated Jul. 16, 2014 (6 pages).
Australian Government, IP Australia, Patent Examination Report No. 1, in Application No. 2012318242, dated Apr. 30, 2014. (6 pages).
State Intellectual Property Office of the People's Republic of China, Notification of the First Office Action, in Application No. 201180023461.5, dated May 21, 2014. (25 pages).
European Patent Office, Communication pursuant to Article 94(3) EPC, in Application No. 10162758.6 dated May 27, 2014. (7 pages).
Australian Government, IP Australia, Patent Examination Report No. 1, in Application No. 2011252925, dated Sep. 6, 2013 (3 pages).
Coating Syringes, http://www.triboglide.com/syringes.htm, printed Aug. 31, 2009.
Coating/Production Process, http://www.triboglide.com/process.htm, printed Aug. 31, 2009.
Munich Exp, Materialica 2005: Fundierte Einblicke in den Werkstofsektor, Seite 1, von 4, ME095-6.
Schott Developing Syringe Production in United States, Apr. 14, 2009, http://www.schott.com/pharmaceutical_packaging, printed Aug. 31, 2009.
Sterile Prefillable Glass and Polymer Syringes, Schott forma vitrum, http://www.schott.com/pharmaceutical_packaging.
Transparent and recyclingfähig, neue verpackung, Dec. 2002, pp. 54-57.
European Patent Office, Communication with European Search Report, in Application No. 10162758.6, dated Aug. 19, 2010.
Griesser, Hans J., et al., Elimination of Stick-Slip of Elastomeric Sutures by Radiofrequency Glow Discharge Deposited Coatings, Biomed Mater. Res. Appl Biomater, 2000, vol. 53, 235-243, John Wiley & Sons, Inc.
European Patent Office, Communication with extended Search Report, in Application No. EP 10162761.0, dated Feb. 10, 2011.
European Patent Office, Communication with partial Search Report, in Application No. EP 10162758.6, dated Aug. 19, 2010.
European Patent Office, Communication with extended Search Report, in Application No. EP 10162758.6, dated Dec. 21, 2010.
Yang, et al., Microstructure and tribological properties of SiOx/DLC films grown by PECVD, Surface and Coatings Technology, vol. 194 (2005), Apr. 20, 2005, pp. 128-135.
European Patent Office, Communication with extended European search report, in Application No. EP10162756.0, dated Nov. 17, 2010.
Prasad, G.R. et al., “Biocompatible Coatings with Silicon and Titanium Oxides Deposited by PECVD”, 3rd Mikkeli International Industrial Coating Seminar, Mikkeli, Finland, Mar. 16-18, 2006.
European Patent Office, Communication with extended European search report, in Application No. EP10162757.8, dated Nov. 10, 2010.
Patent Cooperation Treaty, Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, in PCT/US2010/034568, dated Jan. 21, 2011.
Patent Cooperation Treaty, Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, in PCT/US2010/034571, dated Jan. 26, 2011.
Patent Cooperation Treaty, Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, in PCT/US2010/034576, dated Jan. 25, 2011.
Patent Cooperation Treaty, Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, in PCT/US2010/034577, dated Jan. 21, 2011.
Patent Cooperation Treaty, Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, in PCT/US2010/034582, dated Jan. 24, 2011.
European Patent Office, Communication with Extended Search Report, in Application No. EP 10162755.2, dated Nov. 9, 2010.
European Patent Office, Communication with Extended Search Report, in Application No. EP 10162760.2, dated Nov. 12, 2010.
PCT, Written Opinion of the International Searching Authority with International Search Report in Application No. PCT/US2010/034586, dated Mar. 15, 2011.
Shimojima, Atsushi et al., Structure and Properties of Multilayered Siloxane-Organic Hybrid Films Prepared Using Long-Chain Organotrialkoxysilanes Containing C=C Double Bonds, Journal of Materials Chemistry, 2007, vol. 17, pp. 658-663, © The Royal Society of Chemistry, 2007.
Sone, Hayato et al., Picogram Mass Sensor Using Resonance Frequency Shift of Cantilever, Japanese Journal of Applied Physics, vol. 43, No. 6A, 2004, pp. 3648-3651, © The Japan Society of Applied Physics.
Sone, Hayato et al., Femtogram Mass Sensor Using Self-Sensing Cantilever for Allergy Check, Japanese Journal of Applied Physics, vol. 45, No. 3B, 2006, pp. 2301-2304, © The Japan Society of Applied Physics.
Mallikarjunan, Anupama et al, The Effect of Interfacial Chemistry on Metal Ion Penetration into Polymeric Films, Mat. Res. Soc. Symp. Proc. vol. 734, 2003, © Materials Research Society.
Schonher, H., et al., Friction and Surface Dynamics of Polymers on the Nanoscale by AFM, STM and AFM Studies on (Bio)molecular Systems: Unravelling the Nanoworld. Topics in Current Chemistry, 2008, vol. 285, pp. 103-156, © Springer-Verlag Berlin Heidelberg.
Lang, H.P., Gerber, C., Microcantilever Sensors, STM and AFM Studies on (Bio)molecular Systems: Unravelling the Nanoworld. Topics in Current Chemistry, 2008, vol. 285, pp. 1-28, © Springer-Verlag Berlin Heidelberg.
Patent Cooperation Treaty, Written Opinion of the International Searching Authority with International Search Report in Application No. PCT/US2012/064489, dated Jan. 25, 2013.
Danish Patent and Trademark Office, Singapore Written Opinion, in Application No. 201108308-6, dated Dec. 6, 2012.
Danish Patent and Trademark Office, Singapore Search Report, in Application No. 201108308-6, dated Dec. 12, 2012.
Tao, Ran et al., Condensationand Polymerization of Supersaturated Monomer Vapor, ACS Publications, 2012 American Chemical Society, ex.doi.org/10.1021/la303462q/Langmuir 2012, 28, 16580-16587.
State Intellectual Property Office of Teh People's Republic of China, Notification of First Office Action in Application No. 201080029201.4, dated Mar. 37, 2013. (15 pages).
PCT, Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration, in International application No. PCT/US2013/040380, dated Sep. 3, 2013. (13 pages).
PCT, Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration, in International application No. PCT/US2013/040368, dated Oct. 21, 2013. (21 pages).
PCT, Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration, in International application No. PCT/US2013/048709, dated Oct. 2, 2013. (7 pages).
Coclite A.M. et al., “On the relationship between the structure and the barrier performance of plasma deposited silicon dioxide-like films”, Surface and Coatings Technology, Elsevier, Amsterdam, NL, vol. 204, No. 24, Sep. 15, 2010 (Sep. 15, 2010), pp. 4012-4017, XPO27113381, ISSN: 0257-8972 [retrieved on Jun. 16, 2010]. abstract, p. 4014, right-hand column—p. 4015, figures 2, 3.
Brunet-Bruneau A. et al., “Microstructural characterization of ion assisted Sio2 thin films by visible and infrared ellipsometry”, Journal of Vacuum Science and Technology: Part A, AVS/AIP, Melville, NY, US, vol. 16, No. 4, Jul. 1, 1998 (Jul. 1, 1998), pp. 2281-2286, XPO12004127, ISSN: 0734-2101, DOI: 10.1116/1.581341, p. 2283, right-hand column—p. 2284, left-hand column, figures 2, 4.
Korean Patent Office, Office Action dated Jun. 21, 2016 in Patent Application No. 10-2011-7028713.
Mexican Patent Office, Office Action dated Jun. 7, 2016 in Patent Application No. MX/a/2011/012038 (3 pages).
Japanese Patent Office, Notice of Reasons for Refusal, Patent Application No. 2013-510276, dated Mar. 8, 2016 (15 pages).
European Patent Office, Communication pursuant to Article 94(3) EPC, in Application No. 13 726 337.2, dated Dec. 2, 2016 (6 pages).
Allison, H.L., The Real Markets for Transparent Barrier Films, 37th Annual Technical Conference Proceedings, 1994, ISBN 1-878068-13-X, pp. 458.
Bailey, R. et al., Thin-Film Multilayer Capacitors Using Pyrolytically Deposited Silicon Dioxide, IEEE Transactions on Parts, Hybrids, and Packaging, vol. PHP-12, No. 4, Dec. 1976, pp. 361-364.
Banks, B.A., et al., Fluoropolymer Filled SiO2 Coatings; Properties and Potential Applications, Society of Vacuum Coaters, 35th Annual Technical Conference Proceedings, 1992, ISBN 1-878068-11-3, pp. 89-93.
Baouchi, W., X-Ray Photoelectron Spectroscopy Study of Sodium Ion Migration through Thin Films of SiO2 Deposited on Sodalime Glass, 37th Annual Technical Conference Proceedings, 1994, ISBN 1-878068-13-X, pp. 119-422.
Boebel, F. et al., Simultaneous In Situ Measurement of Film Thickness and Temperature by Using Multiple Wavelengths Pyrometric Interferometry (MWPI), IEEE Transaction on Semiconductor Manufacturing, vol. 6, No. 2, May 1993, , pp. 112-118.
Bush, V. et al., The Evolution of Evacuated Blood Collection Tubes, BD Diagnostics—Preanalytical Systems Newsletter, vol. 19, No. 1, 2009.
Chahroudi, D., Deposition Technology for Glass Barriers, 33rd Annual Technical Conference Proceedings, 1990, ISBN 1-878068-09-1, pp. 212-220.
Chahroudi, D., et al., Transparent Glass Barrier Coatings for Flexible Film Packaging, Society of Vacuum Coaters, 34th Annual Technical Conference Proceedings, 1991, ISBN 1-878068-10-5, pp. 130-133.
Chahroudi, D., Glassy Barriers from Electron Beam Web Coaters, 32nd Annual Technical Conference Proceedings, 1989, pp. 29-39.
Czeremuszkin, G. et al., Ultrathin Silicon-Compound Barrier Coatings for Polymeric Packaging Materials: An Industrial Perspective, Plasmas and Polymers, vol. 6, Nos. 1/2, Jun. 2001, pp. 107-120.
Ebihara, K. et al., Application of the Dielectric Barrier Discharge to Detect Defects in a Teflon Coated Metal Surface, 2003 J. Phys. D: Appl. Phys. 36 2883-2886, doi: 10.1088/0022-3727/36/23/003, IOP Electronic Journals, http://www.iop.org/EJ/abstract/0022-3727/36/23/003, printed Jul. 14, 2009.
Egitto, F.D., et al., Plasma Modification of Polymer Surfaces, Society of Vacuum Coaters, 36th Annual Technical Conference Proceedings, 1993, ISBN 1-878068-12-1, pp. 10-21.
Erlat, A.G. et al., SIOx Gas Barrier Coatings on Polymer Substrates: Morphology and Gas Transport Considerations, ACS Publications, Journal of Physical Chemistry, published Jul. 2, 1999, http://pubs.acs.org/doi/abs/10.1021/jp990737e, printed Jul. 14, 2009.
Fayet, P., et al., Commercialism of Plasma Deposited Barrier Coatings for Liquid Food Packaging, 37th Annual Technical Conference Proceedings, 1995, ISBN 1-878068-13-X, pp. 15-16.
Felts, J., Hollow Cathode Based Multi-Component Depositions, Vacuum Technology & Coating, Mar. 2004, pp. 48-55.
Felts, J.T., Thickness Effects on Thin Film Gas Barriers: Silicon-Based Coatings, Society of Vacuum Coaters, 34th Annual Technical Conference Proceedings, 1991, ISBN 1-878068-10-5, pp. 99-104.
Felts, J.T., Transparent Barrier Coatings Update: Flexible Substrates, Society of Vacuum Coaters, 36th Annual Technical Conference Proceedings, 1993, ISBN 1-878068-12-1, pp. 324-331.
Felts, J.T., Transparent Gas Barrier Technologies, 33rd Annual Technical Conference Proceedings, 1990, ISBN 1-878068-09-1, pp. 184-193.
Finson, E., et al., Transparent SiO2 Barrier Coatings: Conversion and Production Status, 37th Annual Technical Conference Proceedings, 1994, ISBN 1-878068-13-X, pp. 139-143.
Flaherty, T. et al., Application of Spectral Reflectivity to the Measurement of Thin-Film Thickness, Opto-Ireland 2002: Optics and Photonics Technologies and Applications, Proceedings of SPIE vol. 4876, 2003, pp. 976-983.
Hora, R., et al., Plasma Polymerization: A New Technology for Functional Coatings on Plastics, 36th Annual Technical Conference Proceedings, 1993, ISBN 1-878068-12-1, pp. 51-55.
Izu, M., et al., High Performance Clear CoatTM Barrier Film, 36th Annual Technical Conference Proceedings, 1993, ISBN 1-878068-12-1, pp. 333-340.
Jost, S., Plasma Polymerized Organosilicon Thin Films on Reflective Coatings, 33rd Annual Technical Conference Proceedings, 1990, ISBN 1-878068-09-1, pp. 344-346.
Kaganowicz, G., et al., Plasma-Deposited Coatings—Properties and Applications, 23rd Annual Technical Conference Proceedings, 1980, pp. 24-30.
Kamineni, V. et al., Thickness Measurement of Thin Metal Films by Optical Metrology, College of Nanoscale Science and Engineering, University of Albany, Albany, NY.
Klemberg-Sapieha, J.E., et al., Transparent Gas Barrier Coatings Produced by Dual Frequency PECVD, 36th Annual Technical Conference Proceedings, 1993, ISBN 1-878068-12-1, pp. 445-449.
Krug, T., et al., New Developments in Transparent Barrier Coatings, 36th Annual Technical Conference Proceedings, 1993, ISBN 1-878068-12-1, pp. 302-305.
Kuhr, M. et al., Multifunktionsbeschichtungen für innovative Applikationen von Kunststoff-Substraten, HiCotec Smart Coating Solutions.
Kulshreshtha, D.S., Specifications of a Spectroscopic Ellipsometer, Department of Physics & Astrophysics, University of Delhi, Delhi-110007, Jan. 16, 2009.
Krug, T.G., Transparent Barriers for Food Packaging, 33rd Annual Technical Conference Proceedings, 1990, ISBN 1-878068-09-1, pp. 163-169.
Lee, K. et al., The Ellipsometric Measurements of a Curved Surface, Japanese Journal of Applied Physics, vol. 44, No. 32, 2005, pp. L1015-L1018.
Lelait, L. et al., Microstructural Investigations of EBPVD Thermal Barrier Coatings, Journal De Physique IV, Colloque C9, supplément au Journal de Physique III, vol. 3, Dec. 1993, pp. 645-654.
Masso, J.D., Evaluation of Scratch Resistant and Antireflective Coatings for Plastic Lenses, 32nd Annual Technical Conference Proceedings, 1989, p. 237-240.
Misiano, C., et al., New Colourless Barrier Coatings (Oxygen & Water Vapor Transmission Rate) on Plastic Substrates, 35th Annual Technical Conference Proceedings, 1992, ISBN 1-878068-11-3, pp. 28-40.
Misiano, C., et al., Silicon Oxide Barrier Improvements on Plastic Substrate, Society of Vacuum Coaters, 34th Annual Technical Conference Proceedings, 1991, ISBN 1-878068-10-5, pp. 105-112.
Mount, E., Measuring Pinhole Resistance of Packaging, Corotec Corporation website, http://www.convertingmagazine.com, printed Jul. 13, 2009.
Murray, L. et al., The Impact of Foil Pinholes and Flex Cracks on the Moisture and Oxygen Barrier of Flexible Packaging.
Nelson, R.J., et al., Double-Sided QLF® Coatings for Gas Barriers, Society of Vacuum Coaters, 34th Annual Technical Conference Proceedings, 1991, ISBN 1-878068-10-5, pp. 113-117.
Nelson, R.J., Scale-Up of Plasma Deposited SiOx Gas Diffusion Barrier Coatings, 35th Annual Technical Conference Proceedings, 1992, ISBN 1-878068-11-3, pp. 75-78.
Novotny, V. J., Ultrafast Ellipsometric Mapping of Thin Films, IBM Technical Disclosure Bulletin, vol. 37, No. 02A, Feb. 1994, pp. 187-188.
Rüger, M., Die Pulse Sind das Plus, PICVD-Beschichtungsverfahren.
Schultz, A. et al., Detection and Identification of Pinholes in Plasma-Polymerised Thin Film Barrier Coatings on Metal Foils, Surface & Coatings Technology 200, 2005, pp. 213-217.
Stchakovsky, M. et al., Characterization of Barrier Layers by Spectroscopic Ellipsometry for Packaging Applications, Horiba Jobin Yvon, Application Note, Spectroscopic Ellipsometry, SE 14, Nov. 2005.
Teboul, E., Thi-Film Metrology: Spectroscopic Ellipsometer Becomes Industrial Thin-Film Tool, LaserFocusWorld, http://www.laserfocusworld.com/display_article, printed Jul. 14, 2009.
Teyssedre, G. et al., Temperature Dependence of the Photoluminescence in Poly(Ethylene Terephthalate) Films, Polymer 42, 2001, pp. 8207-8216.
Tsung, L. et al., Development of Fast CCD Cameras for In-Situ Electron Microscopy, Microsc Microanal 14(Supp 2), 2008.
Wood, L. et al., A Comparison of SiO2 Barrier Coated Polypropylene to Other Coated Flexible Substrates, 35th Annual Technical Conference Proceedings, 1992, ISBN 1-878068-11-3, pp. 59-62.
Yang, et al., Microstructure and tribological properties of SiOx/DLC films grown by PECVD, Surface and Coatings Technology, vol. 194, Issue 1, Apr. 20, 2005, pp. 128-135.
AN 451, Accurate Thin Film Measurements by High-Resoluiton Transmission Electron Microscopy (HRTEM), Evans Alalytical Group, Version 1.0, Jun. 12, 2008, pp. 1-2.
Benefits of TriboGlide, TriboGlide Silicone-Free Lubrication Systems, http://www.triboglide.com/benfits.htm, printed Aug. 31, 2009.
L. Martinu, O. Zabeida, and J.E. Klemberg-Sapieha, “Plasma-Enhanced Chemical Vapor Deposition of Functional Coatings”, Handbook of Deposition Technologies for Films and Coating, Chapter 9, pp. 392-464, 2010.
Related Publications (1)
Number Date Country
20190358123 A1 Nov 2019 US
Provisional Applications (5)
Number Date Country
61776733 Mar 2013 US
61800746 Mar 2013 US
61645003 May 2012 US
61636377 Apr 2012 US
61558885 Nov 2011 US
Continuations (2)
Number Date Country
Parent 15385150 Dec 2016 US
Child 16029923 US
Parent 14205329 Mar 2014 US
Child 15385150 US
Continuation in Parts (2)
Number Date Country
Parent 16029923 Jul 2018 US
Child 16448689 US
Parent 14357418 US
Child 14205329 US